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SUMMARY 
 
Buruli ulcer (BU) hits thousands of individuals every year in over 30 countries 
worldwide, primarily children in remote areas of sub-Saharan Africa. This devastating 
necrotizing skin infection is caused by Mycobacterium ulcerans, a cytotoxic macrolide 
producing environmental pathogen. The disease distorts and cripples those affected 
and has great socio-economic impact on people living in endemic regions. Currently 
recommended treatment options are surgical excision of the lesion, systemic 
administration of as rifampicin and streptomycin (R-S) or a combination of both. 
Clinical diagnosis of BU lesions requires the expertise of a skilled physician or health 
worker, and proper medical care is expensive, time-consuming or not available at all 
in many BU endemic regions of Africa. Thus, rapid diagnostic tools as well as 
improved established or new alternative therapies which are safe, inexpensive and 
easy to handle in a rural setting are urgently needed and the present work focused 
on these important issues. 
 
Histopathological hallmark of progressing BU disease is a poor inflammatory 
response despite clusters of extracellular bacilli inside necrotic subcutaneous areas. 
We conducted detailed histopathological studies on the efficacy of chemotherapy 
with R-S to restore the local immune responses in early (nodule and plaque) and late 
(ulcerative) BU lesions, respectively. In early lesions AFB internalized by 
macrophages and neutrophils were already found after two to four weeks of 
treatment and started to display irregular ZN staining after eight weeks. Final 
clearance of the bacterial load depended on the initial size of clusters and the 
surrounding necrosis. After eight weeks of R-S therapy ulcerative lesions comprised 
only mycobacterial debris inside focally distributed mononuclear phagocytes. Local 
cellular immune responses were re-activated very quickly (after two weeks acute 
infiltration was already prominent) and developed further during the course of 
antibiotic therapy, resulting in the formation of ectopic tertiary lymphoid tissue. 
Granulomas and other lymphoid structures developed both in early and late stage 
lesions in the course of antibiotic treatment, but only nodules and plaques showed 
abscessus formation, severe haemorrhages and extensive necrosis after completion 
of eight to twelve weeks chemotherapy. Administration of R-S is efficacious to cure 
BU, but immunopathological adverse events due to a chronic overreaction of the 
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immune system may cause healing retardation. Thus, treatment strategies have to 
be further improved. Our results demonstrate that histopathology can serve as a 
valuable tool for efficacy evaluation.  
 
M. ulcerans grows best at temperatures around 30°C and not above 37 °C and this 
property makes the application of heat a treatment option. We employed the phase 
change material sodiumacetatetrihydrate which is widely used in commercial pocket 
heat pads as a heat application system for thermotherapy. Laboratory reconfirmed 
patients with ulcerative BU lesions were included in a proof of principle study and 
treated for four to six weeks. Patients with large defects had skin grafting after 
successful heat treatment while smaller ulcers healed completely without further 
intervention. Punch biopsies were analysed for histopathological changes and local 
immunological reactions during heat therapy. While massive cellular infiltration was 
observed during antibiotic therapy, the extent of total leukocyte infiltration in the 
lesion did not increase during thermotherapy. This may favour a rapid transition from 
inflammation to healing, as indicated by the clinical response to heat treatment, 
which was characterized by an extraordinarily rapid epithelization and healing 
process. All patients remained relapse-free within twelve months of follow-up 
suggesting thermotherapy a future treatment option for BU. 
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ZUSAMMENFASSUNG 
 
Jedes Jahr entwickeln Tausende Menschen in über 30 Nationen weltweit einen 
Buruli Ulkus (BU). Insbesondere Kinder in abgelegenen Regionen West und Zentral 
Afrikas sind betroffen. Das Umweltbakterium Mycobacterium ulcerans produziert ein 
zytotoxisches Makrolid und verursacht diese zerstörerische, nekrotisierende 
Hauterkrankung. Die Krankheit hat gravierende sozio-ökonomische Konsequenzen 
für die endemischen Gebiete, da die Betroffenen nach lang anhaltenden 
Krankheitsverläufen oft entstellt und verkrüppelt sind. Die Behandlung besteht 
gegenwärtig aus der chirurgischen Entfernung der Läsion, systemischer Gabe von 
Rifampicin und Streptomycin (R-S) oder einer Kombination aus diesen beiden 
Optionen. Nur gut ausgebildete Ärzte oder Pfleger mit Expertise können BU 
zuverlässig klinisch diagnostizieren, und eine adäquate medizinische Versorgung ist 
teuer, zeitaufwendig und in vielen BU endemischen Gebieten Afrikas kaum 
verfügbar. Aus diesem Grund ist die Entwicklung von einfachen diagnostischen 
Hilfsmitteln sowie eine Verbesserung der Therapiemöglichkeiten dringend 
erforderlich. Die vorliegende Arbeit konzentriert sich auf diese wichtigen Themen. 
 
Ein fortschreitender BU zeichnet sich durch eine reduzierte Inflammationsreaktion 
aus, trotz grosser Klumpen extrazellulärer Bakterien im nekrotischen subkutanen 
Gewebe. Wir haben histopathologische Studien an frühen (Knoten und Plaques) 
sowie späten (Ulcera) Läsionen durchgeführt, um die Entwicklung lokaler 
Immunantworten im Verlauf der R-S Chemotherapie zu erfassen. In frühen Läsionen 
konnten bereits nach zwei- bis vierwöchiger Behandlung Makrophagen und 
neutrophile Leukozyten mit internalisierten säurefesten Stäbchen beobachtet 
werden, welche nach acht Wochen begannen Unregelmässigkeiten in der ZN 
Färbung aufzuweisen. Die endgültige Beseitigung der Bakterien hing von ihrer 
ursprünglichen Anzahl und dem Ausmass der sie umgebenden Nekrose ab. Nach 
acht Wochen R-S Therapie enthielten ulzerierende Läsionen nur noch fokale 
Ansammlungen von mykobakteriellen Trümmern in mononukleären Phagozyten. Die 
lokale zelluläre Immunantwort wurde sehr schnell reaktiviert (markante akute 
Infiltration bereits nach zwei Wochen) und über die Dauer der Antibiotikatherapie 
fortentwickelt. Sowohl bei frühen als auch chronischen Läsionen bildeten sich 
Granulome und ektopische tertiäre lymphoide Strukturen während der 
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Antibiotikatherapie aus. Allerdings konnten nur in Knoten und Plaques noch nach 
Beendigung der acht- bis zwölfwöchigen Chemotherapie Abzessbildung, heftige 
Einblutungen und ausgedehnte Nekrose beobachtet werden. 
Die Gabe von R-S hat sich als effizientes Heilmittel für BU erwiesen, allerdings 
scheinen die beobachteten immunpathologischen Vorgänge aufgrund einer 
chronischen Überreaktion des Immunsystems Heilungsverzögerungen 
hervorzurufen. Behandlungsstrategien bedürfen daher weiterer Verbesserungen. 
Unsere Resultate demonstrieren, dass die Histopathologie eine nützliche Methode 
zur Beurteilung ihrer Wirksamkeit darstellt. 
 
Da M. ulcerans am besten bei Temperatuen um die 30°C und nicht über 37°C 
wächst, stellt die lokale Anwendung von Wärme eine mögliche Behandlungsoption 
dar. Wir haben das Phasenwechselmaterial Sodiumacetat-trihydrat, welches 
weitverbreit in kommerziell hergestellten Wärmetaschen genutzt wird, als Wärme-
Applikationssystem zur Thermotherapie eingesetzt. Durch Laboranalysen bestätigte 
BU Patienten mit ulzerativen Läsionen wurden in einer Pilot-Studie vier bis sechs 
Wochen lang behandelt. Patienten mit grösseren Wunden erhielten zusätzlich eine 
Hauttransplantation nach erfolgreicher Wärmebehandlung, während kleinere Ulcera 
ohne weitere Interventionen komplett ausheilten. Stanzbiopsien wurden auf 
histologische Veränderungen und lokale immunologische Reaktionen während der 
Behandlung hin untersucht. Im Gegensatz zur Antibiotikatherapie, die mit massiven 
Infiltraten einhergeht, rief die Thermotherapie keinen Anstieg der 
Gesamtleukozytenzahl innerhalb der Läsion hervor. Dies scheint einen raschen 
Wechsel von Entzündungsreaktionen zu Heilungsprozessen zu begünstigen. 
Unterstützt wird diese Hypothese durch die während der Wärmebehandlung zu 
beobachtende, aussergewöhnlich schnelle Epithelbildung und Wundheilung. Da in 
einem Nachsorgezeitraum von zwölf Monaten alle Studienpatienten rezidiv-frei 
blieben, kann die Behandlung von BU mittels Wärme als potentielle 
Alternativtherapie betrachtet werden. 
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ABBREVIATIONS 
 
AFB   Acid-Fast Bacilli 
ALES   Aide aux Lépreux Emmaüs Suisse 
BCG   Bacillus Calmette-Guèrin 
BU   Buruli Ulcer 
CD20   Cluster of Differentiation 20 
DCs   Dendritic cells 
ELISA   Enzyme-Linked Immunoabsorbent Assay 
HE   Haematoxylin and Eosin staining 
IFN   Interferon 
IgG   Immunoglobulin G 
IHC   Immunohistochemistry 
IS   Insertion Sequence 
kD   kilo Dalton 
mAb(s)  monoclonal Antibody(s) 
MIC   Minimum Inhibitory Concentration 
NGO   Non Gouvernemental Organisation 
PCR   Polymerase Chain Reaction 
PFA   Paraformaldehyde 
POD   Prevention Of Disability 
PPD   Purified Protein Derivative 
R-S   Rifampicin and Streptomycin 
STI   Swiss Tropical Institute 
TB   Tuberculosis 
Th   T helper 
TLR   Toll-Like Receptor 
WHO   World Health Organization 
ZN   Ziehl-Neelsen staining 
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1.1 Epidemiology of M. ulcerans infection 
 
Buruli ulcer is a necrotizing skin disease due to infection with Mycobacterium 
ulcerans, a slow growing environmental pathogen producing a potent toxin with 
cytotoxic properties causing devastating ulcerative lesions. The main burden lies on 
individuals living in rural areas of sub-Saharan Africa, primarily young children under 
the age of 15. 
M. ulcerans has been isolated for the first time in 1948 by McCallum and colleagues 
from six Australian patients presenting with unusual skin lesions 1. Retrospectively, 
large ulcers described by Sir Robert Cook already in 1897 in the population of 
northeast Congo were almost certainly caused by M. ulcerans 2. Before the 1980s 
several countries reported focal areas endemic for Buruli ulcer 3. The Uganda Buruli 
Group introduced the name “Buruli” ulcer referring to the first reported cases coming 
from the Buruli region of Uganda near lake Kyoga 4. Since then, alarming increases 
in case numbers have been reported and over 30 countries worldwide are affected 5.  
 
 
Figure 1. BU situation in Africa 2006 (Source: WHO 2006) 
 
 
To date, Buruli ulcer is one of the most important human mycobacterioses, 
outnumbering tuberculosis and leprosy in some countries such as Benin 6. Efficient 
surveillance of endemic areas and detection of new cases is difficult in many 
developing countries and prevalence rates are suspected to be even higher.  
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1.2 Causative agent 
 
M. ulcerans belongs to a group of mycobacteria called “occasional pathogens” which 
have the potential to cause disease in humans and animals. Most of those bacteria 
have an environmental reservoir and infect their hosts only under special 
circumstances 7. M. marinum, the ancestor of M. ulcerans, has a closely related DNA 
with 99.6% identity. Acquisition of the virulence plasmid and two insertion sequences 
(IS2404 and IS2606) are the hallmarks of the divergence and species diversification 
was further driven by acquisition and concomitant loss of DNA 8. The genome of M. 
ulcerans counts 5.8Mb, carrying over 5000 genes. Two phylogenetic lineages have 
been identified, the “classical” lineage - including the most pathogenic strains from 
Africa and Australia - and the “ancestral” lineage – genetically closer to M. marinum 
comprising strains from Asia and South America 9. African isolates are genetically 
less heterogeneous than all other known mycobacteria, making epidemiological 
analyses extremely demanding 10. 
M. ulcerans is a slow growing bacillus with generation times between hours and 
days. Primary cultures are difficult to obtain and may take between several weeks to 
months to turn positive 11. The best growing rates are achieved at temperatures 
around 30°C on Löwenstein-Jensen medium or with the BacTec system 12. Unlike 
other members of the tuberculosis-complex, M. ulcerans does not have a dominating 
intracellular existence. However, recent studies predominantly in the mouse model, 
but also in humans showed that bacilli are internalized by phagocytic cells during the 
initial phase of infection 13,14. Release of M. ulcerans into the tissue occurs due to the 
action of its exotoxin mycolactone, a polyketide-derived 12-membered ring macrolide 
15
. Enzymes required for the synthesis of mycolactone are encoded by a giant 174kb 
virulence plasmid 16. 
Mycolactone has been shown to have both cytotoxic and immunosuppressive activity 
on leukocytes in vitro, leading to cell growth arrest and apoptosis/necrosis 17. This 
explains the limited cellular immune responses observed in the core of BU lesions, 
despite extensive tissue damage and huge clusters of extracellular bacteria. Injection 
of purified mycolactone into the skin of guinea pigs induces ulceration, whereas 
mycolactone deficient mutants fail to produce disease in these animals 18. 
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1.3 Reservoir and transmission 
 
It is assumed that M. ulcerans is an environmental organism but the reservoir(s) 
remain(s) yet unacquainted. BU often strikes individuals living and working in 
wetlands close to rivers, lakes or other water bodies and increasing incidence rates 
have been reported in areas where major environmental rearrangements took place 
19,20
. Especially in Western Africa the disease is significantly spreading which might 
be partially due to populations moving into endemic areas as well as increased 
deforestation, flooding, dam construction or other topographical alterations.  
To date the transmission of M. ulcerans cannot be fully explained but some sort of 
skin trauma seems to provide the entry site for infection. Occupational exposure to 
contaminated soil, for example on plantations or river banks, seems to be associated 
with development of the disease 21.  
 
1.1.1 Figure 2. The Common Brushtail Possum (Trichosurus vulpecula) and its faeces                      
(Source: www.anbg.gov.au) 
 
One hypothesis links the disease to aquatic predatory insects. It has been shown that 
M. ulcerans replicate inside the salivary glands of Naucoris spp. and can be 
transmitted by these biting insects to laboratory mice 22. Additionally, DNA assigned 
to M. ulcerans has been detected by PCR analysis in other aquatic animals and 
biofilm formations on aquatic plants 23-25. In 2008, Portaels et al published the first 
cultivation of M. ulcerans from the environment out of a water strider from Benin 26. 
More recently, in an unpublished study in Australia the faeces of possums, small 
marsupials living in trees (Figure 2), turned out highly positive when tested by real-
time PCR. However, no acid-fast bacilli could be detected and culture remained 
negative.  
The discovery of main reservoir(s) and exact mode of transmission of M. ulcerans 
are two important research priorities of the global BU research community. 
 
 CHAPTER 1.  In t roduc t ion 5               
1.4 The pathology of Buruli ulcer disease 
 
1.4.1 Clinical presentation 
The early and less severe forms of BU lesions are mobile subcutaneous nodules (or 
papules) which are usually painless (Figure 3). Primarily cooler body parts such as 
the limbs are affected. When left untreated, lesions often become indurated plaques 
associated with varying degrees of oedema. At this stage bacterial burden is 
especially high and subcutaneous necrosis spreads relatively fast occasionally 
involving the underlying fascia and bones 27. Eventually, plaques turn into an 
ulcerative lesion, with characteristic cotton wool-like discharge inside the necrotic 
slough and undermined skin margins where the better part of bacterial burden is 
located once the central necrosis has been removed 28.  
 
 
 
 
 
 
 
 
Figure 3. Various stages of M. ulcerans infection (Buruli ulcer) 
 
 
Patients usually present to hospital late, when large plaques or ulcers are established 
or secondary infections cause additional symptoms such as fever and pain. 
Therefore, disabling contractures and scarring or even amputation of a limb are 
common sequelae with great socio-economic consequences for those affected 29.  
 
 
1.4.2 Histopathological changes 
On microscopic level BU presents with a distinct histopathology serving as one of the 
pillows to confirm clinical diagnosis. All stages have in common a coagulative 
subcutaneous necrosis, mainly of the adipose and deep dermal connective tissue, 
which is advancing almost unlimited driving progression of the disease. Huge 
clusters of extracellular M. ulcerans are usually located within the necrotic tissue and 
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inflammatory responses are mild to absent especially in early lesions 30. Eventually, 
all compartments of the affected skin undergo apoptosis/necrosis including vessels, 
nerves and the epidermal layer, turning structural details into an amorphous 
eosinophilic coagulum (Figure 4a). As disease progresses into its chronic form, 
elevated leukocyte infiltration associated with granuloma formation can be observed 
towards the macroscopically healthy lesion margins 28.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Characteristic BU coagulative necrosis of the subcutaneous tissue (a) with masses of acid-
fast bacilli in the adipose layer (b) 
 
 
Histopathological specimens typically show clumps or microcolonies of acid-fast 
organisms (Figure 4b), but more recent studies indicate a transient intracellular stage 
of M. ulcerans during the early phase of infection. Phagocytes, occasionally carrying 
internalized mycobacteria, may be observed at the necrotic rim where some 
leukocytes managed to infiltrate the tissue despite the immunosuppressive activity of 
mycolactone 13. In the mouse foot pad model this phenomenon can be seen more 
clearly during the very early i.e. pre-nodular stage of the infection. Leukocytes 
carrying intact bacilli are finally destroyed and release their contents into their 
environment. 
a b 
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Antibiotic therapy abolishes the characteristic immunosuppression and leads to the 
development of local strong, organized chronic inflammatory responses and 
subsequently the destruction of the bacteria (see Chapter 4). 
1.4.3 Immune response 
BU disease predominantly follows an indolent course, with little inflammatory 
response and mostly negative M. ulcerans or M. bovis PPD skin tests 31. The latter 
may switch to a positive reaction over time suggesting the development of a systemic 
response 32,33.  
Similar to most mycobacteria, M. ulcerans proceeds through an initial intracellular 
phase, where bacilli are internalized by phagocytes, before transition to the 
extracellular phase due to cell death caused by mycolactone. This first step may lead 
to the induction of a Th-1 host response which is ineffective against extracellular 
pathogens. Suppression of TNF-α in the presence of inflammatory chemokines 
produced by macrophages may prevent granuloma formation 14. Several studies on 
T-helper subset responses have been carried out, because cellular TH-1 responses 
with high levels of IFN-γ are regarded as crucial for the host defence against 
mycobacteria 34. Study protocols implemented were very heterogeneous leading to 
controversial results. Although one case study reports a shift from Th-1 to Th-2 
phenotype during ulceration 35 it is still unclear whether the disease can be 
associated with a shift in T-helper responses (see Chapter 11). 
Mycolactone is not only cytotoxic but at lower concentrations has also immuno-
modulatory attributes 36. Recent evidence suggests that the toxin acts suppressive on 
antigen presenting leukocytes such as dendritic cells hence disrupting the signal 
transduction to draining lymph nodes necessary for the activation and homing of 
lymphocytes 37. 
However, people who recovered from BU after surgical excision are not at all 
protected against recurrences or novel infections. The fact that antibiotic therapy 
leads to pronounced local leukocyte activation 38 could hint towards a possible “semi-
vaccination” based on rifampicin/streptomycin treatment, but long-term follow-ups of 
patients who recovered solely by administration of antibiotics have not yet been 
accomplished. 
During active disease the majority of M. ulcerans are extracellularly located which 
suggests that antibodies could play a role in immunoprophylaxis and spontaneous 
healing. Sera from infected individuals have sometimes high antibody titres against 
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M. ulcerans antigens, not correlated with disease stages 33,39. Unfortunately, normal 
BCG vaccination does not provide satisfactory protection 40,41. Current strategies for 
better vaccines include repeated or improved BCG vaccination, rational attenuation 
of a M. ulcerans strain and subunit vaccines aimed at immunodominant antigens 42-
44
. Vaccination with a compound eliciting the development of neutralizing antibodies 
against mycolactone is considered an alternative to protein based approaches.  
 
 
1.5 Diagnostic tools and treatment strategies 
 
1.5.1 Diagnosis 
The heterogeneous presentation of BU with its different stages requires an 
experienced physician for a proper differential diagnosis on clinical grounds.  
Developed ulcers are more easily recognized by means of their typical undermined 
edges and painless nature, although cutaneous leishmaniasis, squamous cell 
carcinoma or tropical phagedenic ulcer show certain similarities 29. Examination of 
swabs or small biopsies taken from the undermined lesion margins is commonly 
used for confirmation of the clinical diagnosis. Smears can be stained with ZN and 
assessed for the presence of AFB even in remote areas of resource poor countries 
45
, but this method has low sensitivity and specificity.  
 
 
Figure 5. Schematic display of sampling a punch biopsy (source: www.answers.com) and two 
possible diagnostic applications: PCR of a DNA extract (a) and ZN staining of a smear (b) 
a 
b 
 CHAPTER 1.  In t roduc t ion 9               
PCR based on the amplification of IS2404 and IS2606 is another standard diagnostic 
tool widely used in better equipped reference laboratories 8. It is a rapid, sensitive 
and specific method but requires technical expertise and is not everywhere available. 
When it comes to the early nodular stage, clinical diagnosis of BU may even be more 
often confused with other diseases forming localized swellings such as 
onchocercoma, lymphadenitis, mycosis or lipoma. The diffuse clinical picture of the 
oedematous and plaque forms might be mistaken for leprosy, osteomyelitis or 
psoriasis 29. In all these cases the skin surface is still intact making invasive sampling 
for laboratory confirmation of the clinical diagnosis unavoidable. Since recently, 
punch biopsies are more often used to obtain material which can be used not only for 
PCR and ZN staining but also for culturing and histopathological assessment (Figure 
5). Culture of M. ulcerans is a very time-consuming, non-sensitive procedure 11. 
Detection of histopathological changes is a reliable diagnostic method but technically 
demanding and due to the heterogeneous nature of BU lesions often difficult to 
interpret especially when no AFB can be detected inside the biopsy. 
One of the main research priorities of the WHO Global Buruli Ulcer Initiative is the 
development of a simple and rapid diagnostic test with high sensitivity and specificity 
that could be used for early identification of cases and would help to improve the 
implementation of therapeutic interventions and prevention campaigns. 
 
 
1.5.2 Treatment 
During a long period surgical excision of lesions together with subsequent skin 
grafting was the only available therapeutic intervention. Early non-ulcerative lesions 
can often be removed without requiring skin grafting preventing the development of 
disfiguring large ulcers and accompanying deformities. Recurrences after primary 
surgical excision may occur in up to half the cases due to incomplete removal of the 
pathogen 46,47. This invasive therapy and the required long-term care have great 
economic impact on those affected. Furthermore, in developing countries such as 
West Africa skilled health care workers and experienced physicians are not 
commonly in reach and neither are appropriately equipped surgical wards.  
Anecdotal reports on antibiotic treatment of BU, especially of complicated cases, 
have generally been discouraging although M. ulcerans is susceptible to rifampicin, 
some aminoglycosides, macrolides and quinolones in vitro 48,49. In humans, both 
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clofazamine 50 and cotrimoxacole 51 yielded no effect, and the combination 
rifampicin/dapsone had limited success on ulcerative lesions 52. In 2002, Dega et al 
could show that combined rifampicin and amikacin administration over 12 weeks was 
sufficient to cure M. ulcerans infection in mice 53 and unpublished data from several 
health centres in Africa reported promising efficacy in patients. Based on these 
events, WHO launched provisional guidelines on antibiotic therapy of BU patients 
with rifampicin and streptomycin alone or in combination with surgery in 2004 54. One 
year later Etuaful et al could show that already after four weeks of therapy with this 
combination culture was rendered negative 55. A study among patients treated with 
antibiotics for eight weeks in Benin could categorize 96% of patients as successfully 
treated. Nevertheless, in about half the cases additional surgery and subsequent skin 
grafting had to be performed 56.  Recent studies in mice indicate that streptomycin, 
which has to be injected daily and may cause severe side-effects, could possibly be 
replaced by the orally administered clarithromycin 57. Nevertheless, new anti-
mycobacterial compounds which are safe, cheap and easy-to-administer are urgently 
needed as rifampicin is also one out of four frontline drugs in the combat against TB 
infection. 
In the mid-seventies of the last century a small clinical trial was conducted on the 
local application of heat onto lesions to cure the disease 58. Although results were 
quite encouraging, the electricity dependent and complicated device based on water 
circulation to maintain a constant 40°C made this approach inoperative for rural 
African regions. Recently, a proof-of-principal trial was accomplished reviving the 
idea of curing with heat by using bags filled with a cheap, non-hazardous phase-
change material (see Chapter 7). First results are very promising as lesions healed 
rapidly and patients remained free of relapse for over 12 months already, which 
indicates this strategy to be a possible alternative or supplementary treatment 
modality in the near future. 
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2.1 Goal 
 
To investigate current treatment strategies and future anti-mycobacterial drugs as 
well as possible alternative diagnostic tools to improve the health care situation of 
individuals infected with Mycobacterium ulcerans in remote African countries. 
 
 
2.2 Objectives 
 
1. To examine local immunological and histopathological changes during 
antibiotic therapy of the different stages of Buruli ulcer 
2. To compare established treatment modalities and novel therapeutic strategies 
through local histological processes 
3. To assess anti-mycobacterial activity of newly designed bactericidal 
compounds in vitro 
4. To investigate the potential of monoclonal antibodies against surface antigens 
of M. ulcerans to develop a new diagnostic tool 
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Abstract 
Buruli ulcer (BU) caused by Mycobacterium ulcerans is a chronic necrotizing disease 
of the skin and the underlying soft tissue. Fat tissue necrosis accompanied by 
minimal inflammation is considered the most reliable histopathologic feature of BU. 
There may be a constant influx of inflammatory cells to the sites of active infection 
but these are thought to be killed by mycolactone, a polyketide toxin produced by M. 
ulcerans, through apoptosis and necrosis. Here we describe the spatial correlations 
between mycobacterial load and the expression of dendritic cell (DC) surface 
markers (cluster of differentiation (CD) 83, CD11c, and CD123), the Toll-like receptor 
(TLR) 9 and pro- and anti-inflammatory cytokines (IL-8, IL-6, tumor necrosis factor-
alpha (TNF- ), IFN- , IL-12p40, IL-10, and IFN- ) within BU lesions. Although IL-8, 
IL-6, and TNF-  messenger RNA (mRNA) was detectable by real-time PCR in all 
lesions, the expression of the other cytokines was only found as small foci in some 
lesions. Correlations of the distribution of mRNA encoding the activation marker 
CD83 and the DC subset markers CD123 and CD11c indicate that both activated 
plasmacytoid and myeloid dendritic cells were present in the lesions. Results suggest 
that M. ulcerans specific immune responses may develop once therapeutic 
interventions have limited the production of mycolactone. 
 
 
Abbreviations 
BU, Buruli ulcer; CD, cluster of differentiation; DC, dendritic cell; mRNA, messenger 
RNA; P-DC, plasmacytoid dendritic cell; TLR, Toll-like receptor; TNF- , tumor 
necrosis factor-alpha 
 CHAPTER 3. Innate immune response in Buruli  ulcer 21               
Introduction 
Buruli ulcer (BU) caused by Mycobacterium ulcerans is a chronic necrotizing disease 
of skin and soft tissue. Generally it manifests initially as firm, non-tender, 
subcutaneous nodules, probably at the sites of penetrating skin trauma (pre-
ulcerative stage). Subsequently, these areas become fluctuant, followed by the 
formation of an ulceration with undermined edges (ulcerative stage). Ulcers can be 
extensive, involving more than 10% of the patient's skin surface (Johnson et al., 
2005). Subcutaneous fat is particularly affected, but underlying bone may also 
become involved in advanced cases. In BU lesions clumps of extracellular acid-fast 
bacilli surrounded by areas of necrosis are found. Fat tissue necrosis accompanied 
by minimal inflammation is considered the most reliable histopathologic feature of BU 
(Hayman and McQueen, 1985; Hayman, 1993; Guarner et al., 2003). In late stages 
of the disease, intralesional influx of leukocytes and granulomatous responses in the 
dermis and panniculus has been described. If left untreated, spontaneous healing of 
BU lesions can occur after extended periods of progressive ulceration (Asiedu et al., 
2000). Traditionally, BU is treated by wide surgical excision, drug therapy has been 
considered ineffective, but recent data suggest that combinations of anti-
mycobacterial antibiotics can support or replace surgical treatment (Etuaful et al., 
2005). Provisional World Health Organization (WHO) guidelines now recommend the 
use of rifampicin and streptomycin for the treatment of BU 
(http://www.who.int/buruli/information/antibiotics/en/index1.html). 
M. ulcerans is unique among mycobacterial pathogens in that it is mainly 
extracellular and produces a plasmid-encoded toxin with a polyketide-derived 
macrolide structure, named mycolactone (Stinear et al., 2004). Mycolactone is 
believed to play a central role in determining the extracellular localization of the 
bacteria and modulation of immunological responses to M. ulcerans (Adusumilli et 
al., 2005). Observations in rodents experimentally infected with mycolactone 
producing and mycolactone-negative M. ulcerans strains suggested that 
inflammatory cells are rapidly killed by necrosis when encountering high toxin 
concentrations. Inflammatory cells more distant from the necrotic center are thought 
to be killed via apoptosis resulting in extracellular bacteria surrounded by an area of 
coagulation necrosis. In contrast, granulomatous lesions with strong self-healing 
tendencies were observed with mycolactone-negative mutants (Oliveira et al., 2005). 
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Intrigued by the described lack of inflammatory responses in BU lesions, we have 
analyzed the impact of M. ulcerans infection on the activation of the skin innate 
immune system, including dendritic cells (DC). Here we describe the spatial 
correlations between bacterial load and the expression of DC-surface markers 
(cluster of differentiation (CD)83, CD11c, and CD123), the intracellular receptor Toll-
like receptor (TLR)9 and pro- and anti-inflammatory cytokines (IL-8, IL-6, tumor 
necrosis factor-alpha (TNF- ), IFN- , IL-12p40, IL-10, and IFN- ) within BU lesions. 
 
Results 
Quantitative real-time PCR was used to determine the spatial distribution of 
messenger RNA (mRNA) encoding cytokines and cell-surface markers of the innate 
immune system within surgically excised early ulcerative BU lesions of three selected 
patients. Histopathological changes and M. ulcerans DNA levels in the same tissue 
samples have been described previously (Rondini et al., 2006). A summary of these 
data is provided in Figures 1 and 2 for direct comparison with the distribution of 
cytokine and DC marker mRNA. 
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Figure 1. 
 
Spatial localization of bacterial load and DC markers in BU lesions. Patients A, B, 
and C excisions with tissue samples: A–N, A–K, A–I; respectively. Relative quantity 
of mRNA for the surface markers (d–f) CD83, (g–i) CD11c, (j–l) CD123, and (m–o) 
intracellular receptor TLR9 expressed in percent relative to -actin gene expression. 
(a–c) M. ulcerans DNA load and histopathological changes of the excisions (Rondini 
et al., 2006). 
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Figure 2. 
 
 
Distribution of bacterial load and cytokine mRNA in BU excisions. Patient A, B, 
and C excisions with tissue samples: A–N, A–K, A–I; respectively. Relative quantity 
of mRNA for the cytokines (a–c) IL-8, (d–f) IL-6, (g–i) TNF- , (j–l) IFN- , (m–o) IL-10 
and IFN-  expressed in percent relative to -actin gene expression. (a–c) M. 
ulcerans DNA load and histopathological changes of the excisions (Rondini et al., 
2006). 
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Distribution of DC marker mRNA 
Figure 1 shows the spatial pattern of mRNA encoding the cell-surface marker CD83, 
CD11c, CD123, and the intracellular receptor TLR9. Percent values normalized to -
actin mRNA are provided. In all three patients CD83 (Figure 1d–f) and CD123 mRNA 
(Figure 1j–l) was detectable along the entire lesions. Relative levels ranged from 0 to 
4.2% (as compared to 0.2 0.1% in normal skin) and from 0 to 7.4% (0.2 0.2% in 
normal skin), respectively. CD11c (Figure 1g–i) and TLR9 mRNA (Figure 1m–o) 
showed a more focal distribution with relative levels ranging from 0 to 92% (0.4 0.2% 
in normal skin) and 0–1.2% (<0.01% in normal skin), respectively. For all four 
markers peak values were thus much higher than in normal skin. In many cases 
peaks were located close to foci of M. ulcerans DNA (sample G in patient A, samples 
D and F in patient B, and samples D and E in patient C). 
Distribution of cytokine mRNA 
Expression of cytokines with pro-inflammatory or anti-inflammatory activity was 
analyzed (Figure 2). IL-8, IL-6, and TNF-  mRNA was detectable in all three BU 
lesions, albeit in different amounts and in markedly different spatial patterns. Peaks 
of the relative levels of IL-8 mRNA were associated with the ulcerations and the 
histological detection of neutrophils (Figure 2a–c). In contrast, location of the relative 
peaks of IL-6 mRNA with respect to the location of ulcerations and peaks of M. 
ulcerans DNA varied markedly between lesions. In patient A, the relative IL-6 mRNA 
levels were highest at the less affected borders of the excised tissue, in patient B it 
was peaking at the nodular pre-ulcerative lesion and in patient C at and around the 
ulceration (Figure 2d–f). TNF-  mRNA was broadly distributed over the lesion. 
Relative peak levels of IL-8, IL-6, and TNF-  mRNA (130.395, 10, and 2.3%, 
respectively) were dramatically higher than the levels found in normal skin (4.7 5.1, 
0.1 0.1, and 0.1 0.1%, respectively). 
Like in normal skin, IL-12p40 mRNA levels were below the detection limit in all three 
BU lesions analzsed (<0.03%) (data not shown). In contrast, IFN- , IFN- , and IL-10 
mRNA, also undetectable in normal skin, was found at least in one of the three 
analyzed lesions in spatially highly restricted foci. IL-10 and IFN-  mRNA was 
detected only in patient B (Figure 2n). Although a peak of IL-10 mRNA was 
associated with the secondary non-ulcerated nodule (peak value 1.2%), IFN-  
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mRNA was found in one sample close to the small ulceration and the associated 
granulomas (peak value 0.2%) (Figure 2n). Significant levels of IFN-  mRNA were 
primarily found in patient C (Figure 2j–l), peaking towards the right margin of the 
excised tissue (Figure 2l, peak value in sample I, 246%). 
Correlations of the spatial distribution of mRNA species 
The spatial mRNA distributions of the two DC subset markers CD11c and CD123 
were positively correlated with that of the cellular maturation marker CD83 (CD83 vs 
CD123: r=0.63, P<0.0001; CD83 vs CD11c: r=0.54, P=0.001; Figure 3a and b). Also 
strong positive correlations of the distribution of CD83 with IL-6 and TNF-  were 
observed (r=0.67, P<0.0001, and r=0.80, P<0.0001, respectively; Figure 3c and d). 
Correlation of IL-6 expression with CD123 was tighter (r=0.66, P<0.001; Figure 3e) 
compared with CD11c (r=0.41, P=0.02; Figure 3f). The correlation of both DC subset 
markers with TNF-  expression was moderate (CD11c vs TNF- : r=0.50, P=0.002; 
CD123 vs TNF- : r=0.48, P=0.004; data not shown). There was no indication of a 
correlation between IFN-  and CD123, CD83, or CD11c (data not shown). 
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Figure 3. 
 
 
Correlations of DC markers and cytokine expression. Patient A ( ), B ( ), and C 
(+). Spearman's correlations of the mRNA spatial distribution in the excisions are 
given. (a) CD123 versus CD83; (b) CD11c versus CD83; (c) IL-6 versus CD83; (d) 
TNF-  versus CD83; (e) IL-6 versus CD123; (f) IL-6 versus CD11c. Spearman's 
correlations with an r ranging from 0.4 to 0.6 and P-value of <0.05 are moderate 
positive; with r>0.6 and P<0.05 are positive to strong positive. Each point represents 
the values of one tissue sample. 
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Immunohistochemical detection of CD123 and TLR9-positive cells 
Results of quantitative real-time PCR and immunohistochemistry were highly 
associated, that is the relative numbers of CD123 and TLR9-positive cells were 
consistent with the mRNA levels detected by real-time PCR (Figure 4). In the thin 
sections of lesions positive for CD123 and TLR9 mRNA, CD123, and TLR9 
antibodies stained cells with plasmacytoid features (inset Figure 4b and d). 
 
 
Figure 4. 
 
 
Immunohistochemical analysis of P-DC recruitment to BU excisions. 
Immunohistochemical stainings in thin sections of tissues samples B and F of patient 
B. (a, b) CD123 staining (original magnification 100, inset original magnification 
400) and (c, d) TLR9 staining (original magnification 200, inset original magnification 
1,000), bars=40 m. 
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Discussion 
Under homeostatic conditions, cutaneous DCs include epidermal Langerhans cells 
and interstitial/dermal DCs that are of myeloid origin (Kupper and Fuhlbrigge, 2004). 
Our real-time PCR and immunostaining data indicate that in addition to the CD11c-
positive CD123-negative myeloid DCs (Colonna et al., 2004), CD123-positive 
plasmacytoid DCs (P-DC), are present in early ulcerative lesions. P-DC are of 
lymphoid origin (Colonna et al., 2004), CD11c-negative and known to be recruited to 
diseased skin in conditions such as systemic lupus erythematosus, atopic dermatitis, 
psoriasis vulgaris, and contact dermatitis (Wollenberg et al., 2002; Bangert et al., 
2003; Nestle et al., 2005). 
One of the surface molecules upregulated upon DC activation and maturation is 
CD83 (Lechmann et al., 2002). Although CD83 is also expressed on activated human 
B and T cells and a subpopulation of activated monocytes (Lechmann et al., 2002), 
the observed correlations of mRNA expression between CD83 and CD123, or CD11c 
indicated, that both P-DC and myeloid DC were activated in the BU lesions. The 
distribution of mRNA encoding the highly expressed pro-inflammatory cytokines IL-6 
and TNF-  was also strongly correlated with the activation marker CD83. Expression 
of IL-6 was additionally strongly correlated with that of CD123, indicating that 
activated P-DC may represent the major source of IL-6 expression in the BU lesions. 
In contrast to myeloid DC, P-DC express TLR7 and TLR9 but lack TLR2, TLR3, 
TLR4, and TLR5. In the majority of patient samples analyzed, expression of TLR9 
and CD123 mRNA was consistent, supporting the presence of P-DC in BU lesions 
(Figure 1). Signalling through TLR7 and TLR9 results in P-DC activation to secrete 
large amounts of type I IFN and moderate amounts of TNF-  and IL-6 (Colonna et al., 
2004). In contrast to IL-6, no correlation between CD123 and IFN-  mRNA was 
observed. IFN-  expression by P-DC seems to be variable; whereas P-DC activation 
by TLR9 in response to viruses results in secretion of large amounts of IFN-  
(Colonna et al., 2004), during the development of psoriatic phenotype IFN-  
expression by P-DC seems to be only an early and transient event (Nestle et al., 
2005). Consistent with published data (Prevot et al., 2004; Kiszewski et al., 2006; 
Phillips et al., 2006), TNF-  and IL-8 mRNA levels were, like those of IL-6 and IFN-  
mRNA, much higher in the BU lesions than in normal skin. As moderate correlation 
between DC markers and TNF-  mRNA was observed, TNF-  mRNA expression may 
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be in part associated with other cell types, like monocytes, activated T cells, or 
natural killer cells. 
The mechanism of immune protection in M. ulcerans remains unclear. Evidence from 
genetic defects in the IFN-  signalling pathway supports the role of IFN-  in 
protection against a range of non-tuberculous mycobacterial disease, including M. 
ulcerans (Ottenhoff et al., 2005). Peripheral blood mononuclear cells from BU 
patients with active disease showed significantly reduced lympho-proliferation and 
IFN-  production in response to stimulation with live or dead M. bovis Bacillus 
Calmette-Guérin, M. ulcerans, purified protein derivative of M. tuberculosis, 
isopentenyl pyrophosphate, and non-mycobacterial antigens like reconstituted 
influenza virosomes (Gooding et al., 2001, 2002, 2003; Prevot et al., 2004; Yeboah-
Manu et al., 2006). Prevot et al. (2004) showed with semiquantitative PCR analyses 
that the systemic Th1 downmodulation was mirrored by local, intralesional cytokine 
profiles. High IFN-  with low IL-10 mRNA levels were present in early, nodular 
lesions, and low IFN-  mRNA levels were detected in late ulcerative lesions (Prevot 
et al., 2004). Hence, in active M. ulcerans disease, the Th1 response seemed to be 
downregulated both locally and systemically. The presence of IL-6 during T-cell 
priming may promote Th2 differentiation and simultaneously inhibit Th1 polarization 
(Diehl and Rincon, 2002). Therefore the close association of CD123 (P-DC) with IL-6 
in conjunction with the lack of IFN-  production may favor Th2 development and 
result in the observed Th1 downmodulation in BU. IL-6 is a pleiotropic cytokine 
involved in the growth and differentiation of numerous cell types, including those of 
dermal and epidermal origin (Paquet and Pierard, 1996). In the skin, it is induced in a 
broad range of dermatotoxic reactions and may be involved in wound healing 
(Hernandez-Quintero et al., 2006). The presence of high numbers of P-DC in the 
lesions in the absence of IFN-  gene expression raises also the issue of a tolerogenic 
role of these cells, as suggested in primary cutaneous melanomas (Vermi et al., 
2003). 
IL-10 and IFN-  mRNA was detected in one of the three analyzed BU lesions, where 
it was present only in highly focal areas. Phillips et al. (2006) showed wide variations 
in IL-10 and IFN-  mRNA expression among individual skin punch biopsies. 
Generally, our results demonstrate that expression of cytokines and cell-surface 
markers can vary considerably within a BU lesion. Therefore, results obtained with 
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biopsies of BU lesions do not necessarily reflect the overall profile of a lesion. Our 
comparison of the spatial relationship between bacterial load, DC marker, and pro-
inflammatory cytokine mRNA suggests that the presence of clusters of M. ulcerans 
does not exclude innate immune system recruitment to the site of infection. This 
conclusion is consistent with the hypothesis of Oliveira et al. (2005) suggesting a 
constant influx of neutrophils, monocytes/macrophages, and lymphocytes to active 
M. ulcerans lesions. Potentially, M. ulcerans specific immune responses may 
therefore develop, once a therapeutic intervention, such as a successful antibiotic 
treatment, is limiting the production of mycolactone. 
 
Materials and Methods 
Clinical specimens 
Three BU patients with ulcerative lesions, who received standard treatment at the 
Amasaman Health Centre in the Ga district in Ghana, were enrolled in this study. The 
standard treatment comprised wide surgical excision including margins of 
macroscopically healthy tissue followed by skin grafting. BU clinical diagnosis was 
reconfirmed by IS2404 PCR, microscopic detection of acid-fast bacilli, and 
observation of characteristic histopathological changes. The distribution of M. 
ulcerans DNA and histopathological examination within the excised tissue samples 
analyzed here, have been described elsewhere (Rondini et al., 2006). Patient A 
presented with an ulcerated plaque (ulcer size 4 5 cm) on the dorsal aspect of the 
left upper arm. The central necrotic slough was associated with typical inflammatory 
cells whereas no granulomas were seen in any zone of the excision. The highest 
mycobacterial DNA burden was present at the base of the ulcer and decreased 
towards the margins of the excision (Figure 1a). Patient B presented with a small-
ulcerated lesion (  1 cm) and a larger non-ulcerated nodule located about 3 cm 
apart on the dorsal aspect of the right elbow. The M. ulcerans DNA was present with 
high load within the non-ulcerated nodule and, with lower load, in the ulcerated 
region. Between these two lesions no bacterial DNA was detected. Granulomas were 
present across the tissue from nodule to ulcer till the right margin of the excision 
(Figure 1b). Patient C presented with a small ulcer 5 cm away from a larger ulcer, 
which was surrounded by scar tissue and showed evidence of previous treatment. M. 
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ulcerans DNA was only present at the base of the small ulcer and no granulomas 
were detected in the whole excision (Figure 1c). Ethical approval for analyzing 
patient specimens was obtained from the local ethical review board of the Noguchi 
Memorial Institute for Medical Research and participants gave their written informed 
consent. The study was conducted according to the Declaration of Helsinki 
Principles. 
RNA extraction, removal of genomic DNA, and reverse transcription 
RNA was extracted from several samples of equal size, each comprising skin and fat 
tissue, which were obtained from BU patients' excised lesions: patient A, 14 samples 
(A–N); patient B, 11 samples (A–K); patient C, nine samples (A–I). Samples were 
disrupted by sonication for 2 minutes (Sonifer® Branson 250, Branson Ultrasonics 
Corporation, Danbury, CT) and centrifuged for 3 minutes at 10,000 g. RNA was 
extracted from the tissue lysate using the RNeasy Mini Kit (Qiagen AG, Basel, CH) 
and treated with DNase I (Invitrogen, Paisley, UK) to remove genomic DNA. 
To synthesize complementary DNA, total RNA was incubated with oligo d(T) for 
10 minutes at 65°C, and put on ice. A reaction mixture containing dNTP mix 
(125 nM), dithiothreitol (10 mM) and reverse transcriptase Moloney murine leukemia 
virus (200 U) with corresponding first strand buffer was added (Invitrogen, Paisley, 
UK). The reaction mix was incubated for 60 minutes at 37°C before enzyme 
inactivation for 5 minutes at 94°C. 
Quantitative real-time polymerase chain reaction 
Gene transcription was evaluated using the ABI Prism 7700 Sequence Detection 
System (Applied Biosystems, Foster City, CA). Primers and probes for six human 
cytokines (IL-6, IL-8, IL-10, IL-12p40, TNF- , IFN- , and IFN- ), cell-surface proteins 
(CD11c, CD83, CD123, and TLR9) were used to amplify specific complementary 
DNA in duplicate, according to the manufacturers instructions (Applied Biosystems, 
Foster City, CA). The -actin gene was used as an internal house keeping gene 
reference. Primers and probes for -actin, IL-8, IL-12p40, IFN- , CD11c, CD83, 
CD123, and TLR9 were obtained from Applied Biosystems. Primer and probes for IL-
6 (Hartwig et al., 2002), IL-10 (Giulietti et al., 2001), TNF-  (Razeghi et al., 2001), and 
IFN-  (Kammula et al., 1999) were synthesized by Mycrosynth (Balgach, CH). 
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Having verified that the amplification dynamic remains proportional at all tested 
dilutions, RNA expression of each surface marker and cytokine was presented as 
percentage relative to -actin gene expression. The assays were run in duplicates 
and the results with a standard deviation >2% were excluded. Correlation analyses 
were performed in Prism using the Spearman rank correlation coefficient. Mean 
values of surface markers and regulatory cytokines in six samples of healthy skin 
tissue are as follow: CD11c (0.4 0.2%), CD123 (0.2 0.2%), CD83 (0.2 0.1%), TLR9 
(<0.01%), TNF-  (0.1 0.1%), IL-6 (0.1 0.1%), and IL-8 (4.7 5.1%). IFN- , IFN- , IL-
10, and IL-12p40 mRNA were undetectable. 
Immunohistochemistry 
Tissue samples were fixed overnight in neutral buffered 4% paraformaldehyde, 
embedded in paraffin according to standard protocol and cut into 5 m sections 
using a microtome. After de-paraffinization, sections were re-hydrated through 
graded alcohols and washed in distilled water. Antigen retrieval was performed by 
microwave unmasking technique in 10 mM EDTA pH 8.0. Subsequently, endogenous 
peroxidase was blocked with 0.3% H2O2 for 30 minutes and unspecific binding 
prevented by incubating with blocking serum for 20 minutes at room temperature. 
CD123 (clone 6H6) and TLR9 (clone eB72-1665) antibodies (eBiosciences, San 
Diego, CA) were diluted 1:100 and 1:1,000, respectively, in phosphate-buffered 
saline plus 0.1% Tween-20 and slides incubated in a humid chamber for 1 hour at 
room temperature. Sections were incubated for 30 minutes at room temperature with 
the secondary antibody biotin labelled (Vector Laboratories; 1:200 in phosphate-
buffered saline). Slides were then labelled with streptavidin horseradish peroxidase 
conjugate (Vector Laboratories, Vectastain Elite ABC kit) for 30 minutes at room 
temperature and staining was performed by using Vector NovaRed and hematoxylin 
(counter stain). 
Acknowledgements 
We are grateful to Laura Gosoniu for support in statistical analysis and Fabrice 
Cognasse for help with TLR9 staining. This work was supported in part by the 
Stanley Thomas Johnson Foundation and the Swiss National Science Foundation to 
G.C.S. (3200B0-104060-1). 
 CHAPTER 3. Innate immune response in Buruli  ulcer 34               
References 
1. Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, Small PL (2005) 
Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host 
immune response and cellular location of M. ulceransin vitro and in vivo. Cell 
Microbiol 7:1295–1304 | Article | PubMed | ChemPort | 
2. Asiedu K, Scherpbier R, Raviglione M (2000) Buruli ulcer: Mycobacterium 
ulcerans infection. World Health Organisation. 
http://whqlibdoc.who.int/hq/2000/WHO_CDS_CPE_GBUI_2000.1.pdf 
3. Bangert C, Friedl J, Stary G, Stingl G, Kopp T (2003) Immunopathologic 
features of allergic contact dermatitis in humans: participation of plasmacytoid 
dendritic cells in the pathogenesis of the disease? J Invest Dermatol 
121:1409–1418 | Article | PubMed | ISI | ChemPort | 
4. Colonna M, Trinchieri G, Liu YJ (2004) Plasmacytoid dendritic cells in 
immunity. Nat Immunol 5:1219–1226 | Article | PubMed | ISI | ChemPort | 
5. Diehl S, Rincon M (2002) The two faces of IL-6 on Th1/Th2 differentiation. Mol 
Immunol 39:531–536 | Article | PubMed | ISI | ChemPort | 
6. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips R et al. 
(2005) Efficacy of the combination rifampin-streptomycin in preventing growth 
of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. 
Antimicrob Agents Chemother 49:3182–3186 | Article | PubMed | ChemPort | 
7. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C 
(2001) An overview of real-time quantitative PCR: applications to quantify 
cytokine gene expression. Methods 25:386–
401 | Article | PubMed | ChemPort | 
8. Gooding TM, Johnson PD, Campbell DE, Hayman JA, Hartland EL, Kemp AS 
et al. (2001) Immune response to infection with Mycobacterium ulcerans. 
Infect Immun 69:1704–1707 | Article | PubMed | ChemPort | 
9. Gooding TM, Johnson PD, Smith M, Kemp AS, Robins-Browne RM (2002) 
Cytokine profiles of patients infected with Mycobacterium ulcerans and 
unaffected household contacts. Infect Immun 70:5562–
5567 | Article | PubMed | ChemPort | 
10. Gooding TM, Kemp AS, Robins-Browne RM, Smith M, Johnson PD (2003) 
Acquired T-helper 1 lymphocyte anergy following infection with 
Mycobacteriumulcerans. Clin Infect Dis 36:1076–1077 | Article | PubMed | 
 CHAPTER 3. Innate immune response in Buruli  ulcer 35               
11. Guarner J, Bartlett J, Whitney EA, Raghunathan PL, Stienstra Y, Asamoa K et 
al. (2003) Histopathologic features of Mycobacterium ulcerans infection. 
Emerg Infect Dis 9:651–656 | PubMed | 
12. Hartwig D, Hartel C, Hennig H, Muller-Steinhardt M, Schlenke P, Kluter H 
(2002) Evidence for de novo synthesis of cytokines and chemokines in platelet 
concentrates. Vox Sang 82:182–190 | Article | PubMed | ChemPort | 
13. Hayman J (1993) Out of Africa: observations on the histopathology of 
Mycobacterium ulcerans infection. J Clin Pathol 46:5–9 | PubMed | ChemPort | 
14. Hayman J, McQueen A (1985) The pathology of Mycobacterium ulcerans 
infection. Pathology 17:594–600 | PubMed | ChemPort | 
15. Hernandez-Quintero M, Kuri-Harcuch W, Gonzalez RA, Castro-Munozledo F 
(2006) Interleukin-6 promotes human epidermal keratinocyte proliferation and 
keratin cytoskeleton reorganization in culture. Cell Tissue Res 325:77–
90 | Article | PubMed | ChemPort | 
16. Johnson PD, Stinear T, Small PL, Pluschke G, Merrit RW, Portaels F et al. 
(2005) Buruli ulcer (M. ulcerans infection): new insights, new hope for disease 
control. PLOS Med 2:282–286 | Article | 
17. Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA et al. 
(1999) Functional analysis of antigen-specific T lymphocytes by serial 
measurement of gene expression in peripheral blood mononuclear cells and 
tumor specimens. J Immunol 163:6867–6875 | PubMed | ISI | ChemPort | 
18. Kiszewski AE, Becerril E, Aguilar LD, Kader IT, Myers W, Portaels F et al. 
(2006) The local immune response in ulcerative lesions of Buruli disease. Clin 
Exp Immunol 143:445–451 | Article | PubMed | ChemPort | 
19. Kupper TS, Fuhlbrigge RC (2004) Immune surveillance in the skin: 
mechanisms and clinical consequences. Nat Rev Immunol 4:211–
222 | Article | PubMed | ISI | ChemPort | 
20. Lechmann M, Berchtold S, Hauber J, Steinkasserer A (2002) CD83 on 
dendritic cells: more than just a marker for maturation. Trends Immunol 
23:273–275 | Article | PubMed | ISI | ChemPort | 
21. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O et al. 
(2005) Plasmacytoid pre-dendritic cells initiate psoriasis through interferon-
alpha production. J Exp Med 202:135–
143 | Article | PubMed | ISI | ChemPort | 
 CHAPTER 3. Innate immune response in Buruli  ulcer 36               
22. Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, Filho AL et al. 
(2005) Infection with Mycobacterium ulcerans induces persistent inflammatory 
responses in mice. Infect Immun 73:6299–
6310 | Article | PubMed | ChemPort | 
23. Ottenhoff TH, Verreck FA, Hoeve MA (2005) Control of human host immunity 
to mycobacteria. Tuberculosis (Edinburg) 85:53–64 | ChemPort | 
24. Paquet P, Pierard GE (1996) Interleukin-6 and the skin. Int Arch Allergy 
Immunol 109:308–317 | PubMed | ISI | ChemPort | 
25. Phillips R, Horsfield C, Mangan J, Laing K, Etuaful S, Awuah P et al. (2006) 
Cytokine mRNA expression in Mycobacterium ulcerans-infected human skin 
and correlation with local inflammatory response. Infect Immun 74:2917–
2924 | Article | PubMed | ChemPort | 
26. Prevot G, Bourreau E, Pascalis H, Pradinaud R, Tanghe A, Huygen K et al. 
(2004) Differential production of systemic and intra-lesional gamma interferon 
and interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect 
Immun 72:958–965 | Article | PubMed | ChemPort | 
27. Razeghi P, Mukhopadhyay M, Myers TJ, Williams JN, Moravec CS, Frazier 
OH et al. (2001) Myocardial tumor necrosis factor-alpha expression does not 
correlate with clinical indices of heart failure in patients on left ventricular 
assist device support. Ann Thorac Surg 72:2044–
2050 | Article | PubMed | ChemPort | 
28. Rondini S, Horsfield C, Mensah-Quainoo E, Junghanss T, Lucas S, Pluschke 
G (2006) Contiguous spread of Mycobacterium ulcerans in Buruli ulcer lesions 
analysed by histopathology and real-time PCR quantification of mycobacterial 
DNA. J Pathol 208:119–128 | Article | PubMed | ChemPort | 
29. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, Brosch R et al. 
(2004) Giant plasmid-encoded polyketide synthases produce the macrolide 
toxin of Mycobacterium ulcerans. Proc Natl Acad Sci USA 101:1345–
1349 | Article | PubMed | ChemPort | 
30. Vermi W, Bonecchi R, Facchetti F, Bianchi D, Sozzani S, Festa S et al. (2003) 
Recruitment of immature plasmacytoid dendritic cells (plasmacytoid 
monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J 
Pathol 200:255–268 | Article | PubMed | ISI | 
 CHAPTER 3. Innate immune response in Buruli  ulcer 37               
31. Wollenberg A, Wagner M, Gunther S, Towarowski A, Tuma E, Moderer M et 
al. (2002) Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset 
with distinct role in inflammatory skin diseases. J Invest Dermatol 119:1096–
1102 | Article | PubMed | ISI | ChemPort | 
32. Yeboah-Manu D, Peduzzi E, Mensah-Quainoo E, Asante-Poku A, Ofori-Adjei 
D, Pluschke G et al. (2006) Systemic suppression of interferon-γ responses in 
Buruli ulcer patients resolves after surgical excision of the lesions caused by 
the extracellular pathogen Mycobacterium ulcerans. J Leukoc Biol 79:1150–
1156 | Article | PubMed | ChemPort | 
 
 
 
 CHAPTER 4. Reversal of immunosuppression in Buruli ulcer 39               
 
 
 
CHAPTER 4 
 
 
 
 
Development of Highly Organized Lymphoid Structures in 
Buruli Ulcer Lesions after Treatment with Rifampicin and 
Streptomycin 
 
 
Daniela Schütte 1, Alphonse Um-Boock 2, Ernestina Mensah-Quainoo 3, Peter Itin 4, 
Peter Schmid 5, Gerd Pluschke 1     
 
 
 
 
1
 Swiss Tropical Institute, Molecular Immunology, Basel, Switzerland 
2
 Leprosy Relief Emmaus-Switzerland (ALES) Cameroon, Yaounde, Cameroon 
3
 Ghana Health Service, Amasaman, Ghana 
4 University Hospital Basel, Department of Dermatology, Basel, Switzerland 
5
 Novartis Institutes of BioMedical Research, Basel, Switzerland 
 
 
 
 
 
 
 
 
This article has been published in: 
Public Library of Science Neglected Tropical Diseases 
 CHAPTER 4. Reversal of immunosuppression in Buruli ulcer 40               
Abstract  
 
Background: Buruli ulcer caused by Mycobacterium ulcerans is an infection of the 
subcutaneous tissue leading to chronic necrotising skin ulcers. The pathogenesis is 
associated with the cytocidal and immunosuppressive activities of a macrolide toxin. 
Histopathological hallmark of progressing disease is a poor inflammatory response 
despite of clusters of extracellular bacilli. While traditionally wide excision of the 
infected tissue was the standard treatment, provisional WHO guidelines now 
recommend an eight week pre-treatment with streptomycin and rifampicin.  
 
Methodology/ Principal Findings: We conducted a detailed immunohistochemical 
analysis of tissue samples from Buruli patients who received antibiotic treatment. 
Cellular immune response along with bacterial load and distribution were monitored. 
We demonstrate that this treatment leads to the development of highly organized 
cellular infiltration surrounding areas of coagulative necrosis. Diffuse infiltrates, 
granulomas and dense lymphocyte aggregation close to vessels were observed. 
Mycobacterial material was primarily located inside mononuclear phagocytes and 
microcolonies consisting of extracellular rod-shaped mycobacteria were no longer 
found. In observational studies some patients showed no clinical response to 
antibiotic treatment. Corresponding to that, one of five lesions analysed presented 
with huge clusters of rod-shaped bacilli but no signs of infiltration.  
 
Conclusions/ Significance: Results signify that eight weeks of antibiotic treatment 
reverses local immunosuppression and leads to an active inflammatory process in 
different compartments of the skin. Structured leukocyte infiltrates with unique 
signatures indicative for healing processes developed at the margins of the lesions. It 
remains to be analysed whether antibiotic resistance of certain strains of M. ulcerans, 
lacking patient compliance or poor drug quality are responsible for the absent clinical 
responses in some patients. In future, analysis of local immune responses could 
serve as a suitable surrogate marker for the efficacy of alternative treatment 
strategies.              
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Synopsis 
 
Buruli ulcer (BU) is a debilitating disease of the skin presenting with extensive tissue 
destruction and suppression of local host defence mechanisms. Surgical removal of 
the affected area has been the standard therapy until in 2004 WHO recommended 
eight weeks treatment with the anti-mycobacterial drugs rifampicin and streptomycin. 
We performed a detailed histological analysis of the local immune response in 
biopsies from five children medicated according to WHO provisional guidelines. One 
patient still revealed all histopathological signatures of an active BU lesion with huge 
bacterial clusters in areas of fatty tissue necrosis. Different factors can contribute to 
treatment failure like poor patient compliance and resistant bacterial strains. In four 
patients, different compartments of the skin presented active immune processes with 
only limited residues of bacterial material persisting. We demonstrated that antibiotic 
treatment not only directly controls the infectious agent but is also associated with 
fulminant host immune responses. Characterization of the healing process in BU due 
to therapy is highly relevant to increase our knowledge on the impact of treatment 
strategies to fight the disease.  
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Introduction 
 
Buruli ulcer (BU) caused by Mycobacterium ulcerans is a chronic necrotizing skin 
disease mainly affecting subcutaneous and adipose tissue [1,2]. The unique 
pathology of BU is primarily attributed to a plasmid-encoded macrolide toxin, 
mycolactone [3,4]. Mycolactone has cytopathic and apoptotic activity and is thought 
to be responsible for local immunosuppression by destroying infiltrating cells [3,5,6]. 
In animal models, injection of purified mycolactone causes lesions similar to those 
produced by wild type M. ulcerans bacteria [3,7].  
 
BU is considered to be the third most common mycobacterial infection after 
tuberculosis and leprosy. Clinical lesions usually start as painless subcutaneous 
nodules that may develop into plaques or oedema. If left untreated, extensive 
ulcerations with typical undermined edges of the dermis develop. Spontaneous 
healing can occur, often leaving the patient behind with extensive scarring, 
retractions and deformities [8-10]. BU has been reported in more than 30 countries 
worldwide, but rural communities in Western and Central Africa are the worst 
affected [2]. Areas endemic for BU are associated with stagnant or slow-flowing 
water bodies. The mode of transmission is not clear; both contamination of wounds 
from environmental reservoirs, such as bio films on aquatic vegetation [11] and 
infection through the bite of insect vectors [12-14] have been discussed.  
 
Until recently, surgery has been the only WHO recommended treatment for BU [15-
17]. Wide excision margins reaching into the healthy tissue are necessary to prevent 
recurrences [18] and often subsequent skin grafting is required. In most endemic 
areas access to surgery is very limited for the majority of BU patients. Moreover, the 
costs for treatment and prolonged hospital stays are often prohibitive. In 2004, WHO 
published provisional guidelines recommending treatment with a combination of 
rifampicin and streptomycin [19] based on results of a small randomised controlled 
clinical trial [20] and observational studies. While no antibiotic therapy has been 
formally proven effective in BU [17], there is evidence that treatment with a 
combination of rifampicin and streptomycin reduces recurrence rates and may help to 
avoid surgery or at least limit its extent [21]. More than 50% of BU cases are children 
below 15 years. Potential long-term side effects of streptomycin in this population 
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restrict the duration of the antibiotic treatment to eight weeks. If surgery is combined 
with antibiotic therapy, the aim is to use minimal surgery to excise necrotic tissue 
when antibiotics have arrested progress of the disease. For yet unknown reasons, a 
proportion of BU patients seem to be refractory for antibiotic treatment.  
 
Histopathological hallmarks of progressing BU are a poor inflammatory response and 
growing regions of necrosis of the dermal and adipose tissue eventually leading to 
the collapse of the overlying epidermis (Figure 1; A to D). Clusters of extracellular, 
mycolactone-producing acid-fast bacilli are usually located within these necrotic 
areas (Figure 1; E and F) [18,22-24]. Granulomatous responses in the dermis and 
panniculus have been described in late stages of BU [18,22,25]. Observations both in 
cell culture and rodents experimentally infected with mycolactone producing and 
mycolactone-negative M. ulcerans strains indicate that infiltrating cells are killed due 
to the cytotoxic and apoptosis inducing activity of mycolactone [5,26,27]. While M. 
ulcerans may be captured by phagocytes during different stages of infection, it 
appears to persist only transiently inside these host cells [6,28]. After killing of the 
phagocytes, extracellular growth leads to the development of extracellular bacterial 
foci in areas of coagulating necrosis [18,27]. The aim of the present study was to 
analyse whether the local immunosuppression in Buruli ulcer lesions can be reversed 
by the combination treatment with rifampicin and streptomycin and if intralesional 
cellular immune responses complement antibiotic therapy. 
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Materials and Methods 
 
Clinical specimens 
Surgical specimens from five patients aged between six and 11 years with ulcerative 
lesions were obtained from the Amasaman Health Centre in Ghana and the Ayos 
district hospital in Cameroon (Table S1; supplementary material). Lesions were not 
older than three months and located at the lower leg (four patients) or arm (one 
patient). Patients had received the currently recommended standard treatment 
comprising surgical excision of lesions after pre-treatment with a combination of 
rifampicin and streptomycin (WHO, 2004). Although no further ulcer enlargement and 
reduction of oedema were observed, the responsible clinicians had decided to treat 
all five patients surgically to remove necrotic tissue and facilitate wound healing. After 
receiving informed consent from the guardians of the patients, surgical specimens 
were used for laboratory reconfirmation of clinical diagnosis and for detailed 
immunohistochemical analysis. All five specimens were positive for at least two of 
three diagnostic tests applied (Buruli ulcer - Diagnosis of Mycobacterium ulcerans 
disease, WHO, 2001), IS2404 PCR, microscopic detection of acid-fast bacilli and 
observation of characteristic histopathological changes. After receiving informed 
consent the immunologically non responding patient was tested for HIV positivity. 
Ethical approval for analysing patient specimens was obtained from the ethical 
review board of the Noguchi Memorial Institute for Medical Research and the 
National Ethics Committee of Cameroon. 
 
 
Immunohistochemistry 
Immediately after surgery, specimens with a volume of about 0.5 cm3 were collected 
from different areas of the excised lesions to characterize the gradient of 
histopathological changes from necrotic areas to healthy appearing tissue at the 
excision margins (Figure S1; supplementary material). Tissue samples were fixed 
overnight in neutral buffered 4% paraformaldehyde, transferred to 70% ethanol, 
embedded in paraffin according to standard protocols and cut into 5 µm sections 
using a microtome. After deparaffinization sections were rehydrated through graded 
alcohols, endogenous peroxidase was blocked with 0.3% H2O2 for 20 min and 
unspecific binding prevented by incubating with blocking serum matching the 
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secondary antibody host (Table1). Antigen retrieval treatment was performed 
according to standard protocol (Dako®). After antigen retrieval antibodies (Table 1) 
were diluted in PBS containing 0.1% Tween-20 and slides incubated for 1 h at room 
temperature under rocking conditions. Afterwards sections were incubated for 30 min 
with a correspondent biotin-conjugated secondary antibody (Table 1) and for another 
30 min with streptavidin-horseradish peroxidase conjugate (VECTASTAIN® ABC Kit, 
Vector Laboratories). Staining was performed using Vector® NovaREDTM and 
haematoxylin (counterstain). Slides were subsequently mounted with Eukitt® 
mounting medium.  
Staining with Ziehl Neelsen (ZN) and Haematoxylin/ Eosin (HE) was performed on all 
collected tissue specimen. Staining for acid-fast bacteria was performed according to 
WHO standard protocol (WHO Diagnostic booklet). In brief, sections were 
deparaffinized and rehydrated followed by incubation with ZN carbolfuchsin for 30 
min at RT. Subsequently slides were washed in cool tap water for 5-10 min and 
individually differentiated with acid-alcohol. Counterstain was completed with 
haematoxylin and slides were mounted with Eukitt® mounting medium.  
Pictures taken with a Nikon optiphot-2 microscope were saved using analySIS® soft 
imaging system and processed with Adobe Photoshop® CS. 
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Results 
 
Lack of a marked inflammatory response and abundant clusters of extracellular 
bacilli in one of five antibiotic treated patients 
The excised lesion of one of the five antibiotic treated patients was almost devoid of 
cellular infiltrates. Only minor superficial vasculitis-associated infiltrates of the dermis 
consisting of lymphocytes and macrophages/ monocytes were found (Figure 2A). 
Extensive connective tissue necrosis and epidermal hyperplasia was observed 
(Figure 2A). The adipose regions displayed fat cell ghosts, extensive calcification and 
massive necrosis, associated with nearly complete absence of intact cell structures 
(Figure 2B; calcified areas stained purple). While the ulcerative centre of the lesion 
harboured numerous large clusters of rod-shaped extra-cellular acid fast bacilli 
(Figure 2C), margins contained only very few small bacterial microcolonies (not 
shown). A polyclonal antiserum, raised against M. leprae and highly cross-reactive 
with other mycobacteria, was used to stain M. ulcerans for confirmation of ZN 
staining results. Staining of common mycobacterial antigens with pAbLep antiserum 
and haematoxylin counterstain revealed an accumulation of mycobacteria (Figure 
2D; red-brown) close to fat cell ghosts and necrotic calcified tissue (purple). In-
between fat cell ghosts leukocytes exhibiting signs of defragmentation of nuclei and 
loss of cytoplasm were found only sporadically (Figure 2E). Taken together, features 
of this lesion resembled that of specimens from untreated patients (Figure 1) [18]. 
The patient was tested negative for HIV. 
 
 
Highly organized inflammatory responses and intracellular bacterial material in 
four of five antibiotic-treated patients 
In the other four patients massive cellular infiltration was observed. Three major 
types of mixed infiltrates, differing in cellular composition, architecture and 
localisation were found in all four specimens: (i) highly organized epithelioid 
granulomas of different size and state of differentiation, primarily located in deeper 
dermal tissue (Figure 3A); (ii) less organized diffuse infiltrates representing the most 
abundant type, present in all areas of the dermal connective and adipose tissue 
(Figure 3B); (iii) dense lymphocyte clusters in proximity to vessels, occasionally 
found in superficial connective tissue (Figure 3C). Cellular composition and 
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localisation of these structures along with the distribution of mycobacterial material 
are also schematically represented in Figure 3. 
 
Histopathological characteristics of BU were still found in all four patients. These 
included psoriasiform and pseudoepitheliomatous epidermal hyperplasia and 
depigmentation (Figure 4A) with exceeding proliferation of keratinocytes (Figure 4B). 
Additionally, extensive necrosis of adipose tissue resulted in the appearance of fat 
cell ghosts (Figure 4C). Cellular infiltration was generally more profuse in vicinity to 
the necrotic centre of a lesion and declined towards the excision margins. 
Granulomas were composed of foamy histiocytes and Langhans’ giant cells 
surrounded by lymphocytes and some plasma cells (Figure 4A). No central caseous 
necrosis was observed. In deeper adipose tissue dense infiltration with high 
proportions of macrophages and new blood vessel formation were observed (Figure 
4C). Occasionally signs for calcification of deep dermal tissue were present (not 
shown). Areas of necrotic connective tissue were encircled by large accumulations of 
leukocytes (Figure 4D). Some leukocytes exhibiting apoptotic features resided inside 
necrotic regions (Figure 4D). The periphery of lesions revealed focal superficial 
eosinophilia (Figure 4E).  
The distribution of mycobacterial material was assessed by ZN staining (Figure 5A - 
5D) and immunostaining with pAbLep antiserum (Figure 5E - 5G). Both staining 
methods were found to be equally sensitive when compared in serial sections (Figure 
5A and 5B vs. 5E and 5F). In all four patients mycobacterial material was 
predominantly found inside macrophages, although some was still located extra-
cellularly; both extra- and intracellular bacilli had lost their characteristic rod-shape 
appearance (Figure 5B and 5F). While the cytoplasm of macrophages frequently 
harboured numerous phagosomes containing mycobacterial material (Figure 5C), 
only a few Langhans’ giant cells with vacuoles containing ZN and serologically 
stainable material were located within granulomas (Figure 5D and 5G, respectively). 
The highest burden of mycobacterial material was found in deep dermal regions 
(Figure 5A and 5E) with a declining gradient from ulcerative areas towards the 
excision margins. Accumulations of mycobacterial material were primarily observed 
in areas of mixed cellular infiltration, but only very rarely in granulomas. Additionally, 
few residues of microcolonies were present in the upper dermal connective tissue or 
close to the epidermal basal layer (not shown).  
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Architecture of granulomas 
A panel of antibodies specific for leukocyte markers (Table 1) were used for 
immunohistochemical characterisation of infiltrates. Serial sections revealed that the 
outer layer of granulomas was mainly composed of CD3+ T lymphocytes (Figure 6A) 
with CD4+ T cells (Figure 6B) always outnumbering CD8+ T cells (Figure 6C). These 
lymphocyte belts were interspersed with S100+ dermal dendrocytes (dDCs) (Figure 
6D). Occasionally dDCs were present in the centre of granulomas (not shown). Focal 
clusters of CD20+ B cells appeared at the outer margins of the T lymphocyte layer 
(Figure 6E). Cytoplasmic CD68+ antigen-presenting cells (APCs) in particular 
Langhans’ giant cells (Figure 6Finsert) and epithelioid macrophages formed the centre 
of granulomas (Figure 6F). Staining of the membrane protein CD14 confirmed the 
macrophage/monocyte origin of giant cells (Figure 6G, arrow). Furthermore, large 
amounts of soluble CD14 were observed within the belt of T lymphocytes (Figure 6G, 
arrowhead). A great proportion of lymphocytes turned out to be activated as 
evidenced by their CD45RO+ phenotype (Figure 6H). Variable numbers of Ki67+ 
(proliferating) cells (Figure 6I) presented a lymphocyte phenotype (Figure 6Iinsert). 
Neither elastase+ polymorphonuclear neutrophilic leucocytes (PMNL) nor CD56+ 
natural killer (NK) cells could be detected in granuloma formations. 
 
Cellular composition of diffuse mixed infiltrates 
In contrast to granulomas, regions of diffuse cellular infiltration contained sparsely 
distributed elastase+ PMNL (Figure 7A) with sporadic focal clusters near ulcerative 
and necrotic areas (not shown). CD56+ NK cells showed a similar distribution with 
even lower cell counts (not shown). Foci of PMNL and NK cells with signs of 
apoptosis were located within necrotic tissue (Figure 7Ainsert and 7B, respectively). 
CD3+ T lymphocyte (Figure 7C) and foamy histiocytes (not shown) were the most 
prominent cell types of mixed infiltrates in the dermal connective tissue. The 
CD4+/CD8+ cell ratio varied widely between different regions of a lesion, but usually 
CD8+ cells were more abundant than CD4+ cells (not shown). Small clusters of 
CD20+ B lymphocytes were scattered within infiltrates (Figure 7D). Counts of CD14+ 
macrophages/monocytes were particularly high in adipose tissue and around necrotic 
areas (Figure 7E). Additionally, vast amounts of sCD14 shed from those cells were 
revealed (Figure 7Einsert). Dendritic cells could be detected in both epidermis and 
dermis. The frequency of epidermal CD1a+ Langerhans cells was strongly elevated 
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(Figure 7F). S100+ dDC were distributed throughout diffuse mixed infiltrates with 
increasing density towards the margins of necrotic areas (Figure 7G). Remarkably, 
dendritic cell appendices reached into the damaged tissue (Figure 7H). Similar to the 
findings in granulomas, a large proportion of lymphocytes stained positive for the 
activation marker CD45RO (Figure 7I) and proliferating Ki67+ cells were scattered 
throughout the infiltrate (Figure 7J). 
 
Aggregates of lymphocytes resembling follicular structures  
Adjacent to lymphatics or blood-vessels a third type of infiltration was found, i.e. 
follicle-like structures with dense aggregations of lymphocytes (Figure 8A). CD20+ B 
lymphocytes were the dominating cell type (Figure 8B) followed by CD3+ T 
lymphocytes (Figure 8C). Here CD4+ T cells (Figure 8D) were more frequent than 
CD8+ T cells (Figure 8E). Additionally, few CD68+ APCs (Figure 8F) and S100+ dDCs 
(Figure 8H) were scattered throughout the aggregate. Similar to the other two 
infiltration types, a large proportion of lymphocytes stained positive for the activation 
marker CD45RO (Figure 8G). Single proliferating Ki67+ cells were evenly distributed 
(Figure 8I) and sporadically hyper-proliferative clusters were encountered (Figure 8I
 
insert). 
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Discussion 
 
It has been demonstrated recently that treatment with a combination of rifampicin and 
streptomycin inhibits the growth of M. ulcerans in pre-ulcerative BU lesions [19]. 
Furthermore, observational studies [21] indicate that at least in some of the BU 
patients antibiotic therapy may reduce the extent of or even circumvent the indication 
for surgery. Here we present results of a detailed immunohistological analysis of 
ulcerative BU lesions from patients treated with rifampicin/streptomycin prior to 
surgery. Findings were compared to those obtained from lesions of patients that have 
been treated merely with wide-ranging surgical excision (Figure 1) according to 
former WHO treatment guidelines [1,18]. To our knowledge this is the first detailed 
immunohistological description of the effect of antibiotic treatment on BU lesions.  
Presentation of the affected tissue of four of the five antibiotic treated patients was 
strikingly different from that of untreated patients, in that immense leukocyte 
infiltrates and the formation of new vessels were observed. These findings reconfirm 
results of Etuaful et al., who observed an induction of chronic inflammation and 
granulomas in pre-ulcerative lesions by antibiotic treatment [19]. Our detailed 
analysis regarding composition and architecture of cellular infiltrates is indicative for 
the development of highly organized tertiary lymphoid tissue. Islands of infiltration 
and scattered granulomas may also develop in untreated late stage lesions 
[18,22,25]. However, infiltration in the patients at hand was much more substantial, 
resembling histopathological patterns observed in conditions such as 
dermatoborreliosis, where lymphoid neogenesis is reported [29]. We found three 
different types of infiltration in all four responding patients (Figure 3): granulomas, 
diffuse mixed infiltrates and dense lymphocyte aggregations in the vicinity to vessels. 
We assume that this clear structural differentiation reflects a range of different 
functional activities required for complete clearance of infection and resorption of 
necrotic tissue. 
In regions of diffuse infiltration, in particular close to areas of necrosis, outstandingly 
large amounts of both membrane-bound and soluble CD14 were found. Consistent 
with this, it has been reported that the development of highly organized structures, 
such as granulomas, is not required for the resorption of destroyed tissue [30]. CD14 
mediated clearance of necrotic tissue is usually not associated with an increased 
expression of inflammatory cytokines [30], which is in line with the observed lack of 
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major inflammatory symptoms in the enrolled patients. Necrotic regions were 
surrounded by a substantial quantity of dDCs and their appendices reached into the 
damaged tissue, indicating enhanced antigen uptake and presentation. Moreover, 
elevated numbers of Langerhans cells were distributed throughout the epidermis, like 
it has been described for tuberculoid and borderline leprosy [31]. A large proportion 
of lymphocytes were expressing activation and proliferation markers. Taken together, 
these observations reveal that adaptive immune responses are taking place 
autonomously.  
While in human tuberculosis granulomas develop a central necrotic core [32], this 
was not observed in the lesions of the antibiotic treated BU patients. Here, the centre 
was mainly formed of foamy histiocytes and Langhans’ giant cells, like reported for 
leprosy [33], and mycobacterial material was only infrequently detected. In leprosy, 
cells of the lymphocyte belt are less tightly packed [34] than in tuberculosis [35], a 
feature we also observed in BU lesions. Thus, BU granulomas may function primarily 
as a place for antigen presentation and adaptive immune response rather than for 
sequestration of the mycobacteria.  
In diffuse infiltrates the CD8/CD4 T lymphocyte ratio was higher than in granulomas. 
Otherwise, the cellular composition of both types of infiltration was largely the same. 
Small islets of Langhans’ giant cells inside the diffuse infiltrates support the 
hypothesis that granulomas represent a more advanced state of the initially 
unorganized infiltrations. In contrast, the dense lymphocyte aggregations we 
observed in vicinity to vessels were of a markedly different cellular composition. Here 
B lymphocytes represented the most dominant cell type in contrast to granulomas or 
unorganized infiltrates, where small B cell clusters were distributed more sparsely. B 
and T lymphocytes were packed in a notably dense manner, with interspersed dDCs 
and APCs and no central core, a composition characteristic also for secondary 
lymphoid organs. Similar structures have also been reported by Ulrichs et al in lung 
tissue from tuberculosis patients [35]. Many lymphocytes were in the activated state 
as demonstrated by CD45RO staining and a substantial proportion displayed the 
proliferation marker Ki67. It has been suggested that these cell aggregations 
represent active centres, which orchestrate the local host defence [35]. It is not clear, 
which factors play a crucial role in the development of ectopic lymphoid tissue 
induced via antibiotic treatment. Plasmacytoid and myeloid dendritic cells present in 
BU lesions prior to antibiotic treatment [36] may play an important role in this 
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process. Lymphangiogenesis and participation of lymphoid tissue-inducer cells may 
represent hallmarks in the process of lymphoid neogenesis [29]. Although tertiary 
lymphoid organs seem to develop in infectious diseases to sequester pathogens, this 
process is often accompanied by tissue damage [29]. Anecdotal reports on the 
emergence of new ulcerations in the course of antibiotic treatment of BU, probably at 
sites containing unrecognized infection foci, may be a hint into this direction. It 
remains to be analysed whether in some cases antibiotic treatment may even 
accelerate the progression of early plaques and oedemas to ulcerative lesions. 
In animal infection models neither wild type nor mycolactone negative M. ulcerans 
strains were strong neutrophilic attractants [6], although other studies reported 
substantial neutrophilic infiltrates in early stage infections [28]. Infiltrates in patients 
treated with antibiotics contained only very low levels of neutrophilic leukocytes. In 
contrast, large numbers of apoptotic cells positive for the neutrophilic leukocyte 
marker elastase and the NK cell marker CD56 were present within necrotic regions. 
Findings with an experimental M. ulcerans mouse infection model [27] indicate that 
these apoptotic cells represent the residues of an early acute defence line. Our data 
show for the first time that cells of this early defence are destroyed together with the 
surrounding tissue, if a substantial infection focus develops. It is most likely that the 
generalized cytotoxic activity of mycolactone is the all-dominant factor.  
Lesions of all four responders still harboured mycobacterial material as revealed by 
ZN and immunohistochemical staining. However microcolonies consisting of 
extracellular [9,22] or intracellular [37] rod-shaped mycobacterial cells were no longer 
found. Stainable mycobacterial material had lost the characteristic shape and was 
primarily located inside mononuclear phagocytes, but was also present in small 
extracellular foci. These data indicate a killing or debilitation of the bacteria in the 
course of antibiotic treatment. Moreover, antigen uptake and presentation via 
macrophages and dendritic cells may be enhanced due to lower levels of 
mycolactone. While bacterial residues were abundant in regions of diffuse infiltration 
of the deeper dermis and in adipose tissue, granulomas were largely devoid of it. 
Only single Langhans’ giant cells contained vacuoles filled with stainable residues of 
the mycobacterial cells. A similar pattern may be found in active pulmonary 
tuberculosis [35,38]. Again, these findings support the theory that granulomas serve 
as a place for antigen encounter.  
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The density of stainable mycobacterial material increased from the outer margins of 
lesions towards the ulcerative centre, which is consistent with the distribution of 
mycobacterial DNA in untreated lesions [18,39]. Moreover, our results demonstrate 
that after antibiotic treatment the mycobacteria are directly taken up by phagocytes at 
the original focus of infection without granuloma formation. M. ulcerans is able to 
destroy phagocytes after transient intracellular growth via the release of mycolactone 
[6,28]. We think that the stainable intracellular mycobacterial material represents the 
remains of phagocytosed dead bacilli or of cells severely impaired in mycolactone 
production due to the antibiotic treatment. In general it is most likely, that a 
pronounced reduction of the concentration of mycolactone in the lesion is a 
prerequisite for the observed reversal of the local immunosuppression. Due to the 
lack of quantitative detection methods for mycolactone, for the time being this aspect 
cannot be studied.  
The BU lesion of one antibiotic-treated patient displayed histopathological features 
similar to active lesions of patients not receiving antibiotic treatment. Only minor 
leukocyte infiltration was found and huge clusters of extracellular mycobacteria were 
located beneath the ulcerative centre. Observational studies indicate that in a certain 
proportion of patients, rifampicin/streptomycin treatment has no clinical curative 
effect. Acquired or inherited host factors, like deficiencies in the IFN-ү and IL-12 
pathways for macrophage activation [40,41], may play a role. Alternatively, antibiotic 
resistance of certain lineages of M. ulcerans could be responsible for this lack of 
response. Therefore major efforts should be made to generate M. ulcerans isolates 
from these patients for susceptibility testing. Another factor to be considered is poor 
patient compliance. Rifampicin is administered once per day orally and the intake of 
tablets may not be monitored. Furthermore, outdated drugs and poorly prepared 
solutions can be possible reasons for treatment failure and clearly need to be taken 
into consideration.   
In summary, we conclude that treatment of BU with rifampicin/streptomycin is 
accompanied by a reversion of the local immunosuppression. The synergistic anti-
mycobacterial action of antibiotics and immune defence mechanisms may be 
required to clear the infection efficiently. In view of these results, it may be suitable to 
replace streptomycin already after a few weeks by a bacteriostatic antibiotic. 
Recently published data of our group indicate that not everyone exposed to M. 
ulcerans develops clinical disease [42]. After exposure a race between front line 
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immune responses and mycobacterial multiplication seems to decide whether a 
chronic infection focus is established or not. Once a bacterial cluster is large enough 
to develop a cytocidal cloud of mycolactone around itself, necrotic areas with only 
minor infiltration develop [18,22-25,43], which is in stark contrast to the vigorous 
immune responses we describe in the present study. We infer that a complex and 
highly organized cellular immune response is crucial for elimination of a chronic M. 
ulcerans infection. Efficient triggering of local immune responses may thus represent 
a suitable auxiliary marker for the efficacy of alternative treatment strategies.  
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Nonstandard abbreviations 
APC  antigen presenting cell 
BU  Buruli ulcer 
dDC  dermal dendritic cell  
HE  haematoxylin/ eosin 
pAbLep polyclonal anti-leprae antibody  
PMNL  polymorphonuclear neutrophilic leukocytes 
ZN  Ziehl Neelsen  
 
 CHAPTER 4. Reversal of immunosuppression in Buruli ulcer 55               
 
Figures 
 
Table1. Antibodies used for immunohistochemistry 
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Figure1. Histopathological characteristics associated with untreated Buruli 
ulcer lesions 
Histological sections of specimen from untreated Buruli ulcer lesions stained with HE 
(A to D) and ZN (E, F), respectively. Photographs are taken at magnification x40 (A, 
B, E), x100 (C, D) or x1000 (F). (A) Vasculitis associated minor leukocyte infiltration 
around vessels with intact dermal connective tissue and epidermal hyperplasia. (B)  
Extensive areas of necrosis in the deeper dermis and large fat cell ghosts with slight 
leukocyte infiltrates. (C) Slight cellular infiltration mainly composed of PMNL. (D) 
Ongoing necrotic/ apoptotic processes surrounding a focus of mycobacterial 
microcolonies. (E) Typical clusters of extracellular bacteria between adipose cell 
ghosts. (F) Sometimes also single bacilli can be spotted inside necrotic regions. 
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Figure2. One patient exhibits strong histopathological signs for a progressive 
Buruli ulcer and large mycobacterial clumps  
Histological sections of the non-responding patient stained with HE (A, B, D) and ZN 
(C) or polyclonal anti-leprae antibody (pAbLep; E). Magnification x40 (A, B, C, E) and 
x100 (D). (A) Tissue shows typical signs of advanced Buruli ulcer as deep dermal 
necrosis, calcification or epidermal hyperplasia. Leucocytes are found in rare cases 
around vessels and hardly ever between fat ghosts. (B) Adipose tissue and its 
surroundings are highly necrotic and happen to accumulate fat ghosts and 
calcification. (C) The centre of the necrotic lesion harbours tremendous clumps of 
rod-shaped mycobacteria. (D) Staining with pAbLep demonstrates the focal clusters 
of live bacteria in the necrotic core. (E) If cellular infiltration occurs in small amounts 
within some parts of the intradermal adipose tissue cells display apoptotic features. 
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Figure3. Three major types of cellular infiltration can be distinguished in 
antibiotic treated BU patients 
Upper part: Schematic overview of cellular infiltration patterns and distribution of 
mycobacterial material. Lower part: Three types of cellular infiltration are documented 
with HE. (A) Granuloma formation in the connective tissue; magnification x40. (B) 
Diffuse heterogeneous cellular infiltration of the connective and adipose tissue; 
magnification x100. (C) Follicle-like lymphocyte focus adjacent to vessels; 
magnification x40. 
 
 CHAPTER 4. Reversal of immunosuppression in Buruli ulcer 59               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure4. Histopathology of four patients in response to rifampicin/ 
streptomycin bi-therapy 
Histological sections representative for four patients stained with HE (A, C, D, E) and 
polyclonal antibody against proliferation marker Ki67 (B). Magnification x40 (A, C, E) 
and x100 (B, E). (A) Psoriatic epidermal hyperplasia typically seen in Buruli. Diffuse 
mixed cellular infiltrates in upper and granuloma formation with Langhans’ giant cells 
lymphocytes in deeper dermis. (B) Ki67 staining reveals elevated proliferation levels 
of keratinocytes in epidermal basal layer. (C) Cell ghosts of the adipose tissue 
characteristic for Buruli infection. Massive mixed cellular infiltrates between fat ghosts 
mainly consisting of macrophages/ monocytes and formation of new blood vessels. 
(D) Necrotic area in deep tissue encircled by extensive cellular infiltrates. (E) Focal 
eosinophilia found at margins of the excised area distant to ulcerative centre. 
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Figure5. Bacterial load and distribution in four patients 
Histological sections representative for four patients stained with ZN (A to D) and 
polyclonal anti-leprae antibody (pAbLep; E to G) to demonstrate distribution of 
mycobacterial material in the excised lesion. Counterstain was performed with 
haematoxylin and pictures taken at magnifications of x100 (A, E), x200 (G), x400 (B, 
F) and x1000 (C, D). (A, E) Serial sections demonstrate equal detection sensitivity 
with ZN and pAbLep. Higher amounts of bacterial material near the ulcerative edges 
with macrophages being the most prevalent leucocytes. (B, F) Close-up of A and E, 
respectively. Foci of rounded bacteria located extra- and intracellular between fat 
ghosts. (C) Macrophage presenting with mycobacterial material within phagosomal 
vesicles. (D) Mycobacterial residues appear in rare cases inside Langhans’ giant cell 
phagosomal vacuoles. (G) Small granuloma with giant cell formation and traces of 
mycobacteria inside a phagosome. 
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Figure6. Detailed organization of granulomas 
Histological serial sections representative for four patients were stained with 
antibodies against different cellular surface or cytoplasmic markers (counterstain 
haematoxylin). Magnification x40 (I), x100 (A, B, C, E, F, G, H, Iinsert), x200 (D) and 
x400 (Finsert). (A, B, C) Staining with CD3, CD4 and CD8, respectively, reveals a belt 
of helper as well as cytotoxic T lymphocytes surrounding the APC core. (D) S100+ 
dermal dendrocytes (dDC) spread among T lymphocytes in the outer layer of a 
granuloma. (E) Focus of CD20+ B lymphocytes at the border of a granuloma. (F) 
CD68+ APC in the centre of a representative granuloma; insert shows large 
Langhans’ giant cell. (G) Remarkable large amounts of membrane bound (arrow) and 
soluble (arrowhead) CD14 can be observed. (H) Distribution of activated CD45RO+ 
lymphocytes. (I) Proliferating Ki67+ cells indicate the active status of granulomas.  
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Figure7. Composite of mixed cellular infiltrates 
Histological sections representative for four patients stained with antibodies against 
different cellular markers (counterstain haematoxylin). Magnifications at x40 (A, E, 
G), x100 (C, D, F, I, J), x200 (Ainsert, B, H) or x1000 (Einsert). (A) Only few scattered 
PMNL staining positive for Elastase were found within cellular infiltrates. (Ainsert, B) 
Neutrophilic and NK cell (CD56+) foci inside necrotic areas display signs of advanced 
apoptosis. (C) Lymphocytes mainly expose a CD3+ phenotype. (D) Small focal 
CD20+ lymphocyte spots are scattered through infiltrates. (E) Staining against CD14 
illustrates large numbers of histiocytes enclosing necrotic tissue shedding massive 
amounts of sCD14 (insert). (F) Levels of epidermal CD1a+ Langerhans cells are 
remarkably elevated compared to healthy skin. (G) Aggregation of S100+ dDCs near 
necrotic spots. (H) Elongated cellular appendices of dDCs reach into the necrotic 
tissue. (I) Large numbers of lymphocytes are CD45RO+. (J) Same area as in (I). 
Proliferating lymphocytes are highly Ki67+. 
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Figure8. Follicle-like lymphocyte foci reveal organized cellular formation 
Serial sections of a representative lymphocyte focus stained with HE (A; 
magnification x40) or with antibodies against different cellular markers and 
haematoxylin as counterstain (B to I; magnification x100). (A) Large aggregate of 
lymphocytes in the upper dermal layer between two venules. Square marks area of 
magnification chosen for pictures B to I. (B) CD20+ B lymphocytes build the most 
abundant cell subset. (C, D, E) Staining against CD3, CD4 and CD8, respectively, 
exposes also high loads of T lymphocytes with T helper clearly being more prevalent 
than cytotoxic T cells. (F) APCs (CD68+) are scattered throughout the entire 
structure. (G) Activated lymphocytes appear positive for CD45RO staining. (H) 
S100+ dermal dendrocytes (dDC) lie in between lymphocytes. (I) Ki67 staining 
demonstrates certain proliferation of cells and occasional appearance of discrete 
spots of hyperproliferation (insert). 
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Supporting information 
 
 
FigureS1. Sampling of tissue for immunohistochemistry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TableS1. Main data of enrolled patients 
 
Patient  age sex location of lesion 
1  6 years m right leg (above ankle) 
2  7 years m right leg (backside) 
3  7 years m left leg (around ankle) 
4  8 years m right arm (ellbow) 
5 11 years f right leg (thigh) 
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Abstract 
 
Background: Infection with Mycobacterium ulcerans involves devastating skin 
disease called Buruli ulcer (BU). Currently, dual therapy with rifampicin and 
streptomycin (R/S) for eight weeks as well as surgery are the standard treatments.  
 
Objectives: To elucidate the processes taking place in Buruli ulcer lesions in the 
course of chemotherapy we performed an in-depth histological analysis of lesions 
after four weeks of rifampicin and streptomycin (R/S) treatment. Results are 
compared to findings in untreated and eight weeks treated lesions, respectively. 
 
Patients/Methods: Tissue specimens were collected from patients without, after four 
and eight weeks of R/S treatment, respectively. Main features evaluated were local 
immune responses, histopathological alterations and bacterial distribution. 
 
Results: After four weeks of R/S treatment we observed a large proportion of 
mycobacteria inside macrophages, occasionally forming globus-like aggregations. 
While distinct bands of inflammatory leukocytes surrounded the necrotic core in an 
ulcer and early granuloma formation was apparent in the healthy appearing margins, 
acute cellular infiltration covering the whole lesion had developed in a nodular lesion. 
In contrast, ulcerative lesions after eight weeks of chemotherapy show intra- and 
extracellular bacterial debris as well as the extensive presence of chronic infiltrates 
forming huge granulomas.  
 
Conclusions: R/S treatment of BU results in a rapid onset of local cellular immune 
responses associated with phagocytosis of the extracellular M. ulcerans. This might 
be related to declining levels of the macrolide toxin mycolactone in the tissue thus 
leading to an enhanced chemotherapy-induced clearance of the infection. 
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Introduction 
 
Buruli ulcer (BU) is a chronic infectious skin disease caused by Mycobacterium 
ulcerans which may produce pronounced deformities and disabilities when left 
untreated. M. ulcerans causes necrotizing lesions due to the release of a diffusible 
macrolide toxin with cytotoxic properties named mycolactone 1-3. Although it can 
affect humans of any age group, a large proportion of patients are children below the 
age of 15 4. There are increasing case-numbers mainly in rural areas of Western 
Africa associated with swamps and slow flowing or stagnant water bodies 5-7, yet the 
mode(s) of transmission along with the reservoir(s) of this disease remain unknown. 
 
Initially BU appears as a mobile subcutaneous nodule, a papule or a raised plaque. 
These develop either into slowly enlarging necrotic ulcers, or rapidly progressing 
oedema sometimes affecting a whole limb. The initial prolonged stages of BU lesions 
can be almost painless and patients do not show signs of systemic infection such as 
fever or malaise 8. At later stages, lesions may heal on their own accord yet are often 
accompanied by contracting scars and ankylosis 9.  
 
Surgical treatment without extended excision into healthy appearing surrounding 
tissue is associated with relapse rates of up to 47% 10-12. In addition, access to health 
care facilities is limited due to the remote nature of most BU endemic areas, and 
treatment is often both lengthy and expensive 9. Since 2004, chemotherapy for eight 
weeks with a combination of rifampicin and streptomycin is recommended by WHO 
13
. Small and/or nodular lesions seem to be curable with low relapse rates, but 
additional surgery and/or skin graft are often needed for larger ulcerative lesions 14,15.  
Inhibition of cellular immune responses in the infected skin 16-18 seems to be a result 
of mycolactone production 1,3,19,20. However, especially in late stage Buruli ulcer, local 
cellular infiltration and cytokine production may occur  21-24. 
 
We recently described the development of ectopic lymphatic tissue in BU lesions 
after eight weeks of R/S treatment 25. Microcolonies of extracellular rod-shaped bacilli 
were no longer observed and only focal, most often intracellular, mycobacterial 
residues were revealed. Furthermore, in 2005 Etuaful et al could demonstrate that 
four weeks of chemotherapy render both in vivo and in vitro cultures negative 26. 
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Here we present results of a histological analysis of skin specimens obtained from 
two patients (one nodule and one ulcer) who had been treated with R/S during four 
weeks. Histopathological pattern, cellular immune responses and localisation of acid 
fast bacilli (AFB) are compared to commonly observed features in untreated as well 
as eight weeks antibiotically treated lesions.  
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Materials and Methods 
 
Study population and sampling 
In total, four patients with clinical diagnosis of BU were recruited in Ayos, Cameroon. 
Two controls were included as representative cases for histopathological alterations 
in (i) untreated lesions and (ii) eight weeks antibiotically treated ulcers, respectively. 
The first control was a 45 year old woman with a nodule and a small ulcer on the left 
calf, both which were excised before the start of antibiotic therapy based on the 
decision made by the local surgeon. The second control was a seven year old boy 
with an ulcer on his left foot who underwent surgery in order to prepare the area for 
skin grafting after the full course of eight weeks R/S. 
The third patient, a 13 year old boy, presented a nodule of about 3,5 cm in diameter 
near his right eye with oedematous swelling of the surrounding area. The fourth 
patient was a 14 year old boy with an early ulcer on his left arm right above the 
elbow. His lesion changed from nodule to ulcer three weeks before treatment was 
commenced and the ulceration was <2cm in diameter. Antibiotic treatment with daily 
administration of streptomycin (15 mg/kg i.m.) and rifampicin (10 mg/kg orally) was 
started immediately and, due to the critical location, surgery performed after (iii) four 
weeks. Afterwards, both patients completed the full eight weeks course of 
chemotherapy.  
Clinical diagnosis was confirmed by Ziehl Neelsen (ZN) staining for acid fast bacilli, 
histopathology and/or standard IS2404 real-time PCR. Ethical clearance was 
obtained from the National Ethics Committee in Yaoundé, Cameroon.  
Tissue samples were obtained as previously described 25, fixed in neutral buffered 
4% paraformaldehyde, embedded in paraffin and sectioned using a HM 335 E rotary 
microtome (MICROM International GmbH). 
 
Staining procedures and section analysis 
Immunohistochemistry (IHC) was performed as described in a previous study 25. In 
brief, sections were deparaffinized and rehydrated, endogenous peroxidase was 
blocked with H2O2 and unspecific binding prevented by incubating with blocking 
sera. Subsequently slides were pre-treated with the adequate antigen retrieval 
method and incubated at room temperature with (i) monoclonal antibodies against 
CD1a (Beckman Coulter), CD56 (Lab Vision), neutrophilic elastase, CD45RO and 
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CD68 (all Dako), CD4, CD8, CD14 and CD20 (all Novocastra) or (ii) polyclonal 
antibodies against S100 and Ki67 (both Dako) and mycobacterial antigens (Colorado 
State University, CO, USA; pAbLep). Afterwards sections were incubated with the 
secondary biotinylated antibody and labelled with streptavidin horseradish 
peroxidase conjugate (both Vector Laboratories). Staining was performed by 
applying Vector NovaRed (Vector Laboratories) and haematoxylin (Sigma). 
Immunofluorescent labelling was achieved using secondary antibodies conjugated 
with Alexa 488 and 568 (Invitrogen), respectively, and 4',6-Diamidino-2-phenylindo 
(DAPI) counterstaining. Slides were mounted with Eukitt® mounting medium. 
HE and ZN staining were performed according to standard protocols. Pictures were 
taken with a Leica® DM5000B microscope equipped with a Leica® DFC300FX® 
camera. Images were saved using Leica® Application Suite and processed with 
Adobe Photoshop® CS. Whole section analysis was performed at different 
magnifications of all samples taken and representative areas were chosen for figure 
preparation. All data about infiltrating cells relate to the necrotic lesions core and its 
immediate surroundings (max. 1 cm). The healthy appearing margins of most 
untreated ulcerative lesions contain cellular infiltrates. The same holds true for late 
pre-ulcerative lesions though at lower rates 17,22. 
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Results 
 
Histopathological features of (i) untreated and (ii) eight weeks antibiotically 
treated Buruli ulcer lesions from representative areas of typical lesions 
 
(i) The nodular lesion excised without R/S treatment showed typical histopathological 
features of an untreated nodule, i.e. a necrotic focus with fat cell ghosts (Fig. 1-A) 
and minor focal acute infiltration of the connective and adipose tissue (Fig. 1-B). 
Foamy Touton giant cells were found surrounding degrading adipose cells (Fig. 1-B; 
arrows). Furthermore, abundant bacterial clusters were located in the necrotic 
connective and adipose tissue (Fig. 1-C) and the cytotoxic activity of mycolactone 
reached beyond the mycobacterial load (Fig. 1-D). Bacterial clusters and even single 
scattered bacteria had no contact to intact leukocytes (Fig. 1-E). 
In the same patient a further early ulcerative lesion, the more advanced stage of BU, 
was detected showing extensive necrosis with decomposing leukocytes and 
erythrocytes (Fig. 1-F). At the borders of the central necrotic area a more substantial 
acute infiltration as well as large haemorrhages were noted (Fig. 1-G). Compared to 
the nodule, the untreated ulcerative lesion revealed a very high bacterial load inside 
a huge necrotic compartment (Fig. 1-H). Some acute leukocyte infiltration, located at 
the circumference of the bacterial distribution (Fig. 1-I) was noticed being in close 
contact with extracellular mycobacteria and exhibited apoptotic signs such as 
nucleus defragmentation (Fig. 1-J).  
(ii) In contrast, a patient who underwent eight weeks of R/S therapy showed diffuse 
mixed chronic leukocyte infiltrates in an early ulcer, which appeared to cover the 
necrotic area (Fig. 1-K) and fully developed granulomas were present towards the 
lesion margins (Fig. 1-L). Only ZN stainable bacterial debris was identified (Fig. 1-M), 
most of it located encased in macrophages (Fig. 1-N) which was confirmed by 
immunohistochemical staining of mycobacterial antigens (Fig. 1-O).  
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Histopathology seen in two lesions after (iii) four weeks of R/S treatment 
 
Emergence of intracellular bacilli both in a nodular and an ulcerative lesion 
After four weeks of R/S treatment a strong generalized infiltration and prominent 
angiogenesis was observed in a nodular lesion (Fig. 2-A). Polymorphonuclear 
neutrophils (PMNs) and macrophages were the main cellular population of the acute 
infiltrate throughout the entire lesion (Fig. 2-B). In the upper dermis prominent 
clusters of eosinophils were revealed (Fig. 2-C). A high power image displayed 
enlarged macrophages with phagocytosed material (Fig. 2-D). M. ulcerans were 
distributed over the whole lesion sometimes as small extracellular clusters, but 
mostly internalized by phagocytes (Fig. 2-E; arrows). Moreover, some macrophages 
engulfed exceptionally large numbers of bacilli until the whole cytoplasm was densely 
packed, appearing as globi-like structures (Fig. 2-E; arrowhead). Macrophages could 
be observed while establishing close contact between their cell membrane and single 
bacteria (Fig. 2-F) and phagocytosing them (Fig. 2-G), respectively. At higher 
magnification, phagosomes containing densely packed rods could easily be spotted 
inside these macrophages (Fig. 2-H). 
In an early ulcerative lesion, four weeks antibiotic therapy led to the development of 
immense cellular infiltration surrounding the core necrosis (Fig. 2-I). Adjacent to the 
necrosis, the infiltrate consisted mainly of PMNs and macrophages (Fig. 2-J) 
whereas infiltration further away displayed a chronic pattern with lymphocytes and 
some Langhans’ giant cells (Fig. 2-K). Formation of granulomatous structures was 
identified towards the excision margins (Fig. 2-L) sometimes containing foci of 
eosinophils (Fig. 2-M). Numerous huge bacterial clusters remained inside the 
completely destroyed tissue (Fig. 2-N). PMNs were found invading this area in vast 
numbers and encountering some of the bacterial foci (Fig. 2-O). Bacilli appeared still 
rod-shaped and the great majority were found to be extracellular (Fig. 2-P), 
nevertheless phagocytes comprising internalized bacteria could also be detected in 
distance to the main bacterial burden (Fig. 2-Q). 
In the four weeks treated nodule, numerous CD68+ antigen presenting cells, mostly 
revealing macrophage morphology, carried phagosomes with mycobacterial material 
(Fig. 3-A). On the other hand mycobacteria were never observed being internalized 
by Elastase+ PMNs (Fig. 3-B). Comparatively few CD68+ macrophages with 
phagocytosed mycobacteria were found in the four weeks treated ulcerative lesion 
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and these cells had already developed karyopyknosis, a sign of apoptosis (Fig. 3-C). 
As in the nodular lesion, there was no evidence for Elastase+ PMNs containing 
intracellular bacilli, moreover, PMNs and macrophages were not co-localized in the 
infiltrate (Fig. 3-D).  
 
Mixed acute cellular infiltration in the nodule  
For a detailed characterisation of the cellular immune response inside the nodule 
treated during four weeks with R/S, IHC was performed on serial sections. Elastase+ 
PMNs (Fig. 4-A), CD56+ natural killer cells (NK cells; Fig. 4-B) and CD68+ 
macrophages (Fig. 4-C) were almost equally abundant. Only few CD4+ T 
lymphocytes (Fig. 4-D) and some more CD8+ T lymphocytes (Fig. 4-E) were 
observed. Single CD20+ B lymphocytes were distributed within the mixed infiltration 
(Fig. 4-F). Large amounts of membrane bound and soluble CD14, a pattern 
recognition receptor expressed by different cell types such as macrophages, were 
displayed throughout the lesion (Fig. 4-G). CD1a+ Langerhans dendritic cells of the 
epidermis residing inside the papillary dermis (Fig. 4-H) as well as numerous S100+ 
dermal dendrocytes distributed within the infiltration (Fig. 4-I) could be detected. 
Moreover, the infiltrated deeper dermis was interspersed with considerable amounts 
of Ki67+ proliferating leukocytes and hyperproliferative foci (arrows), respectively 
(Fig. 4-J). In contrast, in the untreated lesion only destroyed remnants of acute 
response leukocytes such as PMNs (Fig. 4-K), macrophages (data not shown) and 
NK cells (data not shown) were observed inside the necrosis. The surrounding tissue 
stained negative for those cells (data not shown). Mild infiltrates of CD3+ T 
lymphocytes were found around glands and vessels in vicinity to the necrotic core 
(Fig. 4-L) mainly appearing to be CD4+ whereas CD8+ staining was entirely negative 
(data not shown). No CD20+ B lymphocytes were present (data not shown) and only 
single dermal dendrocytes could be spotted (Fig. 4-M). 
 
Distinct bands of inflammatory leukocytes and early granuloma formation in 
the ulcer  
The early ulcerative lesion showed distinct infiltration zones in vicinity to the necrotic 
rim of the excised specimens after four weeks R/S treatment, with each zone having 
its characteristic cellular subsets (Fig. 5a).  
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The first (that is the inner) belt surrounding the necrotic lesion core displayed acute 
cellular infiltrates mainly consisting of Elastase+ PMNs (Fig. 5b-A) and was marked 
off from the second (that is the outer) belt by a line of CD56+ NK cells (Fig. 5b-B) 
with the majority expressing Ki67, indicating strong proliferative activity (Fig. 5b-C). In 
the second belt strong positive signals for membrane bound and soluble CD14 were 
obtained (Fig. 5b-D) and towards the outer margins of this zone increasing numbers 
of both CD8+ T cells (Fig. 5b-E) and CD4+ T cells (Fig. 5b-F) emerged. CD20+ B 
lymphocytes were much less frequent in this region, but some small foci were 
observed in the upper dermis (not shown). Similar to the untreated nodule, high 
levels of CD1a+ Langerhans dendritic cells were abundant both inside the epidermis 
and the upper dermis close to vessels (not shown). Additionally, S100+ dermal 
dendrocytes resided in the outer leukocyte belt around the necrosis (Fig. 5b-G).  
For direct comparison, IHC was performed on an untreated ulcerative lesion. In the 
lesions core and its surroundings staining for PMNs (Fig. 5b-H), NK cells (data not 
shown) and macrophages (Fig. 5b-I) showed, similar as in the nodule, only cellular 
debris. Staining for dermal dendrocytes and B lymphocytes was entirely negative 
(data not shown). Mild infiltrates of CD3+ lymphocytes with apoptotic phenotype, 
most of them revealing a CD8+ phenotype (Fig. 5b-J), were found around the 
necrosis. In the periphery, tissue was focally heavily infiltrated with CD8+ T 
lymphocytes and also some small CD20+ B lymphocyte foci were observed (data not 
shown). 
The dermis of the macroscopically healthy appearing margins of the antibiotic treated 
lesion contained granulomatous structures primarily built by CD8+ T lymphocytes 
(Fig. 6-A). CD4+ T lymphocytes were spread inside in smaller numbers (Fig. 6-B) 
and CD20+ B cell foci could be identified at the rim (Fig. 6-C) of these aggregates. A 
huge proportion of lymphocytes stained positive for the activation marker CD45RO 
(Fig. 6-D) and many leukocytes were identified expressing the proliferation marker 
Ki67 (Fig. 6-G). CD68+ antigen presenting cells were scattered throughout the 
cellular aggregates (Fig. 6-E), not yet developing into foamy, multinucleated 
Langhans giant cells (Fig. 6-Einsert) as observed after eight weeks R/S treatment 25. A 
similar pattern was detected for the distribution of S100+ dermal dendrocytes (Fig. 6-
F). Interestingly, dense CD20+ B cell accumulations, often in vicinity to sweat glands, 
could be identified (Fig. 6-H) and a subset appeared to be Ki67+ due to proliferation 
(Fig. 6-I). 
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Discussion 
 
Although provisional WHO guidelines recommend chemotherapy with a combination 
of R/S for the treatment of all stages of M. ulcerans infection, little is yet known about 
the local and systemic responses to this therapy. In a previous study we observed 
enormous organized local cellular immune responses as well as destruction of 
mycobacteria in ulcerative lesions after the recommended eight weeks of antibiotic 
treatment 25. This raised more questions regarding the immune processes taking 
place in the course of R/S therapy and whether there are differences between 
response patterns in early and late stage disease. On this account, we conducted an 
in-depth pathological study with samples from a nodular and an early ulcerative 
lesion excised from patients who had received only four weeks of antibiotic treatment 
prior to surgery.  
It is well established that M. ulcerans unlike other mycobacteria appear as 
extracellular clumps in necrotic connective and adipose tissue 18,27. Some data also 
suggest intracellular stages at the periphery of lesions 28. After four weeks of 
antibiotic therapy, phagocytosis of large numbers of yet rod-shaped bacilli was 
observed, possibly still leading to a positive culture 26. Whilst high counts of 
mycobacteria were detected inside phagosomes of macrophages in the nodule, most 
bacilli were still located deep inside the necrosis as extracellular clumps in the ulcer. 
It appears that the extended necrosis in the ulcerative lesion delays leukocyte entry 
into the bacterial focus.  
In lepromatous leprosy, intracellular bacilli are known to form structures named globi 
inside histiocytes which are - together with neurotropism - a diagnostic feature of this 
mycobacteriosis 29. We could show for the first time that macrophages internalize M. 
ulcerans in large numbers during R/S therapy developing a similar intracellular 
globus-like packing as seen in leprosy biopsies. Furthermore, after eight weeks 
antibiotic therapy only bacterial debris instead of rod-shaped bacilli was observed 25. 
Macrophages thus seem to be capable of degrading ingested mycobacteria during 
the course of antibiotic treatment.  
It can be assumed that mycolactone production is reduced or abolished early after 
the onset of R/S treatment due to bacterial growth arrest or death, respectively. 
Additionally, chemical instability associated with the unsaturated side chain is 
anticipated, and the core mycolactone itself has no cytopathic activity 30. We 
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speculate that mycolactone degrades inside the lesion, leading to declining toxin 
levels, allowing the establishment of a local immune response and survival of 
macrophages containing intracellular bacteria. 
While there is evidence for the formation of local leukocyte infiltration in untreated 
chronic lesions, lack of pronounced inflammatory responses is still a 
histopathological diagnostic criterion in BU 17,18,22,24. In contrast, after four weeks of 
antibiotic therapy, pronounced leukocyte infiltration was apparent mostly consisting of 
cells related to acute inflammatory responses like PMNs and macrophages. In the 
case of the ulcerative lesion, chronic infiltrates were already present. Here the belt-
like organization of acute and chronic infiltrates surrounding the necrotic core is 
indicative for sequential waves of leukocyte influx. 
Granuloma formation and proliferating B lymphocyte clusters are indicators for an 
adaptive immune response, like it has been reported for chronic pulmonary 
tuberculosis 31. After four weeks of R/S we found early granuloma formation and 
small but highly proliferative B lymphocyte clusters in the ulcerative lesion. In 
comparison, after eight weeks of antibiotic treatment mature granulomas with 
Langhans’ giant cells and large focal B cell aggregations have typically developed 25. 
This is the first work reporting huge amounts of intracellular M. ulcerans 
accompanied by a marked local cellular immune response in patients submitted to 
R/S treatment. The two cases after four weeks of antibiotic therapy presented here 
are outstanding in terms of leukocyte infiltration as well as host-pathogen interaction 
and provide a first insight into the immune response heterogeneity of different 
antibiotically treated BU stages. Nevertheless patient numbers are too small to draw 
conclusions universally valid for the various forms of Buruli ulcer. Further analysis of 
stage-specific differences in local immune responses induced by R/S treatment will 
help to improve treatment strategies.  
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Figure 1: Histopathology of two control lesions without R/S treatment and after 
eight weeks of chemotherapy, respectively 
Histological sections stained with HE (A, B, F, G, K, L), ZN (C, D, E, H, I, J, M, N; 
counterstain methylenblue) or pAbLep (O; counterstain haematoxylin) of a nodule (A 
to E) and an early ulcer (F to J) from the same patient without antibiotic therapy and 
an early ulcer after eight weeks R/S treatment (K to O).  
(A) Necrosis characteristic for BU nodules. (B) Slight infiltration and Touton giant 
cells (arrows) around fat cell ghosts. (C) Focal mycobacterial clusters lying in the 
centre of a wide-ranging necrosis with great numbers of adipose cell ghosts. (D) 
Non-detectable cellular infiltration in this section. (E) Extracellular bacteria between 
erythrocytes from a neighbouring necrotic blood vessel. (F) Developed necrosis with 
apoptotic cells and broad haemorrhages. (G) Focal acute infiltrates at the necrotic 
outline. (H) Dense mycobacterial focus within an extensive necrotic area affecting 
both connective and adipose tissue. (I) Slight acute cellular infiltration in a region 
containing M. ulcerans. (J) PMNs exhibiting apoptotic signs are in close contact to 
extracellular mycobacteria. (K) Chronic cellular infiltrates in the centre of the lesion. 
(L) Fully developed granulomas containing Langhans giant cells without central 
caseous necrosis. (M) Primarily intracellulary located acid-fast bacterial debris can be 
detected. (N) High power image of a macrophage densely packed with phagosomes 
containing acid-fast stained material. (O) Immunohistochemical staining with 
polyclonal antibody pAbLep against mycobacterial surface antigens confirms the ZN 
staining pattern. Scale bars: 8µm (E, J, N), 20µm (M, O), 40µm (F), 80µm (B, D, I, K), 
200µm (A, C, G, H, L). 
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Figure 2: Bacterial load and distribution after four weeks of R/S treatment in a 
nodular and an early ulcerative lesion 
Histological sections stained with HE (A to D and I to M) or ZN (E to H and N to Q; 
counterstain methylenblue) of a nodule (A to H) and an early ulcer (I to Q) after four 
weeks R/S treatment.  
(A) Extensive mixed cellular infiltration into the necrotic area with neovascularisation 
and vasodilatation can be found in the whole lesion. (B) PMNs and macrophages are 
recognized as the prevailing cellular subsets. (C) Focal cluster of eosinophils in 
connective tissue of the upper dermis. (D) Apoptotic material (here: PMNs) is 
phagocytosed by macrophages. (E) Bacteria are located both extra- and intracellular 
(arrows). Infiltrating leukocytes are devoid of apoptotic or necrotic features. (F) Single 
bacteria become attached to the macrophage membrane (arrow) and (G) 
subsequently are internalized. (H) High power image of a macrophage with 
phagosomes containing M. ulcerans. (I) Exceeding mixed cellular infiltrates 
surrounding the expanded necrotic area. (J) Inner belt of infiltration primarily consists 
of PMNs. (K) Outer belt of chronic infiltration and some Langhans giant cells. (L) 
Towards the excision margins early stages of granuloma are revealed. (M) Focal 
cluster of eosinophils together with granuloma formation. (N) In an early ulcerative 
lesion large cluster of bacteria are still present after four weeks R/S therapy. (O) 
Substantial cellular infiltrates inside the necrotic area reach the bacterial foci (arrow). 
(P) PMNs in contact with bacteria reveal apoptotic signs. (Q) Some macrophages 
can be observed harbouring phagocytosed rod-shaped mycobacteria. 
Scale bars: 4µm (H), 6µm (D), 8µm (F, G, P, Q), 20µm (J), 40µm (B, E), 80µm (K, 
M), 200µm (A, C, I, L, N, O) 
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Figure 3: Fluorescence IHC displays rod-shaped mycobacteria residing 
intracellulary inside macrophages 
Immunofluorescent staining for cellular markers (CD68 [A, C] or Elastase [B, D]), 
polyclonal antibody against mycobacterial antigens (pAbLep) and DAPI in sections 
from a nodule (A, B) or an ulcer (C, D) treated during four weeks with R/S.   
(A) CD68+ antigen presenting cells with macrophage appearance carrying numerous 
phagosomes containing mycobacteria. (B) PMNs show no co-localization with or 
internalization of bacterial material. (C) Some slightly apoptotic macrophages 
comprise intracellular bacteria. (D) No bacteria can be detected inside PMNs. Scale 
bars: 8µm. 
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Figure 4: IHC with cellular markers after four weeks R/S treatment and in an 
untreated nodule 
Immunohistochemical staining for cellular markers (red-brown) with haematoxylin as 
counterstain (blue) in serial sections of a nodule after four weeks R/S therapy (A to J) 
and an untreated one (K to M), respectively. 
(A to C) Acute immune response can be observed consisting of Elastase+ PMNs (A), 
CD56+ NK cells (B) and CD68+ macrophages (C). (D to F) CD4+, CD8+ and CD20+ 
lymphocytes are scarce. (G) Macrophages express vast amounts of either surface-
bound or soluble CD14. (H) CD1a+ Langerhans dendritic cells migrate from and/or to 
the epidermal layer. (I) S100+ dermal dendrocytes are distributed over the infiltrate 
(arrows). (J) A large proportion of the infiltrate are Ki67+ i.e. proliferating cells. 
Numerous hyperproliferative centres can be observed (arrows).  
(K) Only debris of elastase+ PMNs remains inside the necrosis. (L) Focal slight CD3+ 
T lymphocyte infiltrates is observed around glands and vessels in the subcutaneous 
tissue. (M) Staining for S100+ dermal dendrocytes is negative apart from very few 
single cells. Scale bars: 40µm (A, C, D, F), 80µm (B, E, G, H, J, L, M) and 200µm (I, 
K).  
 
 
 
 
 CHAPTER 5. Intracellular M. ulcerans  during chemotherapy 88               
 
 
 
 
Figure 5a: Schematic illustration of the early ulcerative lesion after four weeks 
R/S therapy  
Infection focus (necrosis), acute (1. belt) and chronic (2. belt) infiltration. 
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Figure 5b: IHC with cellular markers in the core of an early ulcer after four 
weeks R/S treatment and an untreated control 
Immunohistochemical staining with cellular markers (red-brown) and haematoxylin as 
counterstain (blue) in serial sections from an early ulcer after antibiotic therapy (A to 
G). (A to C) 1. belt of infiltration and its borders. (D to G) 2. belt of infiltration. (H to J) 
Control tissue from an untreated ulcerative lesion. 
(A) Elastase+ PMNs are the most predominant cell type in the inner layer 
surrounding the necrosis. (B) CD56+ NK cells build the border between acute and 
chronic belt and (C) are highly Ki67+ i.e. proliferating. (D) 2. belt of infiltration reveals 
substantial amounts of membrane bound and soluble CD14. (E) CD8+ and (F) CD4+ 
lymphocytes are present in this area with rising abundance towards lesion margins. 
(G) Dispersed S100+ dermal dendrocytes can be observed. (H) Elastase+ staining 
reveals cellular debris of PMNs. (I) CD68+ macrophages are present in low amounts 
and show clear signs of apoptosis and necrosis. (J) CD8+ T lymphocytes 
surrounding the necrotic core undergo apoptosis. Scale bars: 20µm (I, J), 40µm (F), 
80µm (G, H, L, M) and 200µm (A, B, C, D, E, K). 
 
 CHAPTER 5. Intracellular M. ulcerans  during chemotherapy 91               
 
 
 
 
 CHAPTER 5. Intracellular M. ulcerans  during chemotherapy 92               
 
Figure 6: Early granuloma formation in the healthy appearing margins of an 
early ulcer after four weeks R/S treatment  
Immunohistochemical staining for cellular markers (red-brown) with haematoxylin as 
counterstain (blue) on serial sections from an early ulcer.  
(A) Low power image showing the architecture of granulomas. A large outer layer 
with CD8+ T lymphocytes being the predominant cell subset surrounds a small non-
necrotic core. (B) CD4+ lymphocytes are much less abundant. (C) CD20+ B 
lymphocytes can be found near the outer rim of granulomas. (D) A great proportion of 
lymphocytes stain positive for the activation marker CD45RO. (E) CD68+ antigen 
presenting cells are present without forming a concrete centre not yet starting to 
become foamy and multinucleated (insert). (F) S100+ dermal dendrocytes and (G) 
Ki67+ proliferating cells are displayed. (H) In vicinity to vessels and glands dense 
clusters of CD20+ B lymphocytes are developing. (I) Ki67+ staining reveals 
proliferative activity inside these lymphocyte foci. Scale bars: 40µm (Binset, Dinset, 
Einset, I), 80µm (B to H), 200µm (A). 
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Abstract 
 
Buruli ulcer is a necrotizing skin disease caused by Mycobacterium ulcerans. Major 
necrosis with abundant clusters of extracellularly replicating mycobacteria and only 
minor infiltration are characteristic histopathological features of the disease. 
Mycolactone, a macrolide exotoxin of M. ulcerans has cytotoxic activities and plays a 
key role in the development of this pathology. Current treatment strategies include 
rifampicin-streptomycin chemotherapy with or without additional surgery and/or skin-
graft.   
Here we have performed a histopathological analysis of Buruli ulcer lesions excised 
after 0, 2, 4, 8 or 12 weeks of rifampicin-streptomycin treatment. Both localisation 
and morphology of acid-fast bacilli and the composition and organization of leukocyte 
infiltrates were monitored. Mycobacteria started to be internalized by phagocytes 
already after two weeks of treatment and displayed irregular Ziehl Neelsen staining 
after eight weeks. Acid-fast debris was still found after 12 weeks of chemotherapy in 
otherwise Ziehl Neelsen negative areas of sections. Cellular infiltrates were already 
observed after two weeks of chemotherapy and total leukocyte numbers increased 
during the further course of the treatment. Initially unstructured infiltrates converted 
with time into lymphocyte aggregates, associated with granuloma and abscessus 
formation. 
 CHAPTER 6.  Chemotherapy in  ea r ly  s tages  o f  Buru l i  u l ce r  99               
 
Introduction 
 
Mycobacterium ulcerans causes Buruli ulcer (BU), a necrotizing disease of the skin 
and the subcutaneous tissue often leading to extensive ulceration [1,2]. The 
bacterium produces an exotoxin with immuno-modulatory and cytotoxic properties 
named mycolactone [3,4,5,6], which is thought to be responsible for most clinical 
symptoms related to M. ulcerans infection [7,8,9]. Many sub-tropical countries all 
over the world are affected, but the largest numbers of cases are reported from sub-
Saharan Africa [2,10,11,12]. Children develop the disease more often than adults. 
Whether this is due to more intense exposure or differences in immune status is 
unclear, since the mode of transmission of BU and possible environmental 
reservoir(s) of the pathogen are still under investigation [13].  
When left untreated, pre-ulcerative forms of BU - nodules, plaques and oedema - 
break in and form necrotic skin ulcers. Usually the ulcers have deeply undermined 
edges and enlarge over an extended period of time  [12,14].  
 
Until an antibiotic combination therapy with rifampicin and streptomycin (R-S) was 
recommended by WHO in 2004, surgery was the only available treatment [15,16]. A 
clinical trial and observational studies have yielded promising results with the 
combination chemotherapy [17,18]. In a previous study we showed that the treatment 
of patients with ulcerative BU lesions with R-S leads to the development of highly 
structured, ectopic lymphoid tissue [19]. Furthermore, our histopathological analyses 
have provided evidence for a different response pattern in pre-ulcerative lesions 
(Schütte et al, in press). Therefore we investigated in the present study 
histopathological changes in early BU lesions – plaque and nodules – after 0, 2, 4, 8 
and 12 weeks of R-S treatment and compared results with data from ulcerative 
lesions. Samples analysed were collected during a clinical trial assessing clinical 
efficacy of R-S treatment [17] 
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Material and Methods 
 
Study population 
Skin tissue samples used in the present study were collected during a clinical trial 
performed in 2004 assessing clinical efficacy of rifampicin-streptomycin treatment of 
early BU lesions [17]. In brief, patients with clinically diagnosed early BU infection 
(nodules or plaques) were recruited from two endemic districts in Ghana. Only 
patients older than 15 years with a single lesion of maximum 10 cm in diameter were 
included after having given written consent. Clinical diagnosis was confirmed 
retrospectively by culture, histopathology, visible acid fast bacilli (AFB) and/or 
positive IS2404 based PCR. Lesions were excised after 0, 2, 4, 8 and 12 weeks of 
daily administration of R-S, respectively, and tissue specimens equally split for 
microbiological and histopathological analysis.  
 
Histology and immunohistochemistry  
Tissue samples were stored in formalin after surgical excision for various durations 
until committed to paraffin embedding. Histological and immunohistochemical 
staining procedures were performed as previously described [19]. In brief, serial 
sections were stained with haematoxylin-eosin (HE) or monoclonal antibodies 
specific for the leukocyte markers elastase, CD56, CD20, CD3 and CD68. 
Furthermore, staining with Ziehl Neelsen (ZN) and polyclonal anti-leprae antibodies 
(cross-reactive with mycobacterial antigen) was performed to monitor distribution, 
localization and morphology of M. ulcerans. Pictures were taken with a microscope 
equipped with a camera (Leica Microsystems GmbH) or with MIRAX scan (Carl Zeiss 
AG). Images were saved using Application Suite (Leica Microsystems GmbH) or 
MIRAX Viewer and processed with Adobe Photoshop® CS. 
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Results 
 
Leukocyte infiltration and aggregation during antibiotic treatment 
An overview over a representative sample taken after eight weeks of chemotherapy 
displays histopathological features characteristic for antibiotic treated early BU 
lesions (Figure 1). Three main areas can be distinguished: sub-epidermal infiltrate, 
necrosis and deep dermal infiltrates (Fig.1-A). The sub-epidermal layer usually 
contained polymorphonuclear neutrophilic leukocytes (PMNs) and lymphocyte 
accumulations, granulomas and granulation tissue (Fig.1-A1). In all samples varying 
degrees of necrosis were observed (Fig.1-A2). In the subcutaneous region very often 
cellular infiltration and angiogenesis at exceedingly high levels were present (Fig.1-
A3), revealing histological patterns characteristic for healing processes within the 
severely affected tissue. Secondary tissue damage such as neuritis (Fig.1-B1) or 
extensive haemorrhages due to destruction of vessel epithelia (Fig.1-B2 and -B3) 
were observed. On the other hand slight eosinophilia and presence of Langhans’ 
giant cells were markers for transition into a healing process (Fig.1-B4 and -B5). 
Strong leukocyte infiltrations cumulated in abscessus formations (Fig.1-C1), 
occasionally forming purulent centres (Fig.1-C2). Abscesses were of elastase+ PMN 
origin (Fig.1-C3). As an element characteristic for chronic cellular immune responses, 
Granuloma formation with Langhans’ giant cells was found in several lesions of 
different treatment stages (Fig.1-D1). More commonly dense lymphocyte clusters, 
sometimes covering large areas of the sub-epidermal tissue, were observed (no 2, 9, 
15; Table 2) (Fig.1-D2). These were present in all but three samples and consisted 
primarily of CD20+ B lymphocytes (Fig.1-D3), but also scattered CD3+ T 
lymphocytes (not shown). 
 
The three lesions excised from untreated patients contained only low numbers of 
leukocytes, which were largely (>90%) apoptotic or destroyed. In contrast, the 
majority of lesions excised after 2 to 12 weeks of R-S treatment showed acute 
(14/15) and chronic (13/15) infiltrates (Table 1). A high proportion of lesions 
contained granulomas and abscessus-like PMN accumulations. Moreover, dense 
lymphocyte congregations were found in every treatment group. 
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Mycobacterial viability, localisation and morphology during chemotherapy 
Bacterial numbers determined by microscopy and culture of tissue homogenate were 
compared to study loss of viability of M. ulcerans during the course of antibiotic 
therapy (Table 2). While after two weeks of treatment colony forming units (cfu) were 
still found in all samples analysed, all specimens taken after 4, 8 and 12 weeks of R-
S treatment were culture negative. In contrast, bacterial counts in tissue 
homogenates determined by microscopy were relatively stable over the entire period 
of R-S treatment (Table 2). In one culture negative sample, AFB were not found in 
the tissue homogenate, but in the tissue sections. Another sample was positive for 
AFB in the homogenate, but negative in histology. These discrepancies may be 
explained by the focal distribution of M. ulcerans within the lesions. Overall numbers 
of AFB found in the tissue sections were not significantly decreasing over time (Table 
3). Clumps and/or single extracellular AFB were observed. In addition, in most 
samples variable numbers of bacteria were located intracellulary within phagocytes. 
The ratio between extracellular and intracellular bacteria declined with increasing 
treatment duration (Table 3). Bacterial localisation and morphology at different time-
points of antibiotic treatment are shown for representative samples in Figure 2. 
Already after two weeks, strong leukocyte infiltrations into regions of bacterial burden 
were detected at the hypoxic rim of the central necrosis (Fig.2-A). PMNs were very 
abundant in areas of high bacterial burden and had phagocytosed rod-shaped 
bacteria (Fig.2-A1), whereas AFB-containing macrophages were less frequent at this 
stage (Fig.2-A2). Some phagocytes carried globi-like mycobacterial aggregations 
commonly observed in leprosy (Fig.2-A3). At four weeks of R-S therapy solid-stained 
clumps of AFB were observed both inside the necrosis (Fig.2-B) and the 
neighbouring infiltrated connective tissue (Fig.2-B1). PMNs (Fig.2-B2) and 
macrophages (Fig.2-B3) with internalized bacteria were equally abundant. Results 
from ZN stainings were confirmed by immunohistochemical staining of mycobacterial 
antigen (Fig.2-C and -C1). In the group of patients treated for eight weeks sections 
frequently revealed abscessus formation around bacterial clusters and their 
phagocytosis (Fig.2-D). At this stage extracellular mycobacterial clusters inside the 
necrosis revealed irregular ZN staining (Fig.2-D1). Decomposed intracellular bacteria 
were found primarily within macrophages (Fig.2-D2) and only occasionally within 
PMNs (Fig.2-D3). Immunostaining disclosed the same localisation of extracellular 
mycobacterial antigen as ZN positive bacterial structures (Fig.2-E), but antigen 
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staining remained in contrast to ZN staining solid (Fig.2-E2). After twelve weeks of 
antibiotic treatment, one sample contained no bacterial clumps but only few 
extracellular bacilli (Fig.2-F and -F1). ZN positive bacterial debris was found in the 
cytoplasm of macrophages (Fig.2-F2) and PMNs (Fig.2-F3) in the form of 
mycobacterial debris. Interestingly, immunostaining sometimes uncovered in serial 
sections antigen clusters that were ZN negative (Fig.2-G). Single bacteria could be 
stained both in necrotic areas (Fig.2-G1) and inside cellular infiltrations (Fig.2-G2). 
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Discussion 
 
There may be a constant influx of neutrophils, monocytes/macrophages and 
lymphocytes to active BU lesions (Oliveira et al., 2005), but high concentrations of 
mycolactone around the extracellular foci of M. ulcerans are driving these cells into 
apoptosis. In this study we show that antibiotic therapy of BU nodules and plaques 
leads to local cellular immune responses and phagocytosis of the bacteria. 
Intracellular bacteria were found already after two weeks of treatment, when culture 
was still positive. Antibiotic treatment may act rapidly on the bacterial metabolism and 
interfere with mycolactone production, while complete killing of bacteria takes more 
time. Similar findings have been reported for multidrug therapy in leprosy [20]. 
Declining mycolactone concentrations allow infiltrating leucocytes to reach the 
bacterial foci, where they can enhance the anti-mycobacterial activity of the 
antibiotics.  The fact that cultures turned negative after four weeks of chemotherapy 
evidences, that the antibiotics are able to sufficiently penetrate necrotic regions to kill 
the mycobacteria residing there. This observation is emphasized by fading ZN 
staining at coeval solid immunostaining of bacterial clusters after eight and twelve 
weeks of therapy. In M. leprae infections the so-called morphological index 
calculated by counting the numbers of solid-staining acid-fast rods, is used as a 
viability estimation [20]. Development of a similar viability index for M. ulcerans based 
on the bacteria’s morphological changes during therapy are currently under 
investigation.  
 
Extended necrotic areas, typically containing huge extracellular mycobacterial 
clusters, were still found in the BU lesions even 12 weeks after start of the R-S 
treatment. While these areas are at least partially washed out after ulceration, tissue 
debris and huge amounts of mycobacterial antigens and immunostimulators remain 
in the affected tissue after antibiotic therapy of pre-ulcerative lesions. In this respect 
chemotherapy differs profoundly from surgical treatment, where necrotic tissue 
containing the vast burden of mycobacteria is excised. This is a feature most likely 
triggering the strong leukocyte infiltration and abscessus formation observed in the 
BU lesions in the course of chemotherapy. Slow resolution of necrotic areas and 
massive encounter of immune cells with remaining bacterial material may explain 
why re-activation of plaques and/or oedematous forms of BU is observed in some 
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patients several weeks after completion of antibiotic therapy. This reaction is often 
associated with the sensation of heat and pain and a secondary ulceration, but not 
with the development of new mycobacterial foci (unpublished results) [18].  
 
The massive leukocyte infiltrates found in all lesions analysed here may cause a 
retardation of the healing process. In knock-out mice which lack macrophages, 
neutrophils and mast cells, more rapid repair processes and reduced scarring can be 
observed [22]. On the other hand, macrophages and their cytokines are needed to 
govern granulation tissue formation which relies on angio- and vasculogenesis [23]. 
Granulation tissue was observed in most of the samples as were macrophages. 
Moreover, eosinophils were found in varying numbers in all lesions. These act as 
regulators of tissue immune microenvironment and modulate the responses from 
recruited and resident leukocytes [24] .Comparison of our findings with pre-ulcerative 
early stages of BU presented here with results obtained with ulcerative lesions during 
R-S treatment revealed commonalities, but also clear differences. After eight weeks 
of R-S treatment, bacterial debris was barely found in ulcerative lesions and necrotic 
areas were smaller. In contrast to pre-ulcerative lesions infiltrates contained no 
neutrophils [19], indicating that the lower burden of mycobacterial antigen and 
necrotic material permits a faster transition from acute to chronic immune response.  
Taken together our data indicate that persisting mycobacterial antigens and 
immunostimulators may cause excessive immuno-stimulation and some healing 
retardation after successful chemotherapy. Apparent reactivation of the disease in a 
small proportion of patients after chemotherapy should be carefully analysed, but 
appears to be related to immunological factors rather than incomplete killing of the 
pathogen.  
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Figures 
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Figure 1. Local histopathological features of early BU lesions in the course of 
R-S therapy 
Histological sections were stained with HE (A, B, C1, C2, D1, D2) and antibodies 
against elastase (C3) or CD20 (D3).  
(A) Overview a representative sample from an early BU lesion after eight weeks of R-
S treatment. (B) Bystander tissue damage such as severe neuritis (B1), extensive 
haemorrhages (B2) and degradation of vessel epithelia (B3). Presence of eosinophils 
(B4) and Langhans’ giant cells (B5). (C1-3) PMNs gathering as abscessus formation 
with purulent centres. (D) Cellular aggregations in the form of granulomas (D1) and 
lymphocyte clusters (D2) of B cell origin (D3). 
 
 
 
 
 
  
Necrosis   total infiltration   leukocyte infiltration 
duration 
of 
treatment 
(weeks) 
n 
  
▼ ▲   ▼ ▲   acute chronic granuloma abscess b/t cell 
aggregates 
              
2 4  0 4  3 1  4/4 4/4 2/4 2/4 3/4 
4 3  2 1  2 1  3/3 3/3 3/3 3/3 3/3 
8 5  3 2  2 3  5/5 4/5 4/5 4/5 4/5 
12 3  2 1  1 2  2/3 2/3 2/3 2/3 2/3 
                            
              
   
▼necrosis/infiltrate covers 
≤15% of the sample surface; 
▲necrosis/infiltrate covers 
>15% of the sample surface    
 
 
Table 1. Necrotic tissue coverage and leukocyte infiltration pattern during 
chemotherapy 
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duration 
of 
treatment 
(weeks) 
  
patient   
no 
  
CFU¹ 
culture 
  
BC² 
microscopy 
  
AFB³ 
histology 
         
 1  1x104  1x109 
  +  
 2  1x102  9x107 
  +  0 
 3  1x102  6.4x107 
  +  
                  
         
 4  4x103  8x107 
  +  
 5  1x102  1.2x107 
  +  
 6  1x104  6.6x107 
  +  
2 
 7  1x103  1.9x108 
  +  
                  
         
 8  0  2.7x108 
  +  
 9  0  2.2x108 
  +  4 
 10  0  4.9x107 
  +  
                  
         
 11  0  4.8x107 
  +  
 12  0  2x107 
  +  
 13  0  0 
  +  
 14  0  1.2x108 
  +  
8 
 15  0  1.8x108 
  +  
                  
         
 16  0  1.2x108 
  +  
 17  0  1.2x106 
  -  
12 
 18  0  1x107 
  +  
                  
         
¹colony forming units (per gram of tissue homogenate) 
²bacterial counts (bacilli per gram of tissue homogenate) 
³acid fast bacilli (detected in histological tissue sections) 
 
 
Table 2. Bacterial load and viability in response to antibiotics 
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  Bacterial load¹  Proportion of extracellular bacteria² duration of 
treatment 
(weeks) 
  high low   > 90% 10-90% < 10% 
        
0  1 2  3 0 0 
2  4 0  2 2 0 
4  1 2  1 1 1 
8  1 4  1 2 1 
12  1 1  1 0 1 
                
        
¹high: large clusters visible at 200x or less 
¹low: small clumps or single bacteria only visible at 600x and more      
²ratio extracellular/intracellular 
 
 
Table 3. Histological analysis of number and distribution of M. ulcerans during 
R-S treatment 
 
Figure 2. Localisation and morphological changes of M. ulcerans in early 
lesions after 2, 4, 8 and 12 weeks of chemotherapy 
Histological sections were stained with ZN (A, B, D, F) and polyclonal 
antimycobacterial antibodies against surface antigens (C, E, G).  
(A) Strong infiltration into regions of bacterial burden after 2 weeks of R-S therapy. M. 
ulcerans were phagocytosed primarily by PMNs (A1) and to a much lesser extent by 
macrophages (A2), sometimes forming globi-like structures (A3). (B/C) Bacterial 
clumps after 4 weeks of R-S treatment. Solid staining AFB were present both 
extracellularly (B1) and inside PMNs (B2) and macrophages (B3). ZN staining was 
confirmed by IHC (C1). (D/E) Bacterial morphology after 8 weeks of R-S therapy. 
Abscessus formation around M. ulcerans (D). Bacterial cluster inside the necrosis 
revealed irregular ZN staining (D1). ZN positive debris was observed equally inside 
PMNs (D2) and macrophages (D3). (E) Confirmation of AFB picture through IHC 
reveals solid antigen staining (E1). (F/G) Appearance of M. ulcerans after 12 weeks 
of R-S administration. Only single extracellular AFB were found inside the necrosis 
(F1). Both PMNs and macrophages contained mycobacterial debris (F1 and F2, 
respectively). Immunostaining uncovered ZN negative mycobacterial antigen (G). 
Single solid staining bacteria were found both in necrotic (G1) and infiltrated (G2) 
tissue. 
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Abstract 
 
Background: Buruli ulcer (BU) is an infection of the subcutaneous tissue leading to 
chronic necrotizing skin ulcers. The causative pathogen, Mycobacterium ulcerans, 
grows best at 30 °C – 33 °C and not above 37 °C. We explored the safety, tolerability 
and efficacy of phase change material (PCM), a novel heat application system for 
thermotherapy of BU. 
 
Methodology/Principal Findings: In a prospective observational single centre 
proof-of-principle trial in Ayos / Cameroon, six laboratory reconfirmed patients with 
ulcerative Buruli lesions received 28–31 (ulcers ≤ 2 cm) or 50–55 (ulcers > 2 cm) 
days of thermotherapy with the PCM sodium acetate trihydrate as heat application 
system. This PCM is widely used in commercial pocket heat pads, it is easy to apply, 
rechargeable in hot water, non-toxic and non-hazardous to the environment. All 
patients enrolled in the trial completed treatment. Being completely mobile during the 
well-tolerated heat application, acceptability of the PCM bandages was very high. In 
patients with smaller ulcers, wounds healed completely without further intervention. 
Patients with large defects had skin grafting after successful heat treatment. Heat 
treatment was not associated with marked increases in local inflammation or the 
development of ectopic lymphoid tissue. One and a half years after completion of 
treatment, all patients are relapse-free.  
 
Conclusions/Significance: Our reusable PCM-based heat application device 
appears perfectly suited to treat BU in endemic countries with limited resources and 
infrastructure.  
 
 
Trial Registration. Controlled-Trials.com ISRCTN88392614 [http://www.controlled-
trials.com/ISRCTN88392614]  
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Author Summary 
 
Buruli ulcer is an infection of the subcutaneous tissue leading to chronic necrotizing 
skin ulcers. The causative pathogen, Mycobacterium ulcerans, grows best at 30 °C – 
33 °C and not above 37 °C, and this property makes the application of heat a 
treatment option. We achieved a breakthrough in heat treatment of Buruli ulcer by 
employing the phase change material sodium acetate trihydrate as a heat application 
system for thermotherapy, which is widely used in commercial pocket heat pads. It is 
easy to apply, rechargeable in hot water, non-toxic and non-hazardous to the 
environment. Six laboratory reconfirmed patients with ulcerative Buruli lesions were 
included in the proof-of-principle study and treated for four to six weeks. In patients 
with small ulcers, wounds healed completely without further intervention. Patients 
with large defects had skin grafting after successful heat treatment. Heat treatment 
was not associated with marked increases in local inflammation or the development 
of ectopic lymphoid tissue. One and a half years after completion of treatment, all 
patients are relapse-free. The reusable phase change material–based heat 
application device appears perfectly suited for use in remote Buruli ulcer–endemic 
areas of countries with limited resources and infrastructure.  
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Introduction 
 
Buruli ulcer (BU) is a chronic necrotizing disease of skin and soft tissue caused by 
Mycobacterium ulcerans [1]. The disease starts as a subcutaneous nodule, papule or 
plaque that eventually ulcerates and progresses over months to years. In BU lesions, 
clumps of extra-cellular acid-fast organisms surrounded by areas of necrosis are 
found primarily in subcutaneous fat tissue [2]. M. ulcerans produces a macrolide 
toxin, mycolactone, which is associated with tissue destruction and local 
immunosuppression [3]. BU has been reported in >30 countries, but the major 
burden lies on children living in remote areas of West Africa associated with swamps 
and stagnant water bodies. Traditionally wide excision of the infected tissue alone 
was the standard treatment for BU. This is hampered by traumatic interventions, high 
cost and very high recurrence rates [4]. Chemotherapy with streptomycin and 
rifampicin is currently re-evaluated as an adjunct treatment to surgery and as a 
therapy in its own right [5,6,7,8].  
 
M. ulcerans differs from most other pathogenic mycobacteria in that it grows best at 
30 – 33 °C and not above 37 °C [9]. This characteristic feature of the pathogen was 
first used for therapeutic purposes in the early 1970s. Meyers et al. treated 8 patients 
from Zaire maintaining a temperature of approximately 40 ºC in the ulcerated area for 
a mean duration of 68 days [10]. There was no evidence of local recurrence during 
follow-up periods of up to 22 months. Based on this impressive success rate, WHO 
guidelines listed the application of heat as a treatment option for BU [11]. However, 
the heat application devices employed so far were impractical in most endemic 
countries. Here we describe the use of a cheap and easy to apply phase change 
material (PCM) device suitable for thermotherapy of BU in countries with limited 
resources.  
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Methods 
 
Study participants 
Eligibility criteria for participants and case definition. All patients between 6 and 30 
years of age with an ulcer at the lower or upper arm or leg with a diameter of up to 12 
cm suggestive for BU on clinical grounds in the catchment area of the Buruli 
treatment center Ayos / Cameroon were candidates for inclusion in the study. They 
were not admitted to the study if any of the following criteria were present: (1) clinical 
signs and symptoms of communicable diseases other than BU (fever, weight loss, 
night sweats, persistent cough, jaundice, pulmonary or myocardial dysfunction, CNS 
involvement, ascites, pleural effusion), (2) clinical signs and symptoms of non-
communicable diseases (myocardial, pulmonary, renal, CNS) and (3) inability to 
confirm BU using laboratory methods. 
A BU case was defined as a patient with an ulcer diagnosed as BU on clinical 
grounds and positive results in at least two of the three laboratory tests (PCR, 
detection of AFB on microscopy and histopathology) performed. 
 
Laboratory confirmation of clinical diagnosis. On day 0 four swabs from the 
undermined edges and one diagnostic biopsy were taken from all patients enrolled 
into the trial on clinical grounds. A second set of biopsies was taken in week 4 of 
thermotherapy to assess histopathological changes in response to heat treatment. All 
samples were investigated by microscopy for acid-fast bacilli (AFB) after Ziehl 
Neelsen (ZN) staining and by IS2404 real-time PCR [12]. Histopathological changes 
typical for BU [12] were recorded in the initial biopsies and the follow-up biopsies in 
week 4 of thermotherapy.  
 
Immediately after performing the punch biopsies, tissue samples were fixed in 4% 
neutral-buffered PFA (paraformaldehyde) for 24h and subsequently transferred to 
70% ethanol for short term storage and transport. Biopsies were dehydrated, 
embedded in paraffin, cut into 5µm thin sections and retrieved on glass slides. After 
dewaxing and rehydration, sections were stained with haematoxylin/eosin (HE) and 
ZN. Immunohistochemistry (IHC) was performed with antibodies against Elastase 
(polymorphonuclear neutrophils [PMNs]; Dako) and CD3 (T lymphocytes; Dako). 
Staining was performed using Vector NovaRED and haematoxylin.  
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The setting and location where the data were collected. Volunteers were recruited in 
the catchment area of the Buruli treatment center at the hospital Ayos / Cameroon, 
identified by active and passive case detection. The treatment center has a 
longstanding collaboration with and is supported by Leprosy Relief Emmaus-
Switzerland (ALES). It maintains a very well equipped and functioning operation 
theatre, wards for pre- and postsurgical care, physiotherapy and a school which is of 
importance because the majority of patients with this disease are children and 
convalescence after excision of ulcers and skin grafting takes many months in the 
majority of patients. Dr. A. Um Boock, the director of the ALES Bureau Régional pour 
l’Afrique, and his team are very experienced in the diagnosis and management of 
patients with Buruli ulcer, including surgery and skin grafting. 
 
Ethical approval and informed consent. The protocol was approved by the National 
Ethics Committee of Cameroon and the Ethics Committee of the University Hospital, 
Heidelberg, Germany. Patients were enrolled in the study only after informed written 
consent was obtained from them or their care providers.  
 
Interventions 
Heat application. Commercially available plastic bags filled with the PCM sodium 
acetate trihydrate were used. Starters were placed in the bags to initiate the 
crystallisation process (Fig. 1). Size of filled bags is 21 cm x 15 cm x 2 cm with an 
average weight of 800 g. The melting temperature of the PCM sodium acetate 
trihydrate is 58°C. The unique feature of PCM is its thermal energy storing capacity 
combined with an almost constant temperature during the liquid-solid phase 
transition. This property is widely used in commercial pocket heat pads.  
After cleaning and sterile dressing of the ulcers a heat sensor connected to a data 
logger (testo 177-T3, testo AG, Lenzkirch, Germany) was placed on healthy skin at 
the edge of the ulcer. The area of contact between skin and PCM packs was 
protected by tube gauze and a layer of elastic bandage to lower the PCM working 
temperature from 58°C to the therapeutic target temperature of 40°C at skin surface 
(Fig. 1). Temperatures of ≤58°C do not cause burns when not applied for prolonged 
periods of time. Skin temperatures of up to 43°C were accepted and well tolerated for 
short intervals of time immediately after mounting the PCM bandage. The affected 
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skin (ulcer /oedema / induration) plus a safety margin of several centimeters was 
covered by one to four PCM packs per session depending on the size of the total 
area to be treated (Fig. 2). The PCM packs were fixed with several layers of elastic 
bandage. A thermal insulation layer, commercially available to insulate hot water 
pipes, was used to reduce heat loss to the environment and to reinforce positioning 
of the PCM packs (Fig. 1). This allowed patients to move around freely. The 24 hours 
protocol was as follows: 8.00: Clinical progress assessment, cleaning and dressing of 
ulcers and renewal of PCM-packs, photo documentation at, on average, 3 day 
intervals. 12.00: Removal of PCM-packs, dressing of the wound to protect from 
contamination during a 5 hour pause of heat treatment, skin care with fatty cream. 
17.00: Additional wound cleaning and dressing, if needed, renewal of PCM-packs. 
22.00: Renewal of PCM-packs. 
Clinical observations (appearance of the ulcer and the surrounding heat exposed 
skin, overall clinical assessment of the patient) were recorded daily at the above 
mentioned time points on case record forms (CRF). Temperature at the skin surface 
was automatically recorded at 10 minute intervals and stored in a small data logger 
carried by the patients. Temperature data were transferred daily to a notebook and 
checked for therapeutic and safety margins (testo software ComSoft 3.4, testo AG, 
Lenzkirch, Germany).  
Patients with small ulcers and without significant oedema (patients 1, 2, 3) received 
heat treatment for 28-31 days, patients with large ulcers and / or significant oedema 
(patients 4, 5, 6) for 50-55 days. 
 
 
 
Study objectives 
In the current study we tested the hypotheses that  
(1) PCM-based heat application is safe and comfortable for patients  
(2) with PCM based heat application the results of the thermotherapy study of 
Meyers et al [10] can be reproduced, i.e. primary healing of Buruli ulcer 
without relapse can be achieved 
 
Primary outcomes 
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(1) Proportion of patients completing 28-31 days of heat treatment in patients with 
small ulcers (≤ 2 cm) or 50-55 days in patients with large ulcers (> 2 cm) and 
ulcers with prominent surrounding oedema  
(2) Proportion of patients cured 6 months after completing heat treatment (including 
skin grafting where necessary). Cure is defined as complete closure of the wound 
by epithelialisation or scarification or by skin graft. 
(3) Proportion of patients who are recurrence free 18 months after completing heat 
treatment 
 
Secondary endpoint 
Histopathological responses in week 4 of thermotherapy compared to reference 
samples at day 0. 
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Results 
 
Participant flow 
Seven patients with ulcers suggestive for BU on clinical grounds were recruited by 
active and passive case detection. In six of the seven patients enrolled the diagnosis 
was laboratory confirmed.  
 
Protocol deviations 
We extended the total duration of heat application of large ulcers (> 2 cm) and ulcers 
with prominent surrounding oedema from 4 week to 50-55 days and did not, as 
originally planned, treat small and large ulcers equally for 4 weeks only. This was 
done even though all ulcers appeared clinically healed after 4 weeks of heat 
treatment, independent of size and surrounding oedema. This decision was taken on 
the basis of the results of the punch biopsies in week 4 of thermotherapy showing 
residual AFB with intact rod-shaped appearance. 
 
Recruitment and follow-up 
Eligible patients were recruited between February 28, 2007 and March 3, 2007. 
Patients stayed in the hospital during the course of heat treatment and thereafter until 
the wound was closed (patients with small ulcers; patients 1, 2, 3, 4,) or skin grafted 
(patients with large ulcers; patient 5 and 6). All patients were followed up until 18 
months after completion of heat treatment. 
 
Baseline data 
The age range of the seven patients enrolled was six to 21 years. Three patients had 
single ulcers on the upper and four had single ulcers on the lower extremities. 
Medical history and physical examination revealed no significant health problem 
other than BU. In six out of seven patients enrolled in the study on clinical grounds, 
diagnosis was laboratory confirmed. The unconfirmed patient was excluded from the 
analysis (Fig. 2). 
 
Outcomes 
All patients enrolled into the trial completed treatment. In all patients temperatures at 
the lesion and over a wide margin of healthy looking skin were maintained above ≥ 
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39°C for between 8.4 and 13.2 hours and ≥ 40°C for between 4.4 and 9.3 hours per 
day (Fig. 2). Undermined margins collapsed between day 1 and day 3. 
Epithelialization started in all patients between 4 and 11 days after the start and was 
almost completed in patients 1, 2, and 3 at the end of heat treatment (Fig. 2 and Fig. 
3). In particular in patients with oedematous lesions (patients 4, 5) white discharge 
from ulcers was observed during initial treatment for various lengths of time. The two 
patients with large defects (patients 5 and 6) had skin grafting after completion of 
heat treatment (Fig. 3B). 
All six reconfirmed patients were healed and relapse-free 18 months after completion 
of treatment. 
 
In the punch biopsies taken prior to start of treatment, histopathological changes 
characteristic for BU, such as fat cell ghosts, deep dermal necrosis and/or 
psoriasiform epidermal hyperplasia, were found in six patients (Fig. 2). All patients 
yielded positive semi-quantitative IS2404 real-time PCR results. AFBs were detected 
in swabs or punch biopsies of 4 out of 6 patients included in the study.  
 
Analysis of serial sections of punch biopsies taken at day 0 and in week 4 of 
thermotherapy showed, that heat treatment was not associated with marked 
increases in local inflammation, the development of ectopic lymphoid tissue or 
haemorrhages. At both time points small numbers of both polymorphonuclear cells 
as members of the innate and T cells as members of the adaptive immune system 
were present, with polymorphonuclear cells mainly located around necrotic areas and 
T cells more confined to areas close to vessels in the upper dermis. Only the lesion 
of patient 3 contained both on day 0 and in week 4 of thermotherapy mixed cellular 
infiltrates, which were much more pronounced than in typical untreated BU lesions. 
 
Safety and tolerability of PCM-based heat treatment, adverse events 
The heat treatment procedure was very well tolerated by all patients. Patients with 
one (patients 1, 2, 3, 4) and with two PCM packs (patient 5) could move around 
freely and did not feel unacceptably disturbed during their daily activities nor during 
sleep at night. Patient 6 with four PCM packs also walked with acceptable restrictions 
and slept largely undisturbed. None of the patients and their guardians requested 
termination of treatment at any time. Temperatures between 40 - 43°C were 
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observed only for short intervals of time immediately after mounting of the PCM 
packs without causing unacceptable discomfort. Only initially a few small blisters 
were occasionally observed. With a simple patient-controlled method the therapeutic 
target temperature of 40°C at skin surface was quickly reached and maintained 
without further side effects. 
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Discussion 
 
Successful treatment of BU with heat has been reported in individual patients and 
small case series since 1950 [10,13,14,15]. This has not been carried further into 
clinical research and practice due to the fact that available heat application systems 
were cumbersome and not suited for use in developing countries. We achieved a 
break through by employing PCM packs as a cheap heat application system which is 
rechargeable in hot water, non-toxic and non-hazardous to the environment. In this 
proof-of-principle study we demonstrated that our heat application system is easy to 
use and allows the patient to move freely. 
 
Family members and the hospital community accepted the treatment very well and 
favoured it over other treatments currently offered (surgery, antibiotics). Nurses 
quickly adopted the techniques of mounting the PCM packs and of recharging the 
packs in boiling water. The only side effects observed were sensation of excessive 
heat for a short period after applying the PCM packs. Lowering of the temperature at 
the skin surface by an elastic bandage interposed between tube gauze and PCM 
packs reliably prevented skin irritation and development of blisters, which may occur 
if the initial temperature at skin surface is less rigorously controlled.  
 
With our PCM-based heat application system we reproduced the excellent results of 
the thermotherapy study of Meyers’ group in 1974 [10] with significantly shorter heat 
application times both with respect to length of heat treatment per day (close to 24 
hours [39°C – 40.5°C] vs a mean of 10 hours, range 8.4 – 13.2 hours [≥39°C]) and to 
total heat application time (28 to 115 days vs 28 to 55 days). Since both systems 
worked at the same temperature range measured at skin surface, the minimum 
length of heat application to achieve healing of BU appears to be in the range of our 
heat treatment schedule or even shorter. 
 
The initial clinical improvement of ulcerative lesions in our series was as fast as in the 
patient series of Meyers et al. As early as three days after initiation of heat treatment 
undermined ulcer margins collapsed and the skin attached to the underlying 
subcutaneous tissue with re-epithelialization starting at the edges. Discharge of the 
wound decreased over various lengths of time. Firm attachment of the affected skin 
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was complete only after discharge stopped. By using heat treatment alone no viable 
tissue is lost and even the overarching margins at undercutting edges are often 
rescued. Lesions were clinically inactive in all of our patients with very good 
granulation and re-epitheliazation responses after 28 days of heat treatment. In one 
of our patients (patient 6) non-viable tissue extended far beyond the ulcerated area, 
which had to be excised before skin grafting. In this patient and one other patient with 
a large defect (patient 5) skin grafting was performed after a good granulation 
response had been achieved. Currently, all our patients are relapse-free 18 months 
after completion of heat therapy.  
 
Rifampicin/streptomycin chemotherapy of BU is associated with the development of 
ectopic lymphoid tissue in the lesions [16]. In some patients, effects reminiscent of 
the immune reconstitution syndromes observed in tuberculosis and leprosy patients 
after highly active antiretroviral therapy [17] are observed. In contrast, heat treatment 
did not lead to massive increases in local inflammation and this less vigorous 
response may favour rapid re-epithelialization. Also haemorrhages, which are 
regarded as negative indicators for uncomplicated wound healing [18] were not 
observed.  
 
Results of two pilot studies, the study of Meyers et al. in the 1970s [10] and our 
study, demonstrate that heat is a highly efficacious therapy for M. ulcerans disease. 
Use of PCM packs represents a break through for thermotherapy with respect to its 
practicality in endemic areas with poor infrastructure. Further optimization of the heat 
treatment schedule should make it suitable for community application.  
 CHAPTER 7. Phase change material for thermotherapy 128               
 
Acknowledgments 
 
We thank engineer Dr. M. Hellmann for his technical input (Dr. M. Hellmann and TJ 
together developed the idea of adapting PCM as a heat delivery system to treat 
Buruli ulcer). We thank the nursing team, Daniel Ze Bekolo, Ekodogo Kombang, 
Menkaye Samentanga, Serge Ndtoungou, Susan Fese Mboe and Julie Abomo, and 
Dr. Kemo Hans of the hospital in Ayos, Cameroon, for their outstanding work. We 
thank S. Braxmeier, Bavarian Center for Applied Energy Research, Functional 
Materials for Energy Technology, Wuerzburg, Germany, for his technical input in the 
PCM-based heat application device and Dr. M Kaeser, Department of Medical 
Parasitology / Infection Biology, Swiss Tropical Institute, Basle, Switzerland, for 
investigating the samples by real-time PCR. 
 
 CHAPTER 7. Phase change material for thermotherapy 129               
 
Figures 
 
 
 
 
Figure 1. Mounting of the PCM-based heat application system and temperature 
monitoring device. (A) PCM pack and bandage mounted for treating an ulcer on the 
lower limb (patient 2) and temperature monitoring system, (B) PCM pack with sodium 
acetate trihydrate in the fluid phase before initiating the crystallisation process with 
the starter (red), sodium acetate trihydrate in the solid phase after the stored heat 
has been discharged, (C) temperature monitoring system with the sensor connected 
to the data logger to record the temperature at the skin surface as part of the clinical 
trial documentation. This will not be needed when the device is put into routine use. 
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Figure 2.  Baseline data, heat treatment schedules and results. 
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Figure 3. Healing of Buruli ulcers under PCM-based heat treatment and long 
term results. (A) Patient 2, (B) patient 5: Progress of healing during heat treatment. 
Note in particular early onset of epithelialisation. Far right follow-up 12 months after 
completion of heat treatment. Patient 5 (B) after skin grafting. 
 CHAPTER 7. Phase change material for thermotherapy 132               
 
References 
 
1. Johnson PD, Stinear T, Small PL, Pluschke G, Merritt RW, et al. (2005) Buruli 
ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med 
2: e108. doi:10.1371/journal.pmed.0020108. 
 
2. Hayman J (1993) Out of Africa: observations on the histopathology of 
Mycobacterium ulcerans infection. J Clin Pathol 46: 5-9. 
 
3. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999) 
Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. 
Science 283: 854-857. 
 
4. Walsh SD, Portaels F, Meyers WM (2008) Buruli ulcer (Mycobacterium ulcerans 
infection), Trans R Soc Trop Med Hyg 102: 969-978. 
 
5. Sizaire V, Nackers F, Comte E, Portaels F (2006) Mycobacterium ulcerans 
infection: control, diagnosis, and treatment. Lancet Infect Dis 6: 288-296. 
 
6. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, et al. (2005) Efficacy of 
the combination rifampin-streptomycin in preventing growth of Mycobacterium 
ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 49: 
3182-3186. 
 
7. WHO (2004) Provisional guidance on the role of specific antibiotics in the 
management of Mycobacterium ulcerans disease (Buruli ulcer). World Health 
Organization, Geneva, Switzerland. 
 
8. Chauty A, Ardant MF, Adeye A, Euverte H, Guedenon A, et al. (2007) Promising 
clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer 
(Mycobacterium ulcerans disease). Antimicrob Agents Chemother 51: 4029-4035. 
 
9. Eddyani M, Portaels F (2007) Survival of Mycobacterium ulcerans at 37 degrees 
C. Clin Microbiol Infect 13: 1033-1035. 
 
10. Meyers WM, Shelly WM, Connor DH (1974) Heat treatment of Mycobacterium 
ulcerans infections without surgical excision. Am J Trop Med Hyg 23: 924-929. 
 
11. WHO (2000) Buruli Ulcer (eds. K Asiedu, R Scherpbier, M Raviglione) 
WHO/CDS/CPE/ GBUI/2000.1 
 
12. WHO (2001) Buruli Ulcer. Diagnosis of Mycobacterium ulcerans disease (eds F 
Portaels, P Johnson, WM Meyers). WHO/CDS/CPE/GBUI/2001.4 
 
13. Meleney FL, Johnson BA (1950) Supplementary report on the case of chronic 
ulceration of the foot due to a new pathogenic mycobacterium (MacCallum). Ann Soc 
Belg Med Trop 30: 1499-1503. 
 
14. Glynn PJ (1972) The use of surgery and local temperature elevation in 
mycobacterium ulcerans infection. Aust N Z J Surg 41: 312-317. 
 CHAPTER 7. Phase change material for thermotherapy 133               
 
15. Reid IS (1967) Mycobacterium ulcerans infection: a report of 13 cases at the Port 
Moresby General Hospital, Papua. Med J Aust 1: 427-431. 
 
16. Schuette D, Um-Boock A, Mensah-Quainoo E, Itin P, Schmid P, et al. (2007) 
Development of highly organized lymphoid structures in buruli ulcer lesions after 
treatment with rifampicin and streptomycin. PLoS Negl Trop Dis 1: e2. 
doi:10.1371/journal.pntd.0000002. 
 
17. Lipman M, Breen R (2006) Immune reconstitution inflammatory syndrome in HIV. 
Curr Opin Infect Dis 19: 20-25. 
 
18. Waldorf H, Fewkes J (1995) Wound healing. Adv Dermatol 10: 77-96; discussion 
97. 
 
  
 
 
 CHAPTER 8.  Immune response a f t er  hea t  t r ea tment  o f  BU 135               
 
 
 
 
CHAPTER 8 
 
 
 
 
Heat treatment of Buruli ulcer is not associated with massive 
local immune activation 
 
 
Schütte D 1, Junghanss T 2, Um-Boock A3, Pluschke G 1 
 
 
 
 
1Dept. Medical Parasitology / Infection Biology, Swiss Tropical Institute, Basle, 
Switzerland 
2Section Clinical Tropical Medicine, University Hospital, Heidelberg, Germany 
3ALES, Bureau Régional pour l’Afrique, Yaoundé, Cameroon 
 
 
 
 
 
 
 
 
 
 
 
 
This article will be submitted to: 
Journal of Invest igat ive Dermatology 
 CHAPTER 8.  Immune response a f t er  hea t  t r ea tment  o f  BU 136               
 
Abstract 
 
Buruli ulcer is a necrotizing skin disease caused by Mycobacterium ulcerans. These 
bacteria grow best at temperatures of 30 – 33 °C and produce the cytotoxic 
macrolide toxin mycolactone, to which most of the clinicopathological symptoms are 
related. To date, daily intake of rifampicin and streptomycin and/or surgical excision 
of the affected tissue are the standard treatments. 
Therapy with local application of temperatures around 40°C using a phase change 
material-based heat application system is currently under evaluation. Here we have 
analysed punch biopsies taken at treatment days 0 and 28 to monitor 
histopathological changes and local immunological reactions during heat therapy. 
While massive infiltration and development of ectopic lymphoid tissue is observed 
during antibiotic therapy, the extent of total leukocyte infiltration did not increase 
during thermotherapy. While the number of PMNs decreased, T cells became more 
abundant. This may favour a rapid transition from inflammation to healing, as 
indicated by the clinical response to heat treatment, which was characterised by an 
extraordinarily rapid re-epithelization and healing process.  
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Introduction 
 
Buruli ulcer (BU) is a dermatological infection with Mycobacterium ulcerans leading to 
chronic necrotizing skin ulcers. The highest incidence rates are reported from 
countries of Central and Western Africa with the majority of cases being children 1. 
When left untreated the infection spreads locally and can destroy huge parts of the 
patient’s body surface. Treatment with antibiotics and surgery is time-consuming and 
difficult, because most affected communities are located in remote areas of the 
developing countries 2. Spontaneous healing has been reported though is not 
commonly observed and those individuals usually exhibit tremendous scarring 
leading to joint contractures and disabilities 3. 
M. ulcerans grows best at relatively low temperatures around 30°C and already in the 
1970s Meyers et al conducted a small trial on local heat application as treatment 
option. Results were very promising as patients could be cured without any further 
surgical therapy required, but the heat application device used was electricity 
dependent with a complicated thermostat construction 4. Recently, Junghanss et al 
performed proof-of-principle trial with six patients with laboratory reconfirmed 
ulcerative BU lesions in Cameroon with a new low-tech approach of heat application. 
Plastic bags filled with sodiumacetatetrihydrate, a cheap and non-toxic phase-change 
material (PCM), were used to maintain a stable temperature of around 40°C at skin 
level to prevent M. ulcerans from proliferation and toxin production (Junghanss et al. 
2008, submitted). 
The temperature sensitivity of M. ulcerans favours development of lesions in the skin 
and underlying tissue where mycolactone causes progressing dermal necrosis,  
destruction of infiltrating immune cells and a suppression of local immune responses 
5-7
. In active BU lesions, intra-lesional cellular immune responses are usually mild to 
absent and the vast majority of bacteria are extracellularly clustered in the necrotic 
subcutaneous tissue 8,9. Very early lesions or the macroscopically healthy margins of 
chronic BU lesions may contain a more pronounced leukocyte infiltration and here 
intracellular bacteria can occasionally be observed 10-12. In previous studies we could 
show that antibiotic therapy with rifampicin and streptomycin does not only kills the 
bacilli but also reverses local immunosuppression. During therapy a massive 
increase of leukocyte infiltration in the lesions as well as the development of ectopic 
organised lymphoid aggregates is observed 9. 
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Here we report on the local cellular immune response in BU lesions during 
thermotherapy. In patients treated with the PCM-based heat application device the 
clinical picture was ameliorating extraordinarily rapid. Wound closure was achieved 
by self-healing in small ulcers or skin grafting in larger lesions (Junghanss et al. 
2008, submitted). Our histopathological evaluation indicates that lack of massive 
local immune responses favour rapid transition from inflammation to tissue healing. 
 
 
Materials and Methods 
 
Six laboratory-confirmed BU cases were included in this study and admitted to local 
heat treatment of the affected body parts as has been described (Junghanss et al 
2008). Briefly, plastic bags filled with the PCM sodiumacetatetrihydrate were applied 
to the wounds and a therapeutic temperature of about 40°C was kept at skin surface 
level for 15-20 hours per day for at least four weeks. Temperature was recorded 
automatically every 10 min for safety reasons and wounds cleaned and dressed 
three times a day to avoid additional super-infection. While 4/6 lesions healed 
completely without any other medical intervention apart from dressing and heat 
application, 2/6 required additional skin graft to close the large ulcerative areas 
without further delay to circumvent exaggerated scarring. All individuals remained 
relapse free within 12 months of follow-up. Biopsies and swabs were taken and 
assessed for presence of AFB by ZN staining, histopathology, as well as presence of 
M. ulcerans DNA by IS2404 real-time PCR. 
4mm punch biopsies were taken at days 0 and 28 from the lesion margins and fixed 
in 4% neutral-buffered paraformaldehyde for 24h. Tissue samples were stored in 
70% ethanol and transferred to Switzerland, where samples were further processed 
as previously described 9. Paraffin embedded tissue was cut into 5µm thin sections. 
After dewaxing and rehydration, sections were stained with haematoxylin/eosin (HE) 
or Ziehl Neelsen (ZN) for morphological and microbiological assessment, 
respectively. Immunohistochemistry (IHC) was performed with antibodies against 
Elastase (polymorphonuclear neutrophils [PMNs]; Dako), CD3 (T lymphocytes; 
Dako), CD20 (B lymphocytes; Novocastra) and CD14 (macrophages; Novocastra) 
using Vector® NovaRED™.  
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Results 
 
Serial sections from punch biopsies taken at days 0 and 28 from the margins of the 
six ulcerative lesions were stained with HE and ZN. At day 0, the samples taken from 
the three small ulcers showed only slight signs of necrosis and no AFB were 
detected. In these lesions the infection and tissue destruction thus had not yet 
progressed deeply into the tissue adjacent to the border of the ulcers. However, PCR 
performed on swab material was positive for IS2404 and one out of these three small 
ulcers was also AFB positive. 
The biopsies from two of three patients with larger ulcers exhibited histopathological 
changes, i.e. extensive necrosis of the adipose tissue in the absence of inflammation, 
characteristic for undermined edges of BU lesions. In the third patient with a larger 
lesion necrosis was associated with a much stronger leukocyte infiltration than is 
commonly found in BU lesions.  
Compared to the corresponding sample taken at day 0, the biopsy taken on day 28 
showed rather a reduction than an increase in cellular infiltration (Fig.1-c & -d). On 
day 0 infiltrates consisted primarily of histiocytes with only few lymphocytes or PMNs 
and most of the cells were apoptotic/necrotic (Fig.1-c). In contrast, on day 28 the 
infiltration contained in addition to histiocytes a high proportion of T lymphocytes 
(Fig.1-d). Already without treatment on day 0 giant cells but no granulomas were 
found in the deeper dermis (Fig.1-e) and the sub-epidermal layer revealed vasculitis 
and strong infiltration of the papillary dermis (Fig.1-f). After 28 days of heat treatment 
both the deeper dermis (Fig.1-g) and the sub-epidermal region (Fig.1-h) contained 
scarring tissue and elevated levels of fibroblasts building new connective tissue. 
When stained with ZN for acid-fast bacilli only the biopsy from day 0 comprised small 
clusters of extracellular AFB inside the necrotic tissue whereas no AFB were found in 
the biopsy from day 28 (Fig.1-i). 
The largest ulcer treated within the framework of this study showed signs of super-
infection, such as bad odour and greenish necrosis at the time of admission (Fig.2-a). 
Swabs taken from the undermined edges of the lesion were strongly positive for AFB 
and revealed heavy superinfection (Fig.2-b). After 28 days, undermined margins had 
reattached to the underlying tissue (Fig.2-c), the superinfection was eliminated and 
only a few AFB were left (Fig.2-d).  
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To monitor changes in the composition of the cellular infiltrates associated with heat 
treatment we characterised the infiltrating cells in biopsies from two lesions, one 
small ulcer and one large ulcer.  On day 0 the deep dermal necrosis in the biopsy 
from the small ulcer showed mild mixed infiltration (Fig.3-a) primarily consisting of 
Elastase+ PMNs (Fig.3-b) and very few CD3+ T lymphocytes (Fig.3-c). On day 28 
the deep dermal infiltration was very low (Fig.3-d) but the sub-epidermal area 
exhibited increased cellular infiltration mainly around vessels (Fig.3-e). Compared to 
day 0 the density of Elastase+ PMNs was strongly reduced (Fig.3-f), but the infiltrates 
in the sub-epidermal area comprised CD3+ T lymphocyte clusters (Fig.3-g). 
On day 0 the biopsy from the large ulcer showed a minor infiltration in its extended 
necrotic core (Fig.3-h). Elastase+ PMNs located around the necrotic adipose and 
connective tissue in the deeper dermis (Fig.3-i) showed often had apoptotic/necrotic 
appearance (Fig.3-j). CD3+ T lymphocytes were only found around some vessels of 
the sub-epidermal tissue (Fig.3-k). The biopsy taken on day 28 still contained 
necrotic areas in the deeper dermal layer and cellular infiltration remained low (Fig.3-
l) as were the numbers of Elastase+ PMNs (Fig.3-m). In the upper dermis some 
CD3+ T lymphocyte foci could be found near glands and vessels (Fig.3-n). 
In both lesions, numbers of CD14+ macrophages/monocytes were very low on day 0 
and showed only marginal increase on day 28 (not shown). While CD20+ B cells 
were absent on day 0, some scattered CD20+ cells could be found on day 28 (not 
shown). 
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Discussion/Conclusion 
 
Local inflammation of the skin was not evidently altered during thermotherapy, which 
is in accordance with the clinical observation that lesions did not cause increased 
pain. Both PMNs, as members of the innate, and T cells, representing adaptive 
immune response, were present with PMNs mainly located around bacteria 
containing dermal necrosis and T cells confined to vessels in the upper dermis. Total 
amounts of infiltrating cells were rather stable or decreasing after four weeks of 
treatment, leading to the assumption that infection can be cleared without major 
cellular immune modulations necessary. The relative ratio of PMNs vs. T 
lymphocytes shifted from almost equal amounts towards a clear T cell dominance 
over time.  
In skin samples from antibiotically treated patients, vast haemorrhages were 
observed 9 as a negative indicator for uncomplicated wound healing 13 which was not 
the case during heat application. Furthermore, studies on knock-out mice showed 
that the depletion of PMNs enhances the re-epithelization of wounds 14. These data 
are in concordance with the observed enduring discharge from the ulcers together 
with a highly efficient healing process of the lesions during heat therapy.  
 
Mycolactone is likely to be the main causative for the typical clinical and histological 
symptoms observed in Buruli ulcer patients. Although it has been discovered almost 
a decade ago 5 data about its behaviour inside the wounds including released 
amount, diffusion kinetics and chemical stability is difficult to gain and still 
fragmentary. Observational data indicate instability of the unsaturated fatty acid side 
chain of the toxin and cytotoxic properties are lost within few weeks when stored at 
4°C. The question arises whether heat application not only breaks mycolactone 
production by influencing the bacterial metabolism but even enhances degradation of 
already released toxin molecules. This could be a possible explanation for the 
astonishingly quick oedema reduction and re-epithelization of the lesions. 
 
Histopathological results in the present thermo therapy study were in stark contrast to 
findings from antibiotic treated patients were a counterproductive immunopathology 
should be considered possible 9. The fact that punch biopsies are not enough to 
mirror the total infiltration should be regarded which is a clear interpretation limitation 
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taking in account the great heterogeneity usually observed between different areas 
within a lesion 9,15,16. Since all patients showed similarities in both histopathological 
changes and clinical presentation this might be an indication for heat application 
being a potent tool to cure BU lesions without major tissue damage. In combination 
with antibiotic therapy it could prevent disproportionate local leukocyte reactions and 
redundantise additional surgical interventions. 
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Figures 
 
 
Figure1: Patient with larger ulceration reveals uncommonly strong cellular 
infiltration 
(a-b) Clinical progress during four weeks of heat treatment. (c-h) HE and (i-j) ZN 
staining of 5mm sections from punch biopsies taken on days 0 and 28.  
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Figure2: Largest ulcer enrolled in the study exhibits rapid improvement during 
thermotherapy despite heavy superinfection 
(a, c) Clinical picture at days 0 and 28. (b, d, e) ZN staining of smears taken from the 
undermined edges show obvious reduction in bacterial load in the course of heat 
application.
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Figure3: Local leukocyte infiltrations diminish during heat treatment 
Histological examination of punch biopsies taken from (a-g) a small and (h-n) a larger 
ulcerative lesion. (a, d, e, h, l) HE staining of sections from days 0 and 28. 
Immunohistochemistry was performed with antibodies against (b, f, I, j, m) 
neutrophilic elastase and (c, g, k, n) T lymphocyte marker CD3.  
(a-c) Deeper dermis exhibits mild infiltration primarily consisting of elastase+ PMNs 
and few CD3+ T lymphocytes. (d-g) After four weeks of thermotherapy infiltrates are 
mainly located around vessels in the upper dermal layer and cellular subsets reveal a 
switch from acute (elastase+) to chronic (CD3+) infiltrates.  
(h-k) Focal infiltration of tissue surrounding the sub-epidermal necrosis consists 
mainly of elastase+ PMNs. CD3+ T lymphocytes are located around vessels. (l-n) On 
day 28 overall infiltration has dropped significantly. Only scattered elastase+ PMNs 
were observed, but the upper dermis still contains CD3+ T cell clusters. 
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Mycobacterium ulcerans, a human pathogen provoking skin ulceration due to its 
exotoxin mycolactone [1], causes one of the most prevalent mycobacteriosis 
worldwide (Buruli ulcer). Infected individuals suffer from progressing dermal lesions 
which frequently lead to disabilities as a result of extensive scarring and joint 
contractures. Currently recommended therapy includes circumstantial surgical 
excision of the affected tissue and/or eight weeks daily administration of rifampicin 
and streptomycin [2]. 
Surgical treatment is very expensive and time-consuming and needs a well equipped 
and maintained infrastructure. Streptomycin has to be injected daily into the muscles, 
which is not very well tolerated by superstitious African populations and causes 
additional suffering and risks, especially for small children who are most often 
affected [3]. Furthermore, both antibiotics are front-line drugs for TB treatment and 
major concerns arise regarding resistant M. tuberculosis strains developing in co-
infected patients due to the relatively short therapy duration.  
Novel therapeutic approaches or drugs are therefore urgently needed and are 
currently under investigation [4,5]. We tested the in vitro anti-mycobacterial activity of 
compound DS-1 in liquid M. ulcerans cultures. Details of the compound such as 
synthesis or structure can not be disclosed to date due to patent issues. The 
compound was active against M. tuberculosis in previous studies. 
 
20 BacTAlert MB Blood Culture flasks supplemented with 1ml MB/BacT Enrichment 
Fluid and 1.5ml MB/BacT Antibiotic Supplement each were inoculated with M. 
ulcerans strain ifik-1066089 and incubated at 32°C for 2-3 weeks. When exponential 
growth phase was reached cultures were harvested and bacterial pellets retrieved by 
centrifugation for 15 min. After washing with PBS pellets were pooled and 
resuspended in Middlebrook 7H9-T freezing medium by vortexing aliquots containing 
sterile glass beads. Suspensions were calibrated to OD600 1, aliquoted and stored at 
-80°C until further use. 
Growth inhibition was measured using Microplate Alamar blue assay (MABA) in a 96 
well plate format [6]. An appropriate amount of stock solution was diluted 1:4 in 
Middlebrook 7H9 complete medium (containing glycerol, Tween and OADC/ADS). 
200µl of sterile deionised water was added to the outer-perimeter wells of the 96 well 
plates and the remaining wells were filled with 100µl 7H9GC broth. 100µl of 4x drug 
solutions were serially diluted in duplicates using a multi-channel pipette starting from 
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column 2 and 100µl excess medium was discarded from the wells in column 10. 
Column 11 was used for negative and positive growth controls. 100µl prediluted 
bacterial culture was added to all wells except the negative growth controls. Plates 
were incubated at 28-30°C for 6 days without CO2 supply under non-rocking 
conditions. 50 µl of freshly prepared 1:1 mixture of 10XAlamar Blue and 10% Tween 
80 was provided to all wells and plates incubated for another 4-6 days depending on 
intensity of colour change. A digital camera was used to document results and plates 
evaluated based on the observed colour change. Three independent experiments 
were performed for each starting dilution. 
 
Several batches of rifampicin and streptomycin were tried as positive control in this 
assay, but the M. ulcerans strain used here was not susceptible to these drugs for 
unknown reason. The strain was very well adapted to BacTec, indeed keeping its 
ability to produce mycolactone but passing into log phase within 2 weeks after 
inoculation. 
Compound DS-1 had a MIC90 of 0.016 – 0.025 µg/ml or 4.6 – 7.4 µmol/ml for M. 
ulcerans strain ifik9066089 in 7H9-GT medium. Coloric changes of the indicator dye 
Alamar blue were not as clear-cut as observed with faster growing mycobacteria [7]. 
This is mainly due to the fact that replication of M. ulcerans takes much longer from 
few days up to several weeks and therefore metabolic activity is lower. Although 
proliferation of ifik9066089 could be accelerated through adaptation to BacTec 
medium over a long period, the change to 7H9-GT medium obviously slowed it down 
again.  
 
Cytotoxicity assays both in cell culture and animal model as well as bioavailability 
studies have to be performed to evaluate whether compound DS-1
 
or its derivatives 
are suitable candidates for antimycobacterial drug development. Furthermore, the 
MIC90 of a range of other mycobacteria will be tested. 
The here presented data disclose that compound DS-1 is stable in liquid 
mycobacterial culture over weeks without loss of its antibacterial activity, very 
efficiently inhibiting growth of M. ulcerans. The main goal is to obtain a save drug 
which is orally administered, acting rapidly and can be produced at low costs. 
Compound DS-1 may represent a suitable lead structure for the development of a 
novel antimycobacterial drug to treat Buruli ulcer 
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Figure1. MIC90 of DS-1 in µmol/ml 
MABA with liquid M. ulcerans culture on 96 well plates using duplicates of serial 2-
fold dilutions of compound DS-1. Last row represents positive (M. ulcerans without 
any drug) and negative (only medium) growth controls. Blue indicates growth 
inhibition, pink proliferation.  
DS-1 
Start at 
3x10-3 µmol/ml 
DS-1
 
Start at 
3x10-4 µmol/ml 
DS-1 
Start at 
3x10-2 µmol/ml 
DS-1 
Start at 
3x10-3 µmol/ml 
Rifampicin 
Start at 
1x10-2 µmol/ml 
Rifampicin 
Start at 
1x10-3 µmol/ml 
4.6x10-5 µmol/ml 
7.4x10-5 µmol/ml 
 
 
 CHAPTER 9.  Growth  i nh ib i t i on  o f  M.  u l ce rans  153               
 
References 
 
1. George KM, Pascopella L, Welty DM, Small PL (2000) A Mycobacterium ulcerans 
toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture 
cells. Infect Immun 68: 877-883. 
 
2. WHO (2004) Provisional guidance on the role of specific antibiotics in the 
management of Mycobacterium ulcerans disease (Buruli ulcer). World Health 
Organization, Geneva, Switzerland. 
 
3. Sopoh GE, Johnson RC, Chauty A, Dossou AD, Aguiar J, et al. (2007) Buruli ulcer 
surveillance, Benin, 2003-2005. Emerg Infect Dis 13: 1374-1376. 
 
4. Ji B, Chauffour A, Robert J, Lefrancois S, Jarlier V (2007) Orally administered 
combined regimens for treatment of Mycobacterium ulcerans infection in mice. 
Antimicrob Agents Chemother 51: 3737-3739. 
 
5. Onwueme KC, Vos CJ, Zurita J, Soll CE, Quadri LE (2005) Identification of 
phthiodiolone ketoreductase, an enzyme required for production of 
mycobacterial diacyl phthiocerol virulence factors. J Bacteriol 187: 4760-4766. 
 
6. Franzblau SG, Witzig RS, McLaughlin JC, Torres P, Madico G, et al. (1998) Rapid, 
low-technology MIC determination with clinical Mycobacterium tuberculosis 
isolates by using the microplate Alamar Blue assay. J Clin Microbiol 36: 362-
366. 
 
7. Chauca JA, Palomino JC, Guerra H (2007) Evaluation of the accuracy of the 
microplate Alamar Blue assay for rapid detection of MDR-TB in Peru. Int J 
Tuberc Lung Dis 11: 820-822. 
 
 
  
 
 
 
 CHAPTER 10.  D iagnos is  v ia  mAbs  aga ins t  18kD shsp  155               
 
 
 
 
CHAPTER 10 
 
 
 
 
Diagnosis of Mycobacterium ulcerans infection by its 18kD 
small heat shock surface protein 
 
 
Daniela Schütte1, Diana Díaz-Arévalo1*, Thomas Bodmer2, Gerd Pluschke1 
 
 
1Swiss Tropical Institute, Section Molecular Immunology, Basle, Switzerland 
*Current address: City of Hope, Duarte, CA, USA 
2University Hospital Bern, Institute for Infectious Diseases, Bern, Switzerland 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article is in preparation 
 CHAPTER 10.  D iagnos is  v ia  mAbs  aga ins t  18kD shsp  156               
 
Introduction 
 
Buruli ulcer is a chronic necrotizing disease of skin and soft tissue caused by 
Mycobacterium ulcerans. The disease starts as a subcutaneous nodule, papule, or 
plaque that eventually ulcerates and progresses over months to years 1. After 
tuberculosis and leprosy, Buruli ulcer is the third most common mycobacterial 
infection in immunocompetent humans. People of all ages, races, and socioeconomic 
class are susceptible, but the main burden of disease falls on children living in sub-
Saharan Africa 2. Buruli ulcer has mainly been reported in countries with tropical and 
subtropical climates, but it may also occur in some regions where it has not yet been 
recognized. The full extent of the Buruli disease burden is unknown because this 
disease occurs primarily in remote and rural areas. The numbers of cases reported in 
some countries of West Africa are substantial.  
Although not generally a fatal condition, BU lesions can become extensive. When 
diagnosis and treatment are delayed, sufferers are frequently left with long-term 
physical and cosmetic disabilities. In a known area of endemicity, an experienced 
person can diagnose BU on clinical grounds. Any two of the following findings are 
required to confirm clinical diagnosis: (i) acid-fast bacilli (AFB) in a smear stained with 
Ziehl-Neelsen (ZN), (ii) culture of M. ulcerans, (iii) pathognomonic histopathology 
(contiguous coagulation necrosis and the presence of AFB), or (iv) the presence of 
M. ulcerans DNA as detected by PCR 3. Culture confirmation may take 8 to 12 weeks 
and treatment needs to be initiated much sooner than this to ensure an optimal 
outcome for the patient. The use of PCR for diagnosis of BU has been a major step 
forward, most commonly targeting IS2404, a multicopy transposase 4.  However, this 
technique has to be performed in a laboratory with high standards to avoid false 
positives. Histopathology is a reliable diagnostic tool, but certainly a technically 
demanding method. Among the tests recommended for the confirmation of a 
suspected case of Buruli ulcer (BU), only microscopy is simple, less costly and within 
the competence of peripheral treatment centres 5. 
Broad antigenic cross-reactivity between mycobacterial species represents a major 
problem for the development of new tests to identify M. ulcerans with high specificity 
and sensitivity. In a previous work we identified the highly immunogenic 18kD small 
heat shock protein (shsp) of M. ulcerans, which has no homologues in M. bovis and 
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M. tuberculosis, and described humoral responses of individuals exposed to M. 
ulcerans on the basis of this antigen 6. We produced monoclonal antibodies (mAbs) 
against this particular protein which recognize M. ulcerans antigen preparation in 
Western Blot and may become useful in the diagnosis of BU.  
Here we present analysis of mAbs against M. ulcerans 18kD shsp regarding their 
suitability to monitor M. ulcerans infection or exposure. We could show that these 
mAbs detect M. ulcerans in culture and tissue with high sensitivity and specificity and 
may be used in future for the development of an antigen capture assay to rapidly 
diagnose M. ulcerans infection. 
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Results  
 
Expression of 18kD shsp under different growth conditions 
We have evaluated the potential of a monoclonal anti-18kD antibody with very limited 
cross-reactivity with other mycobacterial species, namely M. chelonae 6 to detect M. 
ulcerans inside BU lesions. 
First, we assessed the expression of 18kD shsp in vitro under different growth 
conditions mimicking the change between environment and host. M. ulcerans were 
grown on LJ-medium at 28°C or 32°C under aerobe and at 32°C under anaerobe 
conditions, and protein lysates loaded onto a SDS-Gel. Mycobacterial proteins were 
retrieved by beat-beating with 1% SDS solution and another beat-beating of the solid 
phase with 5% SDS solution. Ponceau staining showed similar protein levels for all 
lanes (Fig.1a). In the 1% SDS fraction 18kD protein could only be detected under 
32°C anaerobic conditions, but the 5% SDS fraction revealed also a certain 
expression in the 28°C and 32°C culture (Fig.1b). Taken together 18kD seems to be 
constitutively expressed, but expression levels may vary with growth conditions. 
 
Evaluation of different staining techniques to detect in vitro grown M. ulcerans 
with a monoclonal anti-18kD antibody (DD3.6)  
We performed immunohistochemistry with the monoclonal anti-18kD antibody DD3.6 
on two different African M. ulcerans strains, namely ifik and afr2, from culture grown 
at 32°C on LJ-medium and several negative controls. Both M. ulcerans cultures 
showed positive staining (Fig.2a) whereas other mycobacterial species, namely M. 
marinum, M. tuberculosis and M. bovis, remained negative (Fig.2b). The ifik strain 
was used to compare different staining methods for sensitivity and specificity. 
Peroxidase-based staining with Vector NovaRed using a horse anti-mouse 
secondary antibody revealed bacterial cluster with blebbing of 18kD containing matrix 
(Fig.2c; left panel). Single bacteria sprouting from huge culture clumps were easily 
identified (Fig.2c; right panel). Fluorescence staining with a goat anti-mouse 
secondary antibody labelled with fluorofore Alexa488 gave a bright signal at lower 
magnifications (Fig.2d; left panel) and clearly labelled the membrane-bound 18kD 
shsp (Fig.2d; right panel). Staining with FastRed using a horse anti-mouse secondary 
antibody labelled with alkaline phosphatase gave a brighter signal compared to (c) 
and (d) both in bright field and fluorescence microscopy (Fig.2e; left panel). At higher 
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magnification a high background noise was observed and no clear staining of bacilli 
could be obtained (Fig.2e; right panel). Secondary antibodies were all manufactured 
by Vector Laboratories. 
To assess the antibody’s potential as diagnostic tool we used different 
immunohistochemistry techniques to detect M. ulcerans in skin tissue from BU 
patients. Staining with Vector NovaRed gave a bright, background-free signal 
(Fig.3a-i). Higher magnification revealed a very distinct staining of the surface-bound 
18kD shsp identifying single organisms within clusters (Fig.3a-ii). Polar accumulation 
of the protein was found in a proportion of bacteria which showed signs of 
decomposition (Fig.3a-iii). With Alexa488 fluorescence staining bacteria were 
efficiently labelled but auto-fluorescent erythrocytes (arrow) inside the tissue 
interfered with the bacterial staining and reduced sensitivity (Fig.3b-i). The close-up 
displayed equally sensitive surface staining of 18kD shsp as with Vector NovaRed 
(Fig.3b-ii). The brightest staining both in bright field and fluorescence was obtained 
with the phosphatase-based FastRed staining (Fig.3c-i). A spotted staining pattern 
was observed not allowing identification of single bacteria (Fig.3c-ii). Furthermore, 
false positive background staining of tissue compartments was produced (not 
shown). 
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Discussion 
 
As diagnosis of BU is usually based on clinical examination and unspecific staining of 
acid-fast bacilli, developing a rapid diagnostic test to identify M. ulcerans infections 
with high specificity and sensitivity is a prioritized topic in BU research. In the present 
work we evaluated the immunodominant 18kD shsp of M. ulcerans and a monoclonal 
antibody against this antigen for their potential to be used as diagnostic tools.  
The environment harbours unknown mycobacterial species that might facilitate 
serum antibody production in humans and therefore contribute as well to false 
positive results based on cross-reactive serum antibodies. Diagnosis of BU based on 
specific monoclonal antibodies against the native M. ulcerans 18kD shsp would 
circumvent those issues. In a former publication of our group monoclonal antibodies 
against this protein was raised in mice and showed no cross-reactivity to other 
mycobacterial species except M. chelonae in Western Blot analysis 6. We could 
reconfirm these results with IHC of different mycobacterial cultures.  
It has been shown that M. ulcerans grows more efficient and rapid under low oxygen 
concentration 7. Moreover, expression of heat shock proteins is commonly up-
regulated under hypoxic conditions or due to elevated temperature 8. Accordingly, 
18kD shsp expression seems to be up-regulated when culture conditions were 
changed from 28°C aerobic towards 32°C anaerobic. We speculate that these 
findings might reflect the natural situation, where the bacteria have to adjust their 
metabolism both to an environmental reservoir (low temperature, high oxygen) as 
well as to a human or animal host (elevated temperature, reduced oxygen). 
Increased resolution and staining intensity inside BU tissue samples compared to 
bacteria cultured on LJ-plates further supports this hypothesis. 
Fluorescence staining gives a very good contrast for identification of single bacteria 
but the complex organization of the skin, which carries auto-fluorescent structures 
such as erythrocytes, confuses the readout and may lead to false positivity. The 
brightest staining assessable in both bright field and fluorescence microscopy can be 
achieved with phosphatase-based FastRed staining, but specificity is very low as 
also nuclei and other structures become lightly stained. The best working procedure 
is peroxidase-avidin/streptavidin-based immunohistochemistry with the substrate 
Vector NovaRed, which can be assessed in bright field microscopy and provides high 
specificity and sensitivity without background noise. Morphology of single M. ulcerans 
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inside and around bacterial clusters can be visualized with this technique. 
Furthermore, decomposing bacilli developing polar accumulation of 18kD can be 
observed. This is probably due to loss of cytoplasm and subsequent collapse of the 
cell wall which results in the “beaded” appearance of bacteria.  
The anti-18kD antibody DD3.6 specifically identifies M. ulcerans in culture as well as 
in tissue and we will assess the possibility to determine viability of M. ulcerans via 
this method. Furthermore, a rapid diagnostic test suitable for sample analysis in the 
field may be developed using monoclonal antibodies against this protein.  
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Figures 
 
 
Figure1. Western blot analysis of protein lysates of M. ulcerans grown under 
different conditions  
Proteins were extracted in two fractions using first 1% SDS and subsequently 5% 
SDS on the bacterial pellets retrieved from the first fraction. (a) Ponceau staining 
showed that equal amounts of protein were loaded onto the gel. (b) Expression of 
18kD shsp is up-regulated due to increased temperature and anaerobic conditions. 
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Figure2. Staining of cultured mycobacteria using monoclonal antibodies 
against 18kD shsp  
(a) Staining of two different African M. ulcerans strains with antibody DD3.6 using 
Vector NovaRed. (b) No cross-reactivity with M. marinum, M. tuberculosis or M. 
bovis. (c) Close-up of (a) reveals blebbing of matrix containing 18kD (left panel) and 
identifies single bacilli (right panel). (d) Fluorescence staining of 18kD shsp with 
Alexa 488 gives sufficient intensity (left panel) and marks the surface of single 
bacteria (right panel). (e) Staining with Vector FastRed can be detected with bright 
field as well as fluorescence microscopy (left panel) but resolution is lower compared 
to (c) and (d) (right panel). 
 
 
Figure3. Detection of M. ulcerans in human tissue samples with monoclonal 
antibodies against 18kD shsp using different staining procedures  
Immunohistochemistry using peroxidase-based Vector NovaRed (a), Alexa488 
fluorofore (b) or phosphatase-based FastRed (c). Vector NovaRed produces a fully 
background-free staining of bacterial clusters (a-i). Higher magnification reveals 
surface staining pattern (a-ii). Distinct bacterial morphology can be visualized (a-iii) 
showing polar accumulation of 18kD protein in decomposing M. ulcerans (a-iv). 
Staining of bacteria with Alexa488 can be easily detected at low magnifications, but 
erythrocytes reveal strong auto-fluorescence (arrow) (b-i). As in (a), surface staining 
(b-ii) can be illustrated. Bright field and fluorescence images of M. ulcerans stained 
with FastRed (c-i). Higher magnification reveals a spotted, non-distinct staining 
pattern, but a very strong fluorescence signal (c-ii).  
Scale bars: 200µm (a-i; b-i), 50µm (c-i), 16µm (c-ii), 10µm (a-ii), 6µm (b-ii), 4µm (a-
iii). 
 CHAPTER 10.  D iagnos is  v ia  mAbs  aga ins t  18kD shsp  165               
 
 
 
 
 
 
 CHAPTER 10.  D iagnos is  v ia  mAbs  aga ins t  18kD shsp  166               
 
References 
 
1 Mensah-Quainoo E, Yeboah-Manu D, Asebi C et al. Diagnosis of 
Mycobacterium ulcerans infection (Buruli ulcer) at a treatment centre in 
Ghana: a retrospective analysis of laboratory results of clinically diagnosed 
cases. Trop Med Int Health 2008; 13: 191-8. 
 
2 Asiedu K, Wansbrough-Jones M. Mycobacterium ulcerans infection (Buruli or 
Bairnsdale ulcer): challenges in developing management strategies. Med J 
Aust 2007; 186: 55-6. 
 
3 Portaels F, Johnson P, Meyers WM. Buruli ulcer. Diagnosis of Mycobacterium 
ulcerans disease. WHO, Geneva 2001. 
 
4 Stinear T, Ross BC, Davies JK et al. Identification and characterization of 
IS2404 and IS2606: two distinct repeated sequences for detection of 
Mycobacterium ulcerans by PCR. J Clin Microbiol 1999; 37: 1018-23. 
 
5 van der Werf TS, Stienstra Y, Johnson RC et al. Mycobacterium ulcerans 
disease. Bull World Health Organ 2005; 83: 785-91. 
 
6 Diaz D, Dobeli H, Yeboah-Manu D et al. Use of the immunodominant 18-
kiloDalton small heat shock protein as a serological marker for exposure to 
Mycobacterium ulcerans. Clin Vaccine Immunol 2006; 13: 1314-21. 
 
7 Palomino JC, Obiang AM, Realini L et al. Effect of oxygen on growth of 
Mycobacterium ulcerans in the BACTEC system. J Clin Microbiol 1998; 36: 
3420-2. 
 
8 Schlesinger MJ. Heat shock proteins. J Biol Chem 1990; 265: 12111-4. 
 
 CHAPTER 11.  Rev iew 167               
 
 
 
 
CHAPTER 11 
 
 
 
 
Immunosuppression and treatment-associated inflammatory 
response in patients with Buruli ulcer 
 
 
 
Daniela Schütte (first author) 
Biologist, PhD student 
Swiss Tropical Institute, Molecular Immunology, Basle, Switzerland 
 
Prof Dr Gerd Pluschke (corresponding author) 
Head of MPI (Medical Parasitology and Infection Biology)  
Group leader Molecular Immunology 
Swiss Tropical Institute, Molecular Immunology, Basle, Switzerland 
 
 
 
 
 
 
 
 
 
 
 
 
This article was invited by: 
Expert Opinion on Biological Therapy 
 CHAPTER 11.  Rev iew 168               
 
Abstract  
 
Buruli ulcer is a necrotizing skin disease caused by Mycobacterium ulcerans. Major 
necrosis with abundant clusters of extracellularly replicating mycobacteria and only 
minor leukocyte infiltration are characteristic histopathological features of the 
disease. Mycolactone, a cytotoxic macrolide exotoxin of M. ulcerans plays a key role 
in the development of this pathology. Antimicrobial therapy, such as 
rifampicin/streptomycin that was recently introduced, appears to lead to phagocytosis 
of mycobacteria and massive leukocyte infiltration which culminates in the 
development of ectopic lymphoid structures in the lesions. While the curative effect of 
the antibiotic treatment may be supported by immune defense mechanisms, 
persisting mycobacterial antigens and immunostimulators occasionally also seem to 
cause apparent reactivation of the disease. This appears to be related to excessive 
immunostimulation rather than incomplete killing of the pathogen.  
 
 
Introduction 
 
Epidemiology of BU 
First reports about extending cutaneous ulcers in the Ugandan population came from 
Sir Albert Cook in 1897 indicating that BU was already present at that time in Africa 
[1]. In 1937 the disease was first recognized in Bairnsdale in Victoria, Australia [2] 
and in 1948 McCallum et al were able to culture and identify Mycobacterium ulcerans 
as the causative agent of the disease [3]. Nowadays, the so-called Bairnsdale or 
Buruli ulcer (named after the Buruli County of Uganda, where a BU epidemic 
occurred in the 1960s) is the third most common mycobacterial infection in 
immunocompetent people [4]. BU has been found by now in more than 30 tropical 
and subtropical countries worldwide [5]. Endemic foci are usually linked to wetlands 
and riverine areas, and especially in many regions of West-Africa including Benin, 
Côte d’Ivoire, Cameroon and Ghana the numbers of reported BU cases have 
dramatically increased in recent years [6,7,8]. Outbreaks appear to be related to 
environmental changes and an increased exposure of affected populations [9,10]. 
Although the disease is known to develop in all age groups with a nearly equal 
gender distribution, children aged between 5 and 15 make up the majority of patients 
 CHAPTER 11.  Rev iew 169               
 
[11,12]. Occasional clustering of cases within one family may reflect a common 
source of infection or increased genetic susceptibility to infection rather than human-
to-human transmission [13].  
 
It is commonly believed that M. ulcerans is an environmental mycobacterium and that 
micro-traumata of the skin during fishing, farming or washing activities represent 
entry-sites for infection [14]. However, it is not clear, whether the natural reservoir 
relevant for M. ulcerans infection in humans has already been identified. Aquatic 
plants are known to carry bio-film formations of M. ulcerans [15] and several groups 
of aquatic animals, such as  aquatic insects, mollusks, frogs and fish have been 
found associated with M. ulcerans. Recently, the first successful isolation of M. 
ulcerans from an environmental source, a water strider collected in West-Africa, has 
been published [16]. Insects such as mosquitoes and biting aquatic hemiptera have 
been implicated as vectors [17,18], but positivity for M. ulcerans may only be an 
indicator for the presence of the pathogen in the environment and not for a role of the 
insects in transmission [19,20]. Ulcerative lesions caused by M. ulcerans have been 
described not only in humans, but also in wild and domestic animals [21,22,23].  
 
Clinical presentation of BU 
BU is primarily an infection of the subcutaneous adipose tissue. Most commonly it 
starts as a painless, movable subcutaneous nodule or papule adherent to the skin 
(Figure1). The painless nature of progressive BU seems to be due to nerve damage 
at the site of the lesions [24]. All parts of the body can be affected, but most lesions 
are located at the extremities. Thermosensitivity of M. ulcerans [25] seems to favor 
development of skin lesions of the limbs. Early lesions may either heal spontaneously 
or break down centrally and form a necrotic skin ulcer. Other manifestations of early 
disease are large plaques or edema, which often extend rapidly, eventually leading to 
large ulcerations [26,27]. Usually the ulcers have deeply undermined edges and 
enlarge over an extended period of time (Figure 1). They are often painless, systemic 
symptoms are largely absent and involvement of visceral organs has not been 
described [26]. After destruction of skin and soft tissue, reactive osteitis or 
osteomyelitis may develop [28]. A subset of patients develops multiple skin lesions, 
and lymphohematogenous spread of the mycobacteria may also lead to metastatic 
osteomyelitis [27]. After extended periods of progressive ulceration, the necrotic 
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stage of the disease may cease and lesions may heal spontaneously. Scarring close 
to joints often result in contractures and severe functional limitations [29]. Since M. 
ulcerans isolates from the same geographical origin are genetically largely 
monomorphic [30,31], variations in disease progression and severity observed within 
a particular endemic area are most likely related to host factors.  
 
Treatment of BU 
Until recently, surgical excision of lesions with a wide margin including healthy 
appearing tissue was the only recommended treatment for all stages of BU 
[11,12,21]. While for pre-ulcerative lesions primary closure after wide excision is 
possible, split skin autografting after development of granulation tissue is required for 
larger lesions. Recurrence rates between 6% to 47% have been reported after 
surgical treatment [32,33,34] and adjunct antibiotic therapy has therefore sometimes 
been implemented [35]. Recurrences may be caused by small numbers of M. 
ulcerans that have spread to non-excised macroscopically healthy tissue surrounding 
the primary lesion [36]. 
 
Since 2004 WHO recommends a dual antibiotic therapy with oral rifampicin (10 
mg/kg) and i. m. streptomycin (15 mg/kg) administered daily for at least eight weeks 
[37]. For nodular lesions it has been shown that culture turns negative after four 
weeks of this chemotherapy [38]. Results of a first published observational study are 
encouraging [39]. Of 215 treated patients, 102 were treated exclusively with 
antibiotics. 113 had to be treated with antibiotics plus surgical excision and skin 
grafting. One year after antibiotic treatment was completed, only 3 of the 208 
retrieved patients had a recurrence [39]. Since both streptomycin and rifampicin 
treatment can be associated with side effects [40], search for alternatives, in 
particular for a fully oral drug treatment is ongoing. Even if showing reasonable 
antimicrobial activity in vitro, some potential alternative drugs such as macrolides and 
fluoroquinolones, had no satisfactory curative effect in experimental animal models 
for BU [41,42,43]. In contrast, moxifloxacin and clarithromycin, have shown 
bactericidal activity in mice [44]. Other topical treatments including application of heat 
[45], mineral clay [46], nitrite ointment [47], hyperbaric oxygen [48], and even honey 
[49] have been suggested. 
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Virulence of M. ulcerans 
 
Evolutionary origin of M. ulcerans 
Comparative genomic analyses have shown that M. ulcerans has developed from a 
progenitor of the aquatic environmental mycobacterium M. marinum  [30,31,50]. In 
contrast to M. ulcerans, M. marinum only causes self-limiting granulomatous 
infections in humans. Acquisition of the virulence plasmid pMUM001, encoding 
polyketide synthases that produce the macrolide cytotoxin mycolactone [30,31,51], 
massive gene decay (loss of 1.1 Mb of genomic DNA) and pseudogene formation 
[50] are hallmarks of the development of M. ulcerans into a pathogen that causes 
chronic infections. Reductive evolution indicates that M. ulcerans is adapting to a 
new niche environment. Gain of the immunosuppressive toxin mycolactone is 
accompanied by loss of highly immunogenic proteins [52], suggesting an adaptation 
to survival in host environments that are screened by immunological defense 
mechanisms. Comparative genomic analyses indicate that M. ulcerans has 
developed two distinct lineages: (i) the “classical” lineage representing the most 
pathogenic genotypes – those that are found in Africa, Australia and South East Asia; 
and (ii) an “ancestral” lineage comprising strains from China/Japan, South America 
and Mexico [30,31]. 
 
Mycolactone structure and activity 
One key to the understanding of the pathology of M. ulcerans infection is the family of 
macrolide exotoxins designated mycolactones. To date, the structure of six different 
forms of mycolactone has been elucidated. These consist of a common lactone core 
to which an unsaturated fatty acyl side chain is appended (Figure 2) [53,54]. 
Variations in length and oxidation state of this side chain defines the different forms, 
i.e. mycolactone A to D produced by M. ulcerans lineages isolated from different 
regions [55,56,57], mycolactone E coming from M. liflandii [58] and mycolactone F 
recently discovered in M. pseudoshottsii [59]. Mycolactones lead to an arrest in the 
G0/G1 of the cell cycle followed by apoptosis [53]. The type(s) of mycolactone 
produced by a certain M. ulcerans lineage may have major implications for its 
virulence. In-vitro, mycolactone C for instance is 10,000-fold less active than A and B 
[57].  
 
 CHAPTER 11.  Rev iew 172               
 
In vitro activities of mycolactone 
The molecular mechanism of mycolactone action on eukaryotic cells is not entirely 
clear, but current evidence indicates that it diffuses through the plasma membrane, 
accumulates in the cytoplasm and interacts with a cytosolic target [60]. Within a short 
time, mycolactone can cause dramatic cell skeletal rearrangements, which may the 
cause for reduced phagocytic activity of mycolactone-treated macrophages 
[61,62,63]. The cytotoxic action of mycolactone is not specifically directed towards a 
certain cell type, but rather affects a broad range of cell types although in differing 
intensity, which is also dependent on the state of maturation of the target cells 
[54,64]. Adipose cells are for instance extremely sensitive to mycolactone and 
undergo apoptosis at low toxin concentrations, whereas other cell types cope better 
[65]. This is in accordance with the histopathological observation of extensive 
adipose coagulative necrosis below a relatively intact sub-epidermal and epidermal 
layer in early BU lesions.  
 
In vitro studies have identified multiple mechanisms by which mycolactone may 
suppress local and systemic immune reactivity. In human monocytes expression of 
tumor necrosis factor alpha (TNF-α), interleukin-2 (IL-2), IL-10 and TNF-α induced 
NF-κB activation is suppressed by mycolactone in vitro in a dose dependent manner. 
Murine bone marrow derived macrophages produce low levels of TNF-α when 
infected with highly virulent but not with intermediately virulent or nonvirulent strains 
of M. ulcerans [64,66]. This finding is supported by another study where reduced 
TNF-α mRNA levels were found in activated macrophages 24h post infection [62]. At 
non-toxic concentrations, mycolactone inhibits functional and phenotypic maturation 
of human dendritic cells [63]. Their ability to activate allogeneic T cell priming and to 
produce inflammatory molecules is highly reduced. Interestingly, in these cells TNF-α 
production is only marginally affected [63]. Suppression of the production of 
chemokines by dendritic cells (DCs) may contribute to the observed lack of local 
inflammatory responses in BU lesions. Furthermore, it is likely that massive 
production of mycolactone in established lesions with large clusters of mycobacteria 
destroys infiltrating leukocytes, explaining why intact inflammatory cells are usually 
only found at the periphery of the necrotic areas [67]. 
 
Activities of mycolactone in animal models  
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When injected into guinea pigs, purified mycolactone produces the typical clinico-
histopathological picture of BU with strong apoptotic and immunosuppressive actions 
[68]. Infection with mycolactone-negative M. ulcerans fails to induce ulceration in this 
animal model, but chemical complementation with purified mycolactone restores wild 
type pathology [61]. Histopathological analysis of guinea pig skin infected with wild 
type M. ulcerans revealed coagulative necrosis to appear already 24h post infection. 
Normal host cells were absent apart from small numbers of shrunken, pyknotic cells 
indicative for apoptosis. Infiltration of mononuclear leukocytes was present at the 
edges of the necrotic area 10 days post infection, some containing intracellular bacilli 
although advanced apoptotic changes were observed in these cells. Inflammatory 
infiltrates increased throughout a six week infection period but were always located at 
some distance from the bacterial foci [61]. In a mouse footpad infection model, 
significant differences in the mean footpad swelling - a macroscopic parameter for 
monitoring pathology - has been observed between a highly virulent strain from 
Benin, a moderately virulent strain from China and a mycolactone-negative mutant. 
Leukocyte infiltration two days post infection consisted predominantly of neutrophils. 
While the two virulent strains solely triggered an acute inflammation in the periphery 
of the necrotic area, mice infected with the mycolactone-negative mutant switched to 
chronic inflammation one week post infection with granuloma-like structures forming 
two weeks post infection and neutrophilic infiltrates vanishing concurrently [67].   
A recently published work from Demangel et al shows that mycolactone diffuses into 
the tissue not only locally but also systemically through migrating monocytes [69]. In 
the mouse model structurally preserved mycolactone was detected in peripheral 
blood mononuclear cells (PBMCs), mononuclear cells of the lymph nodes (both 
draining and distant) and the spleen but not in the sera six weeks post infection. 
These findings support the hypothesis that the toxin exerts immunosuppressive 
effects at the systemic level. 
 
Histopathological features of untreated BU lesions 
Histopathological hallmarks of BU include the presence of extracellular clusters of 
AFB, massive contiguous coagulative necrosis, adipose cell ghosts and a remarkably 
low cellular infiltration [70,71]. In very early stages extensive involvement of 
subcutaneous fat in the form of a septate panniculitis and otherwise little 
inflammatory response apart from a slight histiocytic infiltration in the intermediate 
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area, between necrosis and healthy tissue has been described [72]. Bacteria are 
located focally and total numbers may vary greatly between individual lesions [73]. 
Currently BU lesions are not, like leprosy lesions, routinely classified into 
paucibacillary and multibacillary forms, but a deeper understanding of the influence 
of host factors on M. ulcerans disease progression may lead in future to such a 
classification system. In contrast to M. tuberculosis and M. leprae, M. ulcerans has 
traditionally been classified as an extracellular pathogen [74]. However, in 2002, 
Drancourt et al were able to grow M. ulcerans inside amphibian cells in vitro, and 
three years later Coutanceau et al described intracellular bacteria in a mouse model 
of BU [62]. Recently, Torrado et al provided evidence for a transient intra-
macrophage growth phase in the mouse model and subsequent release into the 
surrounding. In specimens from BU patients this phenomenon is usually not explicitly 
appreciated, as bacilli and inflammatory exudates are not always concomitantly 
represented. An additional reason may be that first clinical symptoms leading to the 
collection of a diagnostic biopsy or surgical excision of the lesion may occur 
substantially later than an early phase of the infection, in which intracellular 
replication may potentially play a major role. 
 
 
Local and systemic immune responses in BU patients 
 
Humoral immune responses  
Currently only limited data on the development of M. ulcerans specific immune 
responses are available and it is not entirely clear to what extent mycolactone 
secretion may lead to a suppression of systemic immune responses. The control of 
M. ulcerans infection may be primarily dependent on cell-mediated immunity involving 
activated macrophages, T cells, and Th type 1 cytokines, as is thought to be the case 
for M. tuberculosis and M. leprae infection. However, also antibodies could provide 
protective mechanisms against the largely extracellular M. ulcerans. Opsonisation 
might improve phagocytosis and killing by neutrophils, increase intracellular killing by 
macrophages or improve antigen presentation and induction of protective T cell 
responses.  
In tuberculosis (Tb) endemic areas, where BCG vaccination is common, broad 
antigenic cross-reactivities of M. ulcerans antigens with M. tuberculosis and M. bovis 
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antigens complicate the analysis of M. ulcerans specific immune responses 
substantially. In studies with M. ulcerans culture filtrates IgG antibody responses 
against the secreted M. ulcerans proteins were frequently found in BU patients, but 
also in Tb patients from BU non-endemic regions [75] [76]. IgM responses of BU 
patients against the filtrate proteins were more distinct  than those of healthy family 
members living in the same village [76], indicative for B cell stimulation. Diaz et al. 
used the highly immunogenic M. ulcerans 18 kD small heat shock protein, which has 
no homologues in M. bovis and M. tuberculosis to monitor M. ulcerans specific IgG 
responses in BU patients and household contacts from Ghana. Under stringent 
assay conditions 75% of patients, independent of disease stage, but also 38% of 
household contacts showed reactivity, whereas samples from Europeans and non-
exposed Africans remained negative [77]. This is indicative for the development of 
specific humoral responses against M. ulcerans in exposed, but otherwise healthy 
individuals. Infection with M. ulcerans may thus lead only in a minority of exposed 
individuals to clinical manifestations. Most of the others may develop transient 
infection foci and even nodular lesions may resolve spontaneously [78]. Immune 
responses in healthy household contacts have also been described in an Australian 
study [79], where a lower background staining than with African sera facilitated 
analysis with M. ulcerans cell extracts. 
 
Systemic cellular immune responses  
While patients with early BU lesions rarely show delayed-type hypersensitivity 
responses to intradermally injected M. ulcerans lysate, reactivity is common in 
patients with healing lesions [75,80]. However, it is currently not clear to what extent 
BU patients can mount a M. ulcerans specific Th1 response. Triggering of pattern 
recognition receptors by structural components of M. ulcerans could lead to 
phagocyte activation and production of proinflammatory cytokines, including TNF-α, 
IL-1ß, and IL-12, and also anti-inflammatory cytokines, including IL-10 and 
transforming growth factor beta. IL-12 could in turn drive T cells and NK cells to 
produce Th1 proinflammatory cytokines, including IFN-γ and TNF-α. In synergy with 
TNF-α, IFN- γ could activate M. ulcerans infected macrophages, leading to 
elimination rather than intracellular multiplication. On the other hand, IL-10, an anti-
inflammatory cytokine produced by differently activated macrophages, Th2 and 
subsets of regulatory T cells and DCs could down-regulate IL-12 production leading 
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to a decrease in IFN-γ production. Several research groups, using different 
experimental approaches, have analyzed expression profiles of these key cytokines 
and proliferative responses of peripheral blood mononuclear cells (PBMCs) of BU 
patients stimulated ex vivo with mycobacterial antigens and immunostimulatory 
compounds (Table 1). Wide individual variations in IFN-γ and IL-10 responses have 
been found in these studies, which may be one reason accounting for discrepancies 
with respect to the influence of the disease stage on the polarization of the Th 
response [81,82,83,84]. In a case report acquired Th cell anergy following infection 
with M. ulcerans has been described in a BU patient from Australia [85]. Before 
infection, the patient's PBMCs responded to ex vivo stimulation with M. ulcerans by 
producing Th1 cytokines, but, after development of BU, a shift toward production of 
Th2 cytokines was found. Taken together the various studies are indicative for a 
generalized impairment in IFN-γ production during active BU. The capacity to 
produce IFN-γ is also depressed in Tb [86,87,88,89], where cellular components of 
M. tuberculosis have been shown to down-regulate IFN-γ receptor signaling [90,91]. 
Similarly, in BU mycolactone may also not be the only component with 
immunosuppressive activity. Data from Yeboah-Manu et al have shown that PBMCs 
recover from the systemic downregulation of IFN- γ production in BU after surgical 
removal of the lesion [92] containing the vast majority of mycobacterial material. It 
should be noted that many conditions frequently found in rural Africa, including 
infections such as malaria [93], helminthiasis [94,95,96] and Tb [88], but also 
malnutrition [97] can lead to a partial suppression of cellular immune responses as 
well. 
 
Local immune response in untreated lesions 
In BU lesions inflammation is usually minor with respect to the extent of necrosis of 
subcutaneous tissues and dermal collagen [72,74]. There may be a constant influx of 
neutrophils, monocytes/macrophages, and lymphocytes to the active lesions, but 
mycolactone produced by clusters of mycobacteria is likely to induce apoptosis and 
necrosis of the inflammatory infiltrate [67]. In particular remainders of early 
neutrophilic infiltrates may still be immunohistochemically detectable inside the 
necrotic areas [98].  
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After long periods of persistent infection, granulomatous reactions with epithelioid 
macrophages, variable numbers of giant cells of the Langhans type, peripherally 
situated lymphocytes, and relatively few AFB develop [72]. Granuloma formation is 
more often found in ulcerative lesions than in pre-ulcerative lesions [74]. In particular 
ulcer edges may show signs of chronic inflammation accompanied by a mixed pro-
inflammatory/anti-inflammatory cytokine balance [99,100]. Vast apoptotic/necrotic 
regions with minimal inflammation may thus be surrounded by a rim of mixed 
leukocyte infiltration. Healing is associated with the development of granulation 
tissue, fibrosis, and granulomatous inflammation [70]. New M. ulcerans satellite 
colonies may still develop in the lesion after the onset of granulomatous inflammation 
[73]. Analyses of intralesional cytokine production patterns have yielded conflicting 
results (Table 1) with respect to the polarization of the local response [81] [101] 
[83,100].  Within a lesion the distribution of different types of leucocytes is extremely 
heterogeneous [73]. Therefore results based on the analysis of single biopsies may 
not be representative for the entire lesion [102]. In addition, it appears that there is a 
great variation in individual response patterns to M. ulcerans infection.  A gradation 
system used for the classification of inflammatory responses in leprosy, ranging from 
foamy macrophages (lepromatous) to well-formed granulomas (tuberculoid), may 
also be useful for the classification of BU lesions. 
 
 
Local immune responses during chemotherapy 
 
In active BU disease, a protective cloud of mycolactone around the mycobacterial 
clusters is thought to both destroy infiltrating leukocytes and hinder them from 
passing pro-inflammatory signals to other cells [63]. It is most likely, but still remains 
to be proven experimentally, that mycolactone production is reduced or abolished 
early after the onset of rifampicin/streptomycin chemotherapy due to bacterial growth 
arrest and/or cell death. Declining toxin levels allow leukocytes to reach the 
extracellular mycobacteria, leading to their phagocytosis and destruction [98]. 
Chronic leukocyte infiltration cumulates in the development of ectopic lymphoid 
structures [98].  
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After eight weeks of chemotherapy antigen presenting cells as well as B and T 
lymphocyte foci are found in large numbers inside the BU lesions [98]. Gathering of 
DCs around the necrotic core as well as development of defined granuloma 
structures indicates that antigen recognition and processing is leading to active M. 
ulcerans specific immune responses [98]. Three major types of mixed infiltrates, 
differing in cellular composition, architecture and localization have been identified in 
the treated lesions: (1) highly organized epithelioid granulomas primarily located in 
deeper dermal tissue; (2) less organized diffuse infiltrates in all areas of the dermal 
connective and adipose tissue; (3) dense lymphocyte clusters in proximity to vessels.  
The outer layer of granulomas is mainly composed of T lymphocytes with CD4+ T 
cells outnumbering CD8+ T cells. These lymphocyte belts are interspersed with 
dermal DCs. Focal clusters of B cells appear at the outer margins of the T 
lymphocyte layer. Antigen-presenting cells, in particular Langhans’ giant cells and 
epithelioid macrophages form the centre of granulomas. Many lymphocytes are 
positive for activation and proliferation markers. Neither PMNs nor NK cells 
contribute significantly to granuloma formations. While in human Tb granulomas 
develop a central necrotic core, this is not observed in the lesions of the antibiotic 
treated BU patients. Here, the centre is mainly formed of foamy histiocytes and 
Langhans’ giant cells, like reported for leprosy. Mycobacterial material is only 
infrequently detected inside these structures. BU granulomas thus may function 
primarily as a place for antigen presentation and adaptive immune response rather 
than for sequestration of the mycobacteria. 
 
In contrast to granulomas, regions of diffuse cellular infiltration in the dermal 
connective tissue contain sparsely distributed PMNs with sporadic focal clusters near 
necrotic areas. Small clusters of B lymphocytes are found, but T lymphocytes and 
foamy histiocytes are the most prominent cell types. Also here a large proportion of 
lymphocytes stain positive for activation proliferation markers. 
Macrophages/monocytes are particularly abundant in adipose tissue and around 
necrotic areas. The frequency of epidermal Langerhans cells is strongly elevated and 
dDC are distributed throughout diffuse mixed infiltrates with increasing density 
towards the margins of necrotic areas. Appendices of dDC reach into the damaged 
tissue. Vast amounts of shed CD14 is observed, which is implicated in the clearance 
of necrotic tissue [103].  Adjacent to lymphatics or blood-vessels follicle-like 
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structures with dense aggregations of lymphocytes are found. Here B lymphocytes 
are the dominating cell type followed by T lymphocytes with CD4+ T cells being more 
frequent than CD8+ T cells.  
 
After eight weeks of chemotherapy, AFBs with beaded appearance may still be found 
inside large necrotic areas. In other areas rod-shaped AFB have largely disappeared. 
However, acid-fast mycobacterial debris that can still be stained with antibodies 
specific for mycobacterial antigens, is still abundant and primarily located inside 
mononuclear phagocytes. AFB start to be internalized by phagocytes already after 
two weeks of treatment, when M. ulcerans can still be cultured from tissue 
homogenates (unpublished results). Also cellular infiltrates and small B cell clusters 
are already observed at this time point. Antibiotic treatment may thus act rapidly on 
the bacterial metabolism and interfere with mycolactone production, while complete 
killing of bacteria takes at least four weeks of chemotherapy. After four weeks of 
antibiotic therapy granulomas have not yet been fully developed and Langhans’ giant 
cells are still rare (Schütte et al, in press), but a shift of infiltrating cells from acute to 
chronic subsets may already have taken place. Abundant clusters of AFB inside 
necrotic tissue may still be found (Figure 3), surrounded by dense bands of acute 
and chronic infiltrates (Schütte et al, in press). Abscess formation by PMNs is 
occasionally found, which may lead to secondary tissue damage and “reactivation” 
phenomena such as ulceration or painful papules weeks to months after completion 
of treatment (Schütte et al, manuscript in preparation).  
 
Marked heterogeneity in response patterns of individual BU patients may be 
observed with respect to both clinical outcome and histopathological findings. This 
may be related to factors such as: (1) lesion stage and size and extent of necrosis (2) 
total burden of M. ulcerans inside a lesion and (3) composition and organizational 
status of cellular infiltrates. It is not clear, which factors play a crucial role in the 
development of ectopic lymphoid tissue during chemotherapy of BU. Plasmacytoid 
and myeloid DCs present in BU lesions prior to antibiotic treatment [102] and 
lymphoid tissue-inducer cells may play an important role. Although tertiary lymphoid 
tissue is thought to develop in infectious diseases primarily to sequester pathogens, 
this process is often accompanied by tissue damage. Occasionally antibiotic 
treatment thus may even accelerate the progression of early plaques and oedemas 
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to ulcerative lesions. In some patients new ulcerations develop in the course of or 
after completion of antibiotic treatment. These are usually not associated with the 
development of new infection foci (Schütte et al., unpublished results), but are most 
likely located at sites containing preexisting unrecognized infection foci in which 
mycobacterial antigens and immunostimulators lead to massive local immune 
responses .  
 
 
Conclusion 
 
The pathogenesis of BU is strongly associated with the cytocidal and 
immunosuppressive activities of the macrolide toxin mycolactone. Histopathological 
hallmark of progressing disease is a poor inflammatory response despite of clusters 
of extracellular bacilli. While traditionally wide excision of the infected tissue was the 
standard treatment, provisional WHO guidelines now recommend eight week 
chemotherapy with streptomycin and rifampicin. Soon after start of the antibiotic-
therapy onset of vigorous local immune responses is observed, which speaks for a 
rapid decline of mycolactone levels in the lesion. Three different general types of 
infiltration, diffuse mixed infiltrates, granulomas and dense lymphocyte aggregation in 
the vicinity of vessels are found in the treated lesions. This structural differentiation 
may reflect a range of different functional activities required for resorption of necrotic 
tissue and complete clearance of residual mycobacterial cells and antigens. After 
eight weeks of antibiotic treatment necrotic regions are surrounded by large numbers 
of dDCs and their appendices reach into the damaged tissue, indicating enhanced 
antigen uptake and presentation. A large proportion of lymphocytes in the infiltrates 
are expressing activation and proliferation markers. It is likely that the curative effect 
of the antibiotic treatment is supported by these immunological reactions. Future 
studies on re-infection rates will show, whether chemotherapy of BU results in long-
lasting immunity and protection against re-infection by M. ulcerans. 
 
 
Expert opinion 
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There is convincing evidence that the macrolide toxin mycolactone of M. ulcerans 
plays a crucial role in the pathogenesis of the chronic necrotizing skin disease BU. 
Tissue destruction, killing of leukocytes that are attracted to the site of a M. ulcerans 
infection and possibly also some downregulation of systemic immune responses can 
be primarily attributed to the apoptotic and direct bactericidal activities of the toxin. 
However, the exact molecular mode of action of mycolactone is not known, nor has 
its distribution and stability in the host been studied. The fact that tissue destruction 
reaches far beyond the tissue areas containing large clusters of extracellular M. 
ulcerans demonstrates that mycolactone diffuses into the tissue. Development of 
leukocyte infiltrates in BU lesions already after one to two weeks of chemotherapy 
indicates on the other hand that the stability of mycolactone in the necrotic tissue is 
limited. However, this represents only indirect evidence for the behavior of 
mycolactone in BU lesions. Due to lack of a sensitive and robust quantification 
method for mycolactone in biological samples it is currently also not clear, whether 
mycolactone related metabolites could potentially be detected in the blood or urine of 
Buruli ulcer patients – a feature that could be used for the development of a specific 
diagnostic test. Various attempts are therefore currently made to develop an 
immunological antigen capture assay or a mass spectrometry-based test system for 
mycolactone. The macrolide toxin could also represent a suitable target for the 
development of a toxoid-based vaccine. However all approaches to develop a protein 
conjugate that elicits high titers of mycolactone-specific and potentially neutralizing 
antibodies have failed so far and only one mycolactone specific monoclonal antibody 
has become available (unpublished results). There is also no evidence for the 
development of natural immune responses against mycolactone in BU patients or M. 
ulcerans exposed, but healthy individuals. 
 
In established M. ulcerans disease the vast majority of AFB are located 
extracellularly in necrotic areas of the lesions. However results from experimental 
infections in mice speak for a transient intracellular stage early in the infection. The 
bacteria appear to kill the phagocytes that have ingested them after a few days and 
may then develop further into microcolonies, which develop a protective cloud of 
mycolactone around them. Since human biopsies or excised tissue is only becoming 
available at an advanced stage of the infection it is not entirely clear, whether the 
same holds true for the infection in humans. However, at the periphery of necrotic 
 CHAPTER 11.  Rev iew 182               
 
areas in established human BU lesions, encounter of spreading M. ulcerans cells 
with human phagocytes can be observed. Here small numbers of intracellular AFB 
are found. Signs of apoptosis at the side of the leukocytes and ‘beaded’ appearance 
of the mycobacteria upon ZN staining indicates that this encounter can be lethal both 
for the invader and the host cells. New satellite colonies and lesions may develop 
from spreading mycobacteria, but this seems to be a relatively rare event. Probably 
only a few spreading mycobacteria succeed in developing satellite cluster of 
mycobacteria that are large enough to form a protective cloud of mycolactone. Host 
factors may largely determine whether a patient develops a single or multiple skin 
lesions or even metastatic osteomyelitis. The most striking finding of immunological 
analyses in BU patients is the wide individual variation in cytokine responses both 
with respect to magnitude and response patterns. This may make it impossible to 
associate different disease stages with either a Th1 or a Th2 dominated response. 
However, a more differentiated gradation system for inflammatory responses in BU 
may turn out to be as useful as the differentiation between lepromatous and 
tuberculoid leprosy. Like in leprosy, also in BU paucibacillary and multibacillary forms 
seem to exist, but this aspect has also not been systematically investigated. 
 
Only a subgroup of individuals exposed to M. ulcerans appears to develop clinical 
disease. This indicates that the human immune system is in principal able to cope 
with a M. ulcerans infection. Spontaneous healing of lesions may occur after 
prolonged periods of progressive ulceration, but also nodular stages may 
occasionally resolve spontaneously. Granuloma formation and conversion to positive 
burulin skin test has been associated with spontaneous healing, suggesting a role for 
cellular immune mechanisms. But also the humoral arm of the adaptive immune 
system may contribute to host defense against the largely extracellular M. ulcerans. 
BU granulomas do not have a necrotic core containing intact mycobacteria, as is 
found in tuberculosis and there is also no other histopathological evidence for the 
development of latent stages of M. ulcerans. However, relapses observed after 
prolonged disease-free intervals in some patients may not only be caused by re-
infection. 
 
Current treatment options for BU include surgical excision, chemotherapy and heat 
treatment. While chemotherapy has for a long time been regarded as largely 
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ineffective for M. ulcerans infection, treatment with a combination of rifampicin and 
streptomycin is currently being re-evaluated with encouraging results. While surgical 
excision aims to remove tissue containing bacterial clusters completely, tissue and 
bacterial cell debris remains after antibiotic therapy, in particular in the case of pre-
ulcerative lesions, in the body. Mycobacterial antigens and immunostimulators can in 
turn attract strong leukocyte infiltration and the formation of abscesses. Development 
of ectopic lymphoid tissue in the lesions demonstrates that BU patients are capable 
of raising local anti-mycobacterial immune responses once the mycolactone levels 
decline. These inflammatory reactions may slow down wound healing after 
successful chemotherapy. Interestingly, thermotherapy is associated with much less 
vigorous local cellular immune responses (unpublished results). Massive 
immunostimulation seems to lead in some patients to apparent reactivations of the 
disease weeks after completion of antibiotic therapy. Secondary ulcerations may be 
observed, which are not associated with the development of new mycobacterial foci 
(unpublished results).  
 
Differentiated treatment strategies for different categories of BU lesions, combining 
the available treatment options, need to be developed and refined. With an improved 
understanding of BU pathogenesis and protective immune responses it may also be 
possible to develop both simple point of care diagnostic tests and a vaccine for 
targeted protection of the populations living in BU endemic areas. 
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Figures 
 
 
 
 
Figure 1. Clinical stages and histopathology of M. ulcerans infection 
(a) Nodular, (b) early ulcerative and (c) late chronic disease stage. (d) Typical 
histopathological picture of BU with masses of acid-fast rods lying in the necrotic 
subcutaneous tissue (Ziehl Neelsen staining on paraffin section, original 
magnification 10x). 
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Figure 2. Structure of Mycolactone B 
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Author Year Country Study population Lesion type Immune 
response Sample Stimulation Analysis IFN-γ IL-10 Others 
Gooding et al. 2001 Australia Patients/ healed Ulcers Systemic PBMC Living M. ulcerans/ living BCG FACS/ ELISA 
Absent in both acute 
or healed disease - 
Very low to absent 
proliferation of 
PBMCs 
Gooding et al. 2002 Australia Healed/ household 
contact Ulcers Systemic PBMC 
Living M. ulcerans/ 
living BCG mRNA/ ELISA 
Present in contacts, 
absent in former 
patients (both mRNA 
and protein) 
Absent in contacts, 
present in former 
patients 
IL-12 in contacts, 
IL-4, -5, -6 in 
former patients 
Prevot et al. 2004 French Guyana Patients Nodules/ ulcers Local 5mm biopsy - mRNA 
High transcripts in 
nodules, low in ulcers 
Low transcripts in 
nodules, high in 
ulcers 
Slightly lower TNF-
α transcripts in 
ulcers 
Prevot et al. 2004 French Guyana Patients Nodules/ ulcers Systemic PBMC 
Whole killed M. 
ulcerans and BCG ELISA 
Lower in patient vs. 
healthy controls/ 
lower in ulcers vs. 
nodules 
Higher in patients vs. 
controls/ higher in 
ulcers vs. nodules 
BCG stimulation 
relatively 
ineffective 
Westenbrink et al. 2005 Ghana Patients 
Early stage (active 
BU or surgery <42 
days ago)/ late stage 
(surgery >42days ago 
or healing) 
Systemic Whole blood PHA, PPD ELISA 
Higher in late stage 
than early stage 
disease 
No difference 
between groups - 
Yeboah-Manu et al. 2006 Ghana 
Patients before and 
after surgery (5 
months)/ 
household contacts 
Nodule, plaque, ulcer Systemic PBMC IPP, PPD, IRIV, PHA 
ELISpot/ 
ELISA 
Increasing presence 
after surgical removal 
of lesions 
n.d. No variation in IL-12 production 
Phillips et al. 2006 Ghana 
Patients/ healed 
BU/ household 
contacts 
Nodules/ ulcers Systemic Whole blood 
M. ulcerans or M. 
tuberculosis 
sonicate 
ELISA 
Slight increase in 
ulcer vs. nodule, 
highest in healed/ no 
difference between 
patients and contacts 
Highest in ulcers/ low 
in contacts 
No differences 
when stimulated 
with Tb sonicate 
Kiszewski et al. 2006 Benin Patients Ulcers (with or without granulomas) Local Tissue section - IHC 
Strong increase in 
sections with 
granulomas vs. 
without 
Slight decrease in 
granulomas 
Increase of CD8 
with granulomas/ 
no change in TNF-
α and TGF-β 
Phillips et al. 2006 Ghana Patients Nodules/ ulcers Local Punch biopsy - 
mRNA 
(relative to 
18S) 
Marginal differences 
(not significant) 
Marginal differences 
(not significant) 
Much higher IL-1β 
and IL-8 in ulcers 
than nodules 
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Peduzzi et al. 2007 Ghana Patients Nodules/ ulcers Local 
Whole 
surgical 
excision 
- 
mRNA 
(relative to 
β-actin) 
Very low to absent Focal peak in one patient 
Great variation of 
TNF-α levels 
throughout the 
lesions 
Schipper et al. 2007 Ghana Patients/ healed BU 
Pre-ulcerative/ 
ulcerative (necrotic, 
organizing, 
granulomatous) 
Local 6mm punch biopsy - IHC 
Rising from necrotic 
over organizational to 
granulomatous stage 
of infection 
Strong in 
endothelium, lower in 
epithelioid and giant 
cells 
Strong TNF-α 
staining 
Schipper et al. 2007 Ghana Patients/ healed BU 
Pre-ulcerative/ 
ulcerative (necrotic, 
organizing, 
granulomatous) 
Systemic Whole blood PHA, PPD ELISA 
Higher in patients 
with ulcerative and 
healed than pre-
ulcerative lesions and 
in controls 
Higher in patients 
with pre-ulcerative 
and healed than with 
ulcerative lesion or in 
controls 
No differences with 
or without BCG 
scar 
 
 
Table 1. In vivo data on local and systemic cytokine responses in BU patients 
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Figure 3. Histopathological changes during chemotherapy  
(a-d) Ulcerative lesions after eight weeks R-S treatment. (a) Follicle-like lymphocyte 
aggregation. (b) Acid-fast mycobacterial debris inside macrophages. (c) Large 
numbers of S100 positive DCs surrounding a necrotic lesion core. (d) CD14 positive 
granulomas in the macroscopically healthy lesion margin. (e) Ulcer after four weeks 
of R-S treatment. Dense mixed leukocyte infiltration at the necrotic border. (f) Early 
nodule after four weeks of R-S treatment. Intracellular AFB phagocytosed by 
macrophages. AFB show signs of degradation (“beading”). (g) Plaque after twelve 
weeks of R-S treatment. Abscess formation by PMNs. (h) Plaque after two weeks of 
R-S treatment. Distinct CD20 positive B lymphocyte cluster. 
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12.1. General remarks 
 
In 1998 WHO established the Global Buruli Ulcer Initiative to coordinate BU control 
and research efforts. Although research on BU has been intensified since then there 
are still many open questions regarding reservoir, transmission, pathology, 
immunology and epidemiology. Furthermore, improvements are necessary with 
respect to health care, prevention, surveillance and awareness of the population. To 
efficiently fight BU and bring this neglected tropical disease out of obscurity, endemic 
countries, NGOs and research institutions actively collaborate and mobilize expertise 
and resources worldwide.  
 
Improved case detection and awareness for the disease of populations in endemic 
areas has led to a better estimation of overall incidence rates. Over 30 countries 
worldwide are affected 1 and more BU foci are likely to be discovered in future, 
especially in sub-Saharan Africa. The most endemic countries such as Benin, Ghana 
and Côte d’Ivoire report already 1,000 to 2,000 new cases per year 2. Assessing the 
burden of BU and establishing a control programme in endemic countries with limited 
resources is very demanding as health care and research infrastructures in those 
countries are usually poorly developed.  
 
Well trained clinicians and health workers who are capable of diagnosing and treating 
the disease are rare, and although community participation in the recognition of 
disease symptoms is advancing, patients often present late with severe ulcerative 
lesions. In many BU endemic regions of Africa sufficient resources to treat and 
rehabilitate these patients are not available. However, more support is gradually 
becoming available to promote research on better diagnostic, treatment and 
preventive tools and to foster cooperation among countries in order to strengthen 
surveillance, control and rehabilitation. 
 
The discussion section of this work is reviewing the current diagnosis and treatment 
strategies for BU as well as the prospects for vaccine design. 
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12.2. Diagnosis of BU 
 
In an area known to be endemic an experienced person can diagnose BU on clinical 
grounds 3, although other ulcerating or boil forming diseases can be confused with M. 
ulcerans infection. Current goal of WHO is to reconfirm at least 50% of the clinically 
diagnosed BU patients by laboratory analyses. With the introduction of antibiotic 
therapy of BU in 2004 4, the necessity of laboratory confirmation became even more 
crucial. Four laboratory-confirmatory methods are used retrospectively on samples 
taken during treatment, namely AFB examination of smears and biopsies, culture, 
PCR and histopathology 5.  
 
 
12.2.1. AFB, culture and PCR 
Exudate smears can only be obtained by taking swabs from ulcerative lesions and 
microscopic examination for AFB is associated with low sensitivity. However, it is the 
only yet available field test which can be carried out rapidly at local facilities. Culture 
of M. ulcerans is an extremely time-consuming technique 6, that requires skilled 
personnel. It yields false-negative results too often to be implemented for routine 
diagnostic purposes, but has recently been used to monitor the kinetics of bacterial 
killing under antibiotic therapy 7. PCR is a test with a sensitivity of up to 100%, which 
often allows confirmation of clinical diagnosis even when samples are culture and 
smear negative. Although the target sequence IS2404 has also been found in some 
other environmental bacteria 8, positivity of clinical specimens is a strong indication 
for a M. ulcerans infection. Swabs or biopsies can both be assessed within two days, 
but in West Africa the expensive equipment and demanding technical skills, 
inevitable to perform this method, are only available in a few reference laboratories. 
Furthermore, the high risk for false positive results caused by contamination requires 
strict quality control, which is not yet implemented. Therefore, the introduction of 
inter-laboratory comparable protocols has been suggested and will be established in 
the near future. We have used real-time PCR, which is less prone to yield false 
positive results than conventional PCR, for diagnosis in our thermotherapy study. In 
combination with histopathology and AFB staining it allowed to unambiguously 
reconfirm clinical diagnosis (see Chapters 7 and 8). 
 
 CHAPTER 12.  D iscuss ion  200               
 
12.2.2. Histopathology 
BU lesions develop a distinctive pathology at the site of infection which allows an 
experienced pathologist to diagnose the disease on these grounds 9. Sampling has to 
be performed with great care to obtain tissue from the presumed lesion core or from 
ulcer edges. Biopsies must include all levels of the integument as focal bacterial 
clusters and the associated pathological changes are primarily located inside the 
adipose region of the deeper dermal layer 10. Though histopathology is a reliable 
diagnostic tool, it requires special equipment and versed scientists to be performed 
and takes at least four days for sample processing and evaluation. Recently, punch 
biopsies have been introduced as standard procedure in the diagnosis of BU allowing 
histological analysis of tissue from both ulcerated and early closed lesions 11. Due to 
the heterogeneity of lesions and the superficial nature of biopsies, sensitivity is much 
lower than for major excision samples. 
 
Given proper processing and storage, tissue embedded in paraffin can be preserved 
over years and used not only for diagnosis, but also additional research, as it is 
shown in the present work (see Chapter 6). Histological analyses can provide insight 
into processes taking place during progressing disease 12, treatment 13 or healing 14 
and are extremely valuable to better understand the natural history of the disease 
(see Chapters 3, 4 and 5). The complete “lack of local immune responses” was 
thought to be a hallmark of progressing BU disease and it was generally assumed, 
that the onset of a granulomatous response marks the beginning of containment and 
eventual healing of a M. ulcerans infection 15. More detailed histological analysis is 
now modifying this point of view. Ulcer edges show signs of chronic inflammation 
accompanied by a mixed pro-inflammatory/anti-inflammatory cytokine balance as 
consistent histopathological features 16. It was demonstrated that new satellite 
lesions can still develop after the onset of these cellular immune response followed 
by granuloma formation 17. It appears that infection with M. ulcerans does trigger a 
local immune reaction, but that infiltrating leukocytes are subsequently destroyed in 
areas with high mycolactone concentration. This may explain the observation of vast 
apoptotic/necrotic regions surrounded by a rim of mixed leukocyte infiltration. In our 
immunohistological studies remainders of early neutrophilic infiltrates were still 
detectable inside the necrotic areas. In chronic progressing ulcerative lesions 
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granulomas are commonly observed at the lesion edges 16,17. This may represent an 
attempt of the immune system to fend off and isolate the invading mycobacteria.  
 
A second conclusion, that M. ulcerans is an extracellular pathogen unlike other 
mycobacteria, was first challenged in 2005, when a transient intraphagocytic stage 
was observed in the animal model 18,19. Examination of the peripheries of necrotic 
acellular areas in BU patients revealed that inflammatory infiltrates containing bacilli 
are consistently present during infection 16,20. This phenomenon is not often 
appreciated because inflammatory exudates and bacilli are not always represented in 
the tissue fragments available for analysis. Monitoring the early development of 
experimental M. ulcerans infection of mice indicates a great proportion of bacilli 
replicating inside phagocytes before their final release into the tissue due to 
mycolactone cytotoxicity (Ruf et al, unpublished data). In future, histological analysis 
of very early BU lesions should be conducted to better understand the factors 
contributing to the establishment of M. ulcerans infection such as intra- and 
extracellular bacterial stages and kinetics of local immune responses. There is 
mounting evidence that a proportion of M. ulcerans infections resolve spontaneously 
before giving rise to clinical disease. 
 
 
12.2.3. Future improvements 
Novel strategies to develop highly predictive but simple “point-of-care” diagnostic 
tests allowing fast confirmation of BU at peripheral treatment centres are considered 
a high research priority. Serological studies have indicated that exposure to M. 
ulcerans leads only in a minority of individuals to clinical symptoms 21. One focus on 
the way to a field-compatible diagnostic test could be the development of an antigen 
capture assay based on antibodies against unique immunodominant proteins of M. 
ulcerans such as its 18kD small heat shock protein (shsp) 21. Immunohistochemistry 
(IHC) performed with monoclonal antibodies (mAbs) against this surface-bound 
protein allows specific and sensitive detection of the pathogen in tissue and culture 
(see Chapter 10). The final goal is a cheap and easy to handle test format such as a 
dip-stick, requiring only small amounts of urine or blood.  
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Another focus is on mycolactone, the macrolide exotoxin, which is supposedly more 
widely distributed inside the lesion than the bacilli. Antibodies against this small 
molecule are not easily elicited and only one mycolactone-specific mAb has been 
generated so far (Dangy et al, unpublished data). A phage-display based approach is 
currently conducted as alternative strategy for the generation of mAbs with 
alternative specificity. The available mAb against the macrolide is currently under 
investigation for potential use in histopathological analysis of frozen sections 
(unpublished data). Since mycolactone is ethanol-soluble, paraffin-embedded thin 
sections are not suitable for such analyses. Excised tissue could be assessed for 
mycolactone distribution not only for diagnostic purpose, but also to obtain more 
detailed information about extent and severity of infection. In addition, decline of 
mycolactone levels could represent a good surrogate marker for the efficacy of 
antibiotic or heat treatment. 
 
 
12.3. Treatment of BU 
 
12.3.1. Antibiotics 
Historically, surgery is the front-line therapy for all stages of BU 22,23. However, only a 
minority of BU patients in West Africa had access to surgical treatment centres. The 
introduction of an efficacious antibiotic combination is currently shifting the balance 
from mere surgery to antibiotic therapy with or without surgical intervention 4. In 
African countries daily administration of both rifampicin and streptomycin is now used 
at a number of treatment centres after a clinical trial and observational studies 
showed its efficacy in humans 7,24. Large observational studies indicate that 30-50% 
of patients can be cured with antibiotics alone, primarily those with early pre-
ulcerative or small ulcerative lesions. Patients who recover without additional surgery 
most often suffer from a minor lesion less than 5cm in diameter. Between experts, 
the rifampicin-streptomycin regimen remains a subject of debate and, although 
promising, has to be improved in several ways 25. Streptomycin is contraindicated 
during pregnancy and although it has been reported to be well-tolerated, there is a 
risk of renal and ototoxicity in particular in children 26. Several studies to simplify 
antibiotic treatment are ongoing. In the mouse footpad model, five days per week R-
S administration are sufficient to cure M. ulcerans infection 27 and the same concept 
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is currently under evaluation in a pilot dose-finding study in Ghanaian BU patients 28. 
Trials to evaluate the potential of the orally administered antibiotic clarithromycin, 
which has excellent bio-availability and penetration into tissue and good anti-
mycobacterial activity in vitro 29, are under way (van der Werf, drug trial 
NCT00321178). This macrolide penetrates phagocytes and accumulates in 
organelles delivering the drug directly to the site of infection 30. Even a treatment 
course of six months can be followed with this combination and curing severe 
disseminated cases becomes imaginable 31. 
 
 
12.3.2. Thermotherapy 
The currently most promising alternative approach is BU therapy through local heat 
application. A small proof-of-principle trial used non-hazardous commercially 
available bags containing phase-change material to locally apply temperatures 
around 40°C over several weeks (see Chapters 7 and 8). Amazingly rapid re-
attachment of undermined skin and subsequent healing processes were achieved. 
Results from this “proof of principle” trial strongly suggest that heat kills or 
suppresses M. ulcerans in the affected tissues and, at the same time, induces a local 
immune response which is carrying the healing process further. These promising 
results encouraged implementation of a larger dose-finding trial and the recruitment 
of complicated cases. Exploration of the turning point is important to determine the 
heat application schedule sufficient for the host’s own defence and healing to take 
over. Furthermore, an “over-night” treatment schedule would be very convenient for 
both patients and health workers. After completion of the dose finding study field 
workers have to be trained to independently administer heat-therapy according to the 
appropriate schedule. This would allow the realization of a community effectiveness 
trial, where thermotherapy is transferred to the community to accomplish “on-the-
spot” treatment of BU patients. The non-invasive heat application was already greatly 
appreciated by all participants during the pilot study. Broad acceptance of a 
treatment modality by both health workers and the local population is thus likely to be 
a major advantage. In regions with limited resources, where the disease is the most 
prevalent, thermotherapy may open up a new era in the treatment of M. ulcerans 
infections and could become a supplementary if not alternative treatment option in 
the fight against BU.  
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12.3.3. Mycobacterial viability studies 
As noted already, histopathology is a good tool to evaluate local immune responses 
and bacterial distribution during therapeutical interventions. Nevertheless, efficacy 
evaluation of a particular treatment should also include determination of 
mycobacterial viability which is, apart from performing time-consuming and 
insensitive culture, not possible to date.  
 
A possible marker of viability loss is the so-called “beading” of mycobacteria. 
Microscopy can be used to evaluate the effects of therapy on M. leprae as it is well 
known that even slight physical damage to the bacterial cell wall is sufficient to 
change the acid fast properties visualized by “beaded” ZN staining 32,33. At close 
examination, the same phenomenon was observed in mouse footpad M. ulcerans 
lesions (Ruf et al, unpublished data) and human BU (see Chapter 6) treated with 
antibiotics for several weeks. Unfortunately, if there is sufficient residual cytoplasm to 
outline the bacillus, thereby appearing solid in ZN staining, the degenerated form can 
only be identified by electron microscopy 33. Therefore, this method is too insensitive 
to monitor viability, but may be used to give a rough estimate of treatment success or 
probability of relapse. 
 
Another surrogate marker to measure viability may be mycolactone content of clinical 
specimens. The observed recovery of local immune responses associated with 
declining necrosis speaks for a reduced mycolactone release during R-S treatment 
(see Chapters 3, 4 and 5). Lipid extracts of punch biopsies from BU patients with and 
without antibiotic treatment could be assessed for mycolactone levels via mass 
spectroscopy (Wansbrough-Jones, unpublished data). Moreover, monoclonal 
antibodies against the toxin may be used in frozen section to monitor mycolactone 
level and distribution to indirectly measure viability of M. ulcerans in the course of 
therapy. Both methods could potentially also be suitable as diagnostic tools 
performed in reference laboratories.  
 
In leprosy, a reverse transcription (RT)-PCR assay targeting 16S rRNA of M. leprae 
has been used to detect specific RNA in biopsy specimens 34. Positive results were 
obtained in biopsies from fresh or short term treated cases. In contrast, from 
specimens of long term treated cases showing clinical features of relapse were 
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negative. DNA targeting PCR showed positivity in both groups. These results 
suggest that RT-PCR positivity possibly reflects the presence of viable organisms 
and that a proportion of supposed relapses may rather appear as secondary immune 
“reactivation” due to remaining dead M. ulcerans. Thus RT-PCR assays may be 
useful for viability determinations of M. ulcerans in response to chemotherapy as well 
as in supposed relapse cases. 
 
 
12.3.4. Vaccine development 
Prevention of clinical disease, as provided by vaccination, is the most desired 
solution to finally control M. ulcerans infection. Studies whether BCG vaccination may 
render herd immunity as it is found for leprosy 35 were not overly successful 36-38, 
although severe disseminated infections may be prevented 39. Other approaches 
based on DNA engineering and virulence factors of M. ulcerans are under evaluation.  
 
For the rational design of a vaccine it is important to identify the immune effector 
functions relevant for a particular infection. In the case of the best studied 
mycobacterial disease TB cellular immune responses are thought to be most crucial. 
Effective immune response against the primarily intracellular pathogen M. 
tuberculosis requires several subsets of immunity. The induction of CD4+ Th-1 cells 
is protective in mice 40 and is mirrored in humans with HIV co-infection who have a 
500-fold increased risk of TB due to their reduced CD4+ leukocyte counts 41. 
Furthermore, CD8+ cytotoxic T cells can recognise and destroy target cells infected 
with intracellular M. tuberculosis 42,43. Mouse models of latent TB indicate that CD8+ 
T lymphocytes are particularly important in the prevention of reactivation 44. Another, 
though not very popular, hypothesis argues that mycobacteria-specific antibodies 
induced by BCG vaccination could target extracellular M. tuberculosis implicated in 
transmission and actively replicating within cavitary pulmonary lesions 45.  
 
In M. ulcerans infection leukocyte subsets required for immunity are supposed to be 
different as replication happens predominantly extracellular. Intracellular M. ulcerans 
are released from phagocytes due to the action of mycolactone and eliciting specific 
CD4+ Th-1 and CD8+ T cells may play a minor role in the containment of infection. 
Therefore, the humoral immune response potentially represents the most important 
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effector arm of the immune system against M. ulcerans. In addition, eosinophils and 
mast cells may play an important role in immunity against the pathogen. This 
hypothesis is supported by results from antibiotic treated lesions where eosinophils 
gather around infected areas (see Chapter 3 and 5).  
 
M. marinum is thought to be the common ancestor of all M. ulcerans strains 46. BCG 
derived from M. bovis may lack proteins crucial for protection against BU 36,38. A 
recombinant BCG strain over-expressing key M. ulcerans antigens might be a 
promising approach to enhance the vaccine’s potency. However, standard BCG 
vaccination can induce prolonged ulcerative lesions at the site of intradermal 
inoculation which might even be enhanced through expression of M. ulcerans 
proteins. Especially immuno-compromised individuals may suffer from severe 
infectious complications 47. An attenuated M. ulcerans strain deprived of mycolactone 
production which can persist only for limited periods in vivo but carries all relevant 
antigens may represent an alternative. In guinea pigs, mycolactone negative M. 
ulcerans strains have been shown to trigger a brisk inflammatory response which is 
limiting the experimental infection 18. Under-attenuation could result in vaccine-
associated BU disease whereas over-attenuation would greatly reduce 
immunogenicity.  
A strategy that avoids risks associated with a life vaccine is the utilization of whole 
killed M. ulcerans to introduce antibody responses against its immunodominant 
antigens. However, this approach might provide rather low protection, because 
antibody responses against molecules with low immunogenicity may be primarily 
relevant.  
 
Subunit vaccines, based on recombinant proteins or plasmid DNA, represent a much 
safer strategy. A major drawback for protein subunit vaccines is the insufficient 
availability of adjuvants to trigger antigen-presenting cells. To date, only alum and 
QS-21 are approved for use in humans. DNA vaccines offer the advantage of 
endogenous antigen production inside antigen-presenting cells and contain CpG 
motifs triggering appropriate responses via TLR9 signalling after vaccination 48. 
However, attempts to use a Mycobacterium leprae Hsp65-based DNA vaccine 
against M. ulcerans infection in mice failed 49. Recently, immunogenicity and 
protective efficacy of Ag85A from M. tuberculosis and M. ulcerans, administered as a 
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plasmid DNA vaccine, as a recombinant protein vaccine in adjuvant or as a 
combined DNA prime-protein boost vaccine, was reported 50. Combination with a 
vaccine targeting mycolactone may be a way to strengthen the effectiveness of this 
potential subunit vaccine. Another market-approved adjuvant and carrier system are 
influenza virosomes 51,52. Antigenic pathogen-specific peptides could be linked to 
virosomes to present M. ulcerans antigens to the immune system. Alternatively, 
synthesized mycolactone could be hooked to the virosomal surface to generate 
immunity against the cytotoxin. 
 
Even if future research will yield promising results with vaccine candidates in the 
animal model it will be hard to raise enough money to implement clinical trials for BU 
vaccine development despite all efforts in rising awareness of the disease. An 
additional opportunity is to wait for the development of an improved TB vaccination 
which may evoke cross-reactive immune responses providing protection against M. 
ulcerans infection.  
 
 
12.4. Future aspects of disease control 
 
One focus to intensify BU control activities lies on the education of the population in 
endemic countries which would improve case management through early case 
detection at community and school level. Patients need to be aware of the early 
symptoms and their confidence in the available treatment options has to be 
strengthened. Many people believe in witchcraft as the main factor to develop such 
diseases and prefer traditional healers over classical medicine 53, so the true cause 
of BU has to be made clear to those affected. In a study in Benin presentation delay 
decreased from four months in 1989 to one month in 2001 due to continuing efforts 
to raise the population’s education and awareness for the disease 54.  
 
A decentralization of health care could help to reach people in the very remote rural 
areas who will not present to a hospital because of the great distance 53. Village 
health workers need to be trained to recognize and treat the disease, especially 
when a fully orally administered antibiotic regimen or thermotherapy is available. 
Diagnostic centres are needed in the periphery, as rural areas suffer from the inability 
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to diagnose M. ulcerans infection in a timely manner, especially to unambiguously 
diagnose closed BU lesions which lack the pathognomonic features of ulcerative 
lesions. Synergies with other disease-control activities using already existing 
networks and infrastructures could help to accelerate implementation of these issues. 
It is important not only to create facilities but also to assure sustainability and a 
continuum of care by strengthening national health systems with the contribution of 
NGOs and thereby guaranteeing provision of equipment and resources.  
 
Correct treatment of BU includes a third essential element apart from surgery and 
drugs, namely prevention of disability (POD). Reduction in the range of motion or 
other more severe functional limitations of joints are commonly observed to 
accompany chronic M. ulcerans infections 55 and have significant impact on 
employment or schooling and farming activities 56. Joint contractures often have to be 
removed surgically, but also aftercare physiotherapy has been shown to improve 
disabilities 57. Some health centres are already equipped with a physiotherapy unit 
including trained personnel and special equipment, but all caregivers should receive 
basic training in POD. WHO is currently working on a POD manual within its series of 
training modules on BU which will be targeted at general health staff 28. 
 
West Africa and other developing countries endemic for BU will never be able to 
cover all communities with high-standard resources, but every small improvement is 
one step further to diminish suffering among affected individuals. General 
practitioners could be educated, for instance, to perform nodulectomies or simple 
split skin grafts, because workload is already too high in most regions to exclusively 
rely on fully-trained surgeons. Only ten years ago BU was an obscure disease to 
many living in endemic regions and even totally unacquainted on international level, 
and research was an extremely tedious business. Nowadays we are witnessing 
growing interest in this particular of defined 13 neglected tropical diseases worldwide  
58
, possibly leading towards an accelerated progress within the ten years to come. 
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 A large range of serum samples collected in Ghana, Cameroon and Australia was 
tested for specific antibody response against the 18kD shsp in a Western Blot 
analysis to see whether infection with or exposure to M. ulcerans could be detected 
as previously described for Ghana [1]. For each country 13 patient sera were tested 
on recombinant 18kD protein for specific antibody responses. All 13 sera from Ghana 
(100%) were strong positive whereas only 5 out of 13 samples (38%) from 
Cameroonian patients showed an intermediate and 8 (62%) an extremely weak 
response which was (Fig.1). In the Australian set of patient sera merely 2 out of 13 
sera (23%) yielded a faint positive and 5 (38%) a nearly invisible result (Fig.1) 
Sera from individuals living in non-endemic countries showed no response to the 
18kD protein at all [1]. We collected sera from non-endemic regions of BU endemic 
countries and tested those for their anti-18kD antibody response in comparison to 
patient sera. 12 out of 30 patients sera (40%) from an endemic BU area in Cameroon 
showed a positive response to the recombinant 18kD protein (Fig.2a). 13 out of 36 
sera (36%) from a BU non-endemic neighbouring region in Cameroon were positive 
for anti-18kD antibodies (Fig.2b). A similar result was obtained for sera retrieved from 
a BU non-endemic area located in the dry northern Ghana, where 13 out of 42 
samples (31%) were Western Blot positive (Fig.2c). Finally, 13 out of 20 samples 
(65%) collected in a BU non-endemic village located inside the Savannah of northern 
Cameroon with a high leprosy incidence rate gave a positive anti-18kD response 
(Fig.2d). 
 
In a previous work we could show that the recombinant 18kD is recognized by 
Ghanaian sera of BU patients and household contacts, therefore identifying exposure 
to the pathogen [1]. Surprisingly, this was not the case for sera collected in 
Cameroon or Australia where percentage of patient samples recognizing the 18kD 
protein was less than in Ghana and positive signals lower in intensity. The reason for 
this phenomenon is unclear, but host factors might play a role as well as severity and 
location of the lesion. When around a third of sera from non-endemic regions within 
Cameroon and Ghana turned out positive, cross-reactivity with another protein 
became conceivable. On this account, sera from a region of Cameroon non-endemic 
for BU but with increasing prevalence of leprosy were tested and 65% showed 
reaction against the recombinant 18kD shsp of M. ulcerans. M. leprae carries a 
homologue of 18kD shsp with 78.8% protein sequence identity and it is likely that 
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individuals infected or exposed to this pathogen elicit a similar immune response as 
against M. ulcerans exposure [1,2]. This would also explain the very low reactivity in 
sera collected in Australia, where leprosy is not endemic.  
 
 
 
Figure1. Western blot analysis of sera from BU patients and individuals living 
in non-endemic regions 
SDS-page gels loaded with recombinant 18kD protein were blotted to nitrocellulose 
membranes and cut into 3mm strips. Strips were incubated with sera samples 
coming from different African regions. Individuals with confirmed BU disease (a), 
healthy individuals living in Buruli non-endemic areas of Cameroon (b) and Ghana (c) 
and individuals from a village non-endemic for BU but with a high prevalence of 
leprosy (d). Positive control (P) with monoclonal antibody and negative control with 
skin milk in PBS-Tween alone. 
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Figure2. Western blot analysis of sera from BU patients of three different 
countries 
SDS-page gels loaded with recombinant 18kD protein were blotted to nitrocellulose 
membranes and cut into 3mm strips. Strips were incubated with sera samples taken 
from Ghanaian, Cameroonian and Australian BU patients. Positive control (P) with 
monoclonal antibody and negative control with skin milk in PBS-Tween alone. 
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